<SEC-DOCUMENT>0001213900-23-065270.txt : 20230810
<SEC-HEADER>0001213900-23-065270.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810080040
ACCESSION NUMBER:		0001213900-23-065270
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		231157242

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea183075-6k_inflarxnv.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:infrx="http://www.inflarx.de.com/20230630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 14pt"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">6-K</ix:nonNumeric></b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REPORT OF FOREIGN PRIVATE ISSUER<br/>
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER<br/>
THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the month of August <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission File Number: 001-38283</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-size: 14pt"><b>InflaRx
N.V.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of registrant&#8217;s name into English)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">Winzerlaer Str. 2</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">07745</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Jena</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Germany</ix:nonNumeric><br/>
</b>(Address of principal executive office)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form 20-F <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>
Form 40-F <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>




</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>EXPLANATORY NOTE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibits 99.1 and 99.2 to this Report on Form 6-K shall be deemed to
be incorporated by reference into (i) the registration statement on <a href="https://www.sec.gov/Archives/edgar/data/1708688/000095010317011321/dp82802_s-8.htm">Form S-8</a> (File No. 333-221656) and (ii) the registration statement
on <a href="https://www.sec.gov/Archives/edgar/data/1708688/000114036123032443/ny20009510x1_f3.htm">Form F-3</a> (File No. 333-273058) of InflaRx N.V. and to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Exhibit 99.3 to this Report on Form 6-K shall not be deemed &#8220;filed&#8221;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended,
or the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>EXHIBIT INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: justify"><b><span style="text-decoration:underline;text-decoration: none">Exhibit No.</span></b></td>
    <td style="padding-bottom: 1.5pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 89%; text-align: justify"><b><span style="text-decoration:underline;text-decoration: none">Description</span></b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.1</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea183075ex99-1_inflarxnv.htm">InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Three and Six Months Ended June 30, 2023</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.2</td>
    <td>&#160;</td>
    <td style="text-align: left"><a href="ea183075ex99-2_inflarxnv.htm">InflaRx N.V. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>99.3</td>
    <td>&#160;</td>
    <td><a href="ea183075ex99-3_inflarxnv.htm">InflaRx N.V. Press Release dated August 10, 2023</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.INS</td>
    <td>&#160;</td>
    <td style="text-align: left">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.SCH</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.CAL</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.DEF</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.LAB</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Label Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>101.PRE</td>
    <td>&#160;</td>
    <td>Inline XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font-size: 10pt">&#160;</td>
    <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>INFLARX N.V.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; width: 60%">Date: August 10, 2023</td>
    <td style="vertical-align: bottom; width: 5%">By:</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 35%">/s/ Niels Riedemann</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Name:&#160;</td>
    <td>Niels Riedemann</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>Title:</td>
    <td>Chief Executive Officer</td>
    </tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>





</div><div style="display: none"><!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nzepm4n+0FFuLalVRRIefqUqHDQ9Csy2gg=] CSR-->
<ix:header>
<ix:references><link:schemaRef xlink:href="infrx-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea183075ex99-1_inflarxnv.htm
<DESCRIPTION>INFLARX N.V. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<html xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:compsci="http://compsciresources.com" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:infrx="http://www.inflarx.de.com/20230630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><b>Exhibit 99.1</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
Condensed Consolidated</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statements &#8211; June 30, 2023</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned
subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the &#8220;Group&#8221;).
The financial statements are presented in euros (&#8364;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. is a company limited by shares, incorporated and domiciled in Amsterdam, The Netherlands.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its
registered office and principal place of business is in Germany, Jena, Winzerlaer Str. 2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Index
to Unaudited Condensed Consolidated Financial Statements</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
the three and six months ended June 30, 2023</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in"><a href="#k_001"><span style="font-family: Times New Roman, Times, Serif">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-3</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 85%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif"><a href="#k_002">Unaudited Condensed Consolidated Statements of Financial Position as of June 30, 2023 and December 31, 2022</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-4</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3" style="text-indent: -0.125in; padding-left: 0.125in"><a href="#k_003"><span style="font-family: Times New Roman, Times, Serif">Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity for the six months ended June 30, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-5</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3"><a href="#k_004"><span style="font-family: Times New Roman, Times, Serif">Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2023 and 2022</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-6</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="3"><a href="#k_005"><span style="font-family: Times New Roman, Times, Serif">Notes to the Unaudited Condensed Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-7</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">1.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_006"><span style="font-family: Times New Roman, Times, Serif">Summary of significant accounting policies and other disclosures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-7</span></td></tr>
  <tr style="vertical-align: top; ">
    <td></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td><a href="#k_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting entity and the Group&#8217;s structure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td><a href="#k_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis of preparation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">2.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_009"><span style="font-family: Times New Roman, Times, Serif">Other income</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-8</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">3.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_010"><span style="font-family: Times New Roman, Times, Serif">Net financial result</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-9</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">4.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_011"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-10</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">5.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_012"><span style="font-family: Times New Roman, Times, Serif">Other assets</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-10</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">6.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_013"><span style="font-family: Times New Roman, Times, Serif">Financial assets and financial liabilities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-11</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">7.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_014"><span style="font-family: Times New Roman, Times, Serif">Cash and cash equivalents</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-11</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">8.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_015"><span style="font-family: Times New Roman, Times, Serif">Equity</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-11</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">9.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_016"><span style="font-family: Times New Roman, Times, Serif">Share-based payments</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-11</span></td></tr>
  <tr style="vertical-align: top; ">
    <td></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td>
    <td><a href="#k_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity settled share-based payment arrangements</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-11</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td>
    <td><a href="#k_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment expense recognized</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-12</span></td></tr>
  <tr style="vertical-align: top; ">
    <td></td>
    <td><span style="font-family: Times New Roman, Times, Serif">c)</span></td>
    <td><a href="#k_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options exercised</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-13</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif">10.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_019"><span style="font-family: Times New Roman, Times, Serif">Protective foundation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-13</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif">11.</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td><a href="#k_020"><span style="font-family: Times New Roman, Times, Serif">Subsequent events</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif">F-13</span></td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
Condensed Consolidated Statements of Operations and Comprehensive Loss <br/>
for the three and six months ended June 30, 2023 and 2022</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
the three months<br/>
ended June 30,</b></p>

</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>For
the six months<br/>
ended June 30</b></p>

</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="12" style="font-weight: bold; text-align: right">(in &#8364;, except for share data)</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 6%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur">10,919,595</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur">11,180,958</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur">25,651,503</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="0" unitRef="eur">21,652,881</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur">3,540,805</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur">4,346,965</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur">7,149,359</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="0" unitRef="eur">8,734,408</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sales and marketing expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur">276,051</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SalesAndMarketingExpense" scale="0" unitRef="eur">276,051</ix:nonFraction></td><td style="text-align: left">)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: center">2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur">4,882,908</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur">14,441,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur">12,629,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncome" scale="0" unitRef="eur">14,443,135</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="eur">2,624</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="eur">279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="eur">3,190</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="eur">844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating Result</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" sign="-" unitRef="eur">9,856,168</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" sign="-" unitRef="eur">1,086,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" sign="-" unitRef="eur">20,451,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RevenueAndOperatingIncome" scale="0" sign="-" unitRef="eur">15,944,999</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Finance income</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur">1,087,011</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur">82,401</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur">1,543,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceIncome" scale="0" unitRef="eur">110,362</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Finance expenses</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur">5,052</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur">7,945</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur">10,580</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinanceCosts" scale="0" unitRef="eur">32,531</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Foreign exchange result</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">767,646</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">1,563,580</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="eur">369,664</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">2,291,513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other financial result</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" sign="-" unitRef="eur">195,567</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" sign="-" unitRef="eur">86,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" unitRef="eur">2,241</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncomeCost" scale="0" unitRef="eur">39,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income Taxes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income (Loss) for the Period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">8,202,130</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" unitRef="eur">465,376</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">19,285,963</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">13,536,654</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">Share Information</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in">Weighted average number of shares outstanding</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">56,985,734</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">44,203,763</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">50,912,459</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:WeightedAverageShares" scale="0" unitRef="shares">44,203,763</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><div style="-sec-ix-hidden: hidden-fact-9; -sec-ix-hidden: hidden-fact-8; -sec-ix-hidden: hidden-fact-7; -sec-ix-hidden: hidden-fact-6">Income (Loss) per share (basic/diluted)</div></td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares">0.14</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" unitRef="eurPershares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares">0.38</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" sign="-" unitRef="eurPershares">0.31</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1" scale="0" sign="-" unitRef="eur">330</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1" scale="0" unitRef="eur">4,408,940</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1" scale="0" sign="-" unitRef="eur">17,116</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1" scale="0" unitRef="eur">5,718,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Comprehensive Income (Loss)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">8,202,460</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="eur">4,874,316</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">19,303,079</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">7,817,839</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt">&#160;</p><div>

</div><div><a id="k_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
Condensed Consolidated Statements of Financial Position <br/>
as of June 30, 2023 and December 31, 2022</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">June 30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Note</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">(unaudited)</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">(in &#8364;)</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Non-current assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 69%; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Property
    and equipment</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 6%; text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="eur">296,382</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PropertyPlantAndEquipment" scale="0" unitRef="eur">328,920</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Right-of-use
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="eur">1,122,183</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RightofuseAssets" scale="0" unitRef="eur">1,311,809</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Intangible
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" unitRef="eur">90,789</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="0" unitRef="eur">138,905</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="0" unitRef="eur">283,784</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherAssets" scale="0" unitRef="eur">308,066</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Financial
    assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="0" unitRef="eur">18,951,267</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentFinancialAssets" scale="0" unitRef="eur">2,900,902</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    non-current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="eur">20,744,405</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentAssets" scale="0" unitRef="eur">4,988,602</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Inventories</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Inventories" scale="0" unitRef="eur">578,705</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: hidden-fact-10; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    other assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">5</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="eur">6,405,867</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentAssets" scale="0" unitRef="eur">14,170,510</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxAssets" scale="0" unitRef="eur">2,925,037</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentTaxAssets" scale="0" unitRef="eur">1,432,087</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Financial
    assets from government grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="eur">5,193,246</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinancialAssets" scale="0" unitRef="eur">732,971</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    financial assets</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="0" unitRef="eur">77,601,286</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinancialAssets" scale="0" unitRef="eur">64,810,135</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Cash and
    cash equivalents</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">7</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">19,515,959</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">16,265,355</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="eur">112,220,100</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssets" scale="0" unitRef="eur">97,411,058</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    ASSETS</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="eur">132,964,505</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Assets" scale="0" unitRef="eur">102,399,660</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">EQUITY
    AND LIABILITIES</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Equity</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Issued
    capital</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="eur">7,065,993</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssuedCapital" scale="0" unitRef="eur">5,364,452</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Share premium</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">8</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="0" unitRef="eur">334,211,338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:SharePremium" scale="0" unitRef="eur">282,552,633</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    capital reserves</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="eur">38,874,961</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherReserves" scale="0" unitRef="eur">36,635,564</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="eur">262,746,253</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:RetainedEarnings" scale="0" sign="-" unitRef="eur">243,460,290</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    components of equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="0" unitRef="eur">7,239,965</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherEquityInterest" scale="0" unitRef="eur">7,257,081</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur">124,646,004</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="0" unitRef="eur">88,349,440</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur">814,560</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:LeaseLiabilities" scale="0" unitRef="eur">987,307</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="0" unitRef="eur">36,877</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherLiabilities" scale="0" unitRef="eur">36,877</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    non-current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="eur">851,437</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentLiabilities" scale="0" unitRef="eur">1,024,184</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Current
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Trade
    and other payables</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="eur">5,200,809</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="0" unitRef="eur">4,987,538</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Liabilities
    from government grants</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="0" unitRef="eur">801,632</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentNonfinancialLiabilities" scale="0" unitRef="eur">6,209,266</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Lease
    liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">6</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="eur">356,099</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLeaseLiabilities" scale="0" unitRef="eur">369,376</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Employee
    benefits</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="0" unitRef="eur">900,474</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShorttermEmployeeBenefitsAccruals" scale="0" unitRef="eur">1,312,248</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Other
    liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="eur">208,051</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentLiabilities" scale="0" unitRef="eur">147,608</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="eur">7,467,065</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentLiabilities" scale="0" unitRef="eur">13,026,036</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="eur">8,318,502</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:Liabilities" scale="0" unitRef="eur">14,050,220</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">TOTAL
    EQUITY AND LIABILITIES</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="0" unitRef="eur">132,964,505</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAndLiabilities" scale="0" unitRef="eur">102,399,660</ix:nonFraction></span></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 4; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity<br/>
 for the six months ended June 30, 2023 and 2022</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">(in &#8364;, except for share data)</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; text-indent: 0pt">Note</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Shares <br/>outstanding</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Issued capital</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Share <br/>premium</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Other capital reserves</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Accumulated deficit</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Other<br/>
components<br/>
of equity</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; text-indent: 0pt">Total equity</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in; font-weight: bold; text-align: center">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; font-weight: bold; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td colspan="2" style="padding: 0pt; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; width: 23%; font-weight: bold; text-indent: -0.125in">Balance as of January 1, 2023</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 6%; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c6" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">44,703,763</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">5,364,452</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">282,552,633</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">36,635,564</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="eur">243,460,290</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">7,257,081</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 1%; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; width: 1%; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; width: 7%; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">88,349,440</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in">Loss for the period</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">19,285,963</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">19,285,963</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in; text-align: left">Exchange differences on translation of foreign currency</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-18">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" sign="-" unitRef="eur">17,116</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" sign="-" unitRef="eur">17,116</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-weight: bold; text-align: left; text-indent: -0.125in">Total comprehensive loss</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-19">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">19,285,963</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">17,116</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">19,303,079</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in">Issuance of common shares</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">8</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="infrx:IssuanceOfCommonSharesAndWarrants" scale="0" unitRef="shares">14,059,252</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur">1,687,110</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur">54,796,819</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-22">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-23">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-24">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IssueOfEquity" scale="0" unitRef="eur">56,483,929</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in">Transaction costs</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">8</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-25">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur">3,360,626</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-27">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-28">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ShareIssueRelatedCost" scale="0" unitRef="eur">3,360,626</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in">Equity-settled share-based payments</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">9</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-29">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur">2,239,397</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-31">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-32">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur">2,239,397</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in">Share options exercised</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">9</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="infrx:ShareOptionsExercised" scale="0" unitRef="shares">120,257</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur">14,431</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur">222,512</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-33">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="0" unitRef="eur">236,943</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-weight: bold; text-indent: -0.125in">Balance as of June 30, 2023*</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" id="ix_0_fact" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">58,883,272</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">7,065,993</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" id="ix_2_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">334,211,338</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" id="ix_3_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">38,874,961</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" id="ix_4_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="eur">262,746,253</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" id="ix_5_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">7,239,965</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" id="ix_6_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">124,646,004</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-weight: bold; text-indent: -0.125in">Balance as of January 1, 2022</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c24" decimals="INF" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">44,203,763</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">5,304,452</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">280,310,744</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">30,591,209</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="eur">213,975,679</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">3,050,271</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">105,280,996</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in">Loss for the period</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-36">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-37">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-38">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">13,536,654</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-39">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLoss" scale="0" sign="-" unitRef="eur">13,536,654</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-indent: -0.125in; text-align: left">Exchange differences on translation of foreign currency</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-40">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-41">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-42">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-43">&#8212;</div></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur">5,718,815</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" scale="0" unitRef="eur">5,718,815</ix:nonFraction></td><td style="padding: 0pt; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-weight: bold; text-align: left; text-indent: -0.125in">Total comprehensive loss</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-44">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-45">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-46">&#8212;</div></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">13,536,654</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" unitRef="eur">5,718,815</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ComprehensiveIncome" scale="0" sign="-" unitRef="eur">7,817,839</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt 0pt 0pt 0.125in; text-align: left; text-indent: -0.125in">Equity-settled share-based payments</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">9</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt">&#8212;</td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-47">&#8212;</div></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-48">&#8212;</div></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur">4,668,481</ix:nonFraction></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-49">&#8212;</div></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><div style="-sec-ix-hidden: hidden-fact-50">&#8212;</div></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: normal; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="0" unitRef="eur">4,668,481</ix:nonFraction></td><td style="padding: 0pt; font-weight: normal; text-align: left; text-indent: 0pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-weight: bold; text-indent: -0.125in">Balance as of June 30, 2022*</td><td style="padding: 0pt; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: center; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c36" decimals="INF" format="ixt:num-dot-decimal" id="ix_7_fact" name="ifrs-full:NumberOfSharesOutstanding" scale="0" unitRef="shares">44,203,763</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" id="ix_8_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">5,304,452</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" id="ix_9_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">280,310,744</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" id="ix_10_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">35,259,689</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" id="ix_11_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" sign="-" unitRef="eur">227,512,333</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">)</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" id="ix_12_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">8,769,086</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; font-weight: bold; text-indent: 0pt">&#160;</td>
    <td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td><td style="padding: 0pt; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right; text-indent: 0pt"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" id="ix_13_fact" name="ifrs-full:EquityAttributableToOwnersOfParent" scale="0" unitRef="eur">102,131,638</ix:nonFraction></td><td style="padding: 0pt; font-weight: bold; text-align: left; text-indent: 0pt">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.4pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unaudited</span></ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<br/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 5; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><div><a id="k_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
Condensed Consolidated Statements of Cash Flows<br/>
 for the six months ended June 30, 2023 and 2022</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended<br/>
June 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2023</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Operating activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">Loss for the period</td><td style="width: 1%">&#160;</td>
    <td style="width: 5%; text-align: center">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="eur">19,285,963</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProfitLossBeforeTax" scale="0" sign="-" unitRef="eur">13,536,654</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments for:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" unitRef="eur">293,328</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="0" unitRef="eur">300,870</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Net finance income</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinanceIncome" scale="0" sign="-" unitRef="eur">1,165,044</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinanceIncome" scale="0" sign="-" unitRef="eur">2,408,345</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Share-based payment expense</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" unitRef="eur">2,239,397</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="0" unitRef="eur">4,668,481</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Net foreign exchange differences</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetForeignExchangeDifferences" scale="0" sign="-" unitRef="eur">23,953</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetForeignExchangeDifferences" scale="0" unitRef="eur">130,347</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets" scale="0" sign="-" unitRef="eur">4,460,274</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets" scale="0" sign="-" unitRef="eur">8,260,503</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Other assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" unitRef="eur">6,295,975</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" scale="0" unitRef="eur">611,843</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Employee benefits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="0" sign="-" unitRef="eur">411,774</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" scale="0" sign="-" unitRef="eur">640,112</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Other liabilities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="0" unitRef="eur">60,443</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities" scale="0" sign="-" unitRef="eur">7,869</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-align: left">Liabilities from government grants received</td><td>&#160;</td>
    <td style="text-align: center">6</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:LiabilitiesFromGovernmentGrants" scale="0" sign="-" unitRef="eur">5,407,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:LiabilitiesFromGovernmentGrants" scale="0" sign="-" unitRef="eur">6,154,865</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="0" unitRef="eur">213,270</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" scale="0" sign="-" unitRef="eur">661,741</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in">Inventories</td><td>&#160;</td>
    <td style="text-align: center">4</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="0" sign="-" unitRef="eur">578,705</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest received</td><td>&#160;</td>
    <td style="text-align: center">3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="eur">556,068</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="0" unitRef="eur">631,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Interest paid</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="eur">10,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="0" unitRef="eur">32,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="eur">21,685,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="0" sign="-" unitRef="eur">25,359,081</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchase of intangible assets, property and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="eur">24,673</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="0" unitRef="eur">9,728</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Purchase of current financial assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfAvailableforsaleFinancialAssets" scale="0" unitRef="eur">83,071,163</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PurchaseOfAvailableforsaleFinancialAssets" scale="0" unitRef="eur">47,031,216</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Proceeds from the maturity of financial assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:ProceedsFromTheMaturityOfFinancialAssets" scale="0" unitRef="eur">55,202,491</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:ProceedsFromTheMaturityOfFinancialAssets" scale="0" unitRef="eur">59,595,044</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash from/(used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" sign="-" unitRef="eur">27,893,346</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="0" unitRef="eur">12,554,101</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Proceeds from issuance of common shares</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:ProceedsFromIssuanceOfCommonShares" scale="0" unitRef="eur">56,483,929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction costs from issuance of common shares</td><td>&#160;</td>
    <td style="text-align: center">8</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="0" unitRef="eur">3,360,626</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Proceeds from exercise of share options</td><td>&#160;</td>
    <td style="text-align: center">9</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="0" unitRef="eur">236,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Repayment of lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:RepaymentOfLeaseLiabilities" scale="0" unitRef="eur">184,791</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:RepaymentOfLeaseLiabilities" scale="0" unitRef="eur">182,014</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Net cash from/(used in) financing activities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" unitRef="eur">53,175,455</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="0" sign="-" unitRef="eur">182,014</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase/(decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" unitRef="eur">3,596,467</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" scale="0" sign="-" unitRef="eur">12,986,995</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Effect of exchange rate changes on cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" sign="-" unitRef="eur">345,862</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="0" unitRef="eur">2,153,152</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">16,265,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">26,249,995</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 4pt">7</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">19,515,959</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CashAndCashEquivalents" scale="0" unitRef="eur">15,416,152</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 6; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p><div>

</div><div><a id="k_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. and subsidiaries</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to the Unaudited Condensed Consolidated Financial Statements</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_006"></a></div><div><a id="k_007"></a></div><div><a id="k_008"></a></div><ix:nonNumeric contextRef="c0" continuedAt="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy-c0_cont_1" escape="true" name="infrx:DisclosureOfSummaryOfSignificantAccountingPolicy"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of significant accounting policies and other disclosures</span></td>
</tr></table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="infrx_DisclosureOfReportingEntityAndGroupsStructure-c0_cont_1" escape="true" name="infrx:DisclosureOfReportingEntityAndGroupsStructure"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
entity and the Group&#8217;s structure</span></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="infrx_DisclosureOfReportingEntityAndGroupsStructure-c0_cont_2" id="infrx_DisclosureOfReportingEntityAndGroupsStructure-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. (the &#8220;Company&#8221; or &#8220;InflaRx&#8221;) is a Dutch public company with limited liability (<i>naamloze vennootschap</i>)
with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company&#8217;s registered office is at Winzerlaer Stra&#223;e 2 in 07745 Jena, Germany.
Since November 10, 2017, InflaRx N.V.&#8217;s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="infrx_DisclosureOfReportingEntityAndGroupsStructure-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize
first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. On April 4, 2023, the US Food and Drug
Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the Company&#8217;s monoclonal anti-C5a antibody
vilobelimab, under the brand name Gohibic, for the treatment of COVID-19 in hospitalized adults. These consolidated financial statements
of InflaRx comprise the Company and its wholly-owned subsidiaries, InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann
Arbor, Michigan, United States (together referred to as the &#8220;Group&#8221;).</span></p></ix:continuation>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of preparation</span></td>
</tr></table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements for the three- and six-month reporting periods ended June 30, 2023, and 2022 have
been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include
all the information and disclosures required in the annual financial statements. Accordingly, this report is to be read in conjunction
with the financial statements in our annual report for the year ended December 31, 2022 on form 20-F.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_3" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the &#8220;Board
of Directors&#8221;) on August 9, 2023.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_4" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are presented in euros (&#8364;). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional
currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. Effective January 1, 2023, the functional currency of InflaRx N.V. changed
from the U.S. dollar to the euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency
of its underlying transactions. This change in functional currency has been accounted for prospectively.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_5" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial information presented in euros have been rounded. Accordingly, numerical figures shown as totals in some tables may not be
an arithmetic aggregation of the figures that precede them or may deviate from other tables.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_6" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies adopted are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial
statements for the year ended December 31, 2022, except for the adoption of new standards effective as of January 1, 2023, as set out
below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_7" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following IFRS standards have been applied starting in Q2 2023 for the first time ever, as no transactions in the scope of these IFRS
standards had been previously recognized and are not expected to have a significant impact on the Company&#8217;s consolidated financial
statements in future periods.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_8" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_7"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 Inventories&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_9" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of cost or their net realizable value. Cost comprises direct materials and, where
applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and
condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less
all estimated costs of completion and costs to be incurred in marketing, selling and distribution.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_10" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_9"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 Revenue from contracts with customers&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_11" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
will be recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer.
An asset is transferred when the customer obtains control of that asset. Revenue will be recognized at the point in time that the control
of the products is transferred to the customer and measured considering return liabilities. As of June 30, 2023, no revenue has been
recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 7; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><ix:continuation id="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy-c0_cont_1"><ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_12" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_13" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_12"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 Insurance Contracts&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_14" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_13"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting
                                            Estimates&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_15" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_14"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_16" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_15"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies -</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_17" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group&#8217;s
consolidated financial statements is being assessed:&#160;</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation continuedAt="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_18" id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_17"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 Leases: Leases on Sale and Leaseback&#160;</span></td></tr></table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory-c0_cont_18"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or
                                            Non-current and Non-current Liabilities with Covenants</span></td></tr></table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_009"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="infrx:DisclosureOfOtherIncomeTextBlock"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_SummaryofotherIncometableTextBlock-c0_cont_1" escape="true" name="infrx:SummaryofotherIncometableTextBlock">Other
income</ix:nonNumeric></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="infrx_SummaryofotherIncometableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended June
    30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>
ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">Other income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt">Income from government grants</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:IncomeFromGovernmentGrants" scale="0" unitRef="eur">4,874,934</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:IncomeFromGovernmentGrants" scale="0" unitRef="eur">14,415,368</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:IncomeFromGovernmentGrants" scale="0" unitRef="eur">12,609,789</ix:nonFraction></td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:IncomeFromGovernmentGrants" scale="0" unitRef="eur">14,415,368</ix:nonFraction></td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; width: 60%">Other</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" scale="0" unitRef="eur">7,974</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" scale="0" unitRef="eur">26,173</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" scale="0" unitRef="eur">19,307</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" scale="0" unitRef="eur">27,767</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherIncomeTotal" scale="0" unitRef="eur">4,882,908</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherIncomeTotal" scale="0" unitRef="eur">14,441,541</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherIncomeTotal" scale="0" unitRef="eur">12,629,096</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherIncomeTotal" scale="0" unitRef="eur">14,443,135</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income for the three months ended June 30, 2023 amounted to &#8364;<ix:nonFraction contextRef="c1" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="6" unitRef="eur">4.9</ix:nonFraction> million (PY: &#8364;<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="6" unitRef="eur">14.4</ix:nonFraction> million) and for the six months ended June
30, 2023 amounted to &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="6" unitRef="eur">12.6</ix:nonFraction> million (PY: &#8364;<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherFinanceIncome" scale="6" unitRef="eur">14.4</ix:nonFraction> million), which is primarily attributable to income recognized from grant payments
received from the German federal government for the development of vilobelimab as treatment for critically ill COVID patients, including
expenses related to clinical development and manufacturing process development. The decrease in income from government grants is primarily
due to a non-recurring catch-up effect of costs incurred in preceding periods for which income recognition was deferred until the three
months ended June 30, 2022 when the recognition criteria were met.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 8; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><div><a id="k_010"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="infrx:DisclosureOfNetFinancialResult"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
financial result</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_ScheduleOfNetFinancialResultTableTextBlock-c0_cont_1" escape="true" name="infrx:ScheduleOfNetFinancialResultTableTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="infrx_ScheduleOfNetFinancialResultTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur">1,087,011</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur">82,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur">1,543,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" scale="0" unitRef="eur">110,362</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur">363</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur">2,243</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur">782</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpense" scale="0" unitRef="eur">22,102</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur">4,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur">5,702</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur">9,798</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="0" unitRef="eur">10,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinancialResult" scale="0" unitRef="eur">1,081,959</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinancialResult" scale="0" unitRef="eur">74,456</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinancialResult" scale="0" unitRef="eur">1,532,467</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:NetFinancialResult" scale="0" unitRef="eur">77,831</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock-c0_cont_1" escape="true" name="infrx:ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Foreign exchange result</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Foreign exchange income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeIncome" scale="0" unitRef="eur">2,090,994</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeIncome" scale="0" unitRef="eur">2,947,221</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeIncome" scale="0" unitRef="eur">2,381,519</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeIncome" scale="0" unitRef="eur">4,057,629</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeExpense" scale="0" unitRef="eur">1,323,348</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeExpense" scale="0" unitRef="eur">1,383,641</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeExpense" scale="0" unitRef="eur">2,751,183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:ForeignExchangeExpense" scale="0" unitRef="eur">1,766,116</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">767,646</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">1,563,580</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" sign="-" unitRef="eur">369,664</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="0" unitRef="eur">2,291,513</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock-c0_cont_1" escape="true" name="infrx:ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock">Foreign
exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx
GmbH and InflaRx N.V.</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Other financial result</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherFinancialResult" scale="0" unitRef="eur">195,567</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherFinancialResult" scale="0" unitRef="eur">86,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherFinancialResult" scale="0" sign="-" unitRef="eur">2,241</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="infrx:OtherFinancialResult" scale="0" sign="-" unitRef="eur">39,000</ix:nonFraction></td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
financial result is attributable to the expected credit loss allowance, which is deducted from the Company&#8217;s current and non-current
financial assets.<span style="clear: both; display: block;"><br/></span></span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_011"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfInventoriesExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory">Inventories</ix:nonNumeric></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_DisclosureOfOperatingSegmentsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" scale="0" unitRef="eur">337,407</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:UnfinishedGoods" scale="0" unitRef="eur">132,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:FinishedGoods" scale="0" unitRef="eur">108,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentFinancialAssets" scale="0" unitRef="eur">578,705</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company valued inventories at manufacturing cost in its consolidated statements of financial position as of June 30, 2023. Inventories
do not include costs relating to production of products before the granting of the EUA for Gohibic (vilobelimab), since those were expensed
in previous reporting periods as research and development expenses in the period incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and the six months ended June 30, 2023, there were <ix:nonFraction contextRef="c1" decimals="0" format="ixt:fixed-zero" name="ifrs-full:ReversalOfInventoryWritedown" scale="0" unitRef="eur"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:fixed-zero" name="ifrs-full:ReversalOfInventoryWritedown" scale="0" unitRef="eur">no</ix:nonFraction></ix:nonFraction> write-downs of inventories.</span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_012"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="infrx:DisclosureOfOtherAssets"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfOtherAssetsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfOtherAssetsExplanatory">Other
assets</ix:nonNumeric></span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:continuation id="_DisclosureOfOtherAssetsExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current other assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:NonPrepaidExpenses" scale="0" unitRef="eur">283,784</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:NonPrepaidExpenses" scale="0" unitRef="eur">308,066</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="0" unitRef="eur">283,784</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherNoncurrentAssets" scale="0" unitRef="eur">308,066</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:PrepaymentsOnResearchDevelopmentProjects" scale="0" unitRef="eur">4,757,771</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:PrepaymentsOnResearchDevelopmentProjects" scale="0" unitRef="eur">9,776,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Prepaid expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" unitRef="eur">1,146,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentPrepaidExpenses" scale="0" unitRef="eur">1,841,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="0" unitRef="eur">501,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentReceivables" scale="0" unitRef="eur">2,552,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:CurrentOtherAssetsTotal" scale="0" unitRef="eur">6,405,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:CurrentOtherAssetsTotal" scale="0" unitRef="eur">14,170,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssetsLiabilities" scale="0" unitRef="eur">6,689,651</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:CurrentAssetsLiabilities" scale="0" unitRef="eur">14,478,577</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, prepayments on research &amp; development projects amounted to &#8364;<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPrepayments" scale="6" unitRef="eur">4.8</ix:nonFraction> million compared to &#8364;<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentPrepayments" scale="6" unitRef="eur">9.8</ix:nonFraction> million as of
December 31, 2022, and consist of prepayments on clinical and R&amp;D material production contracts. The decrease in prepayments results
from manufacturing development activities, which were partly completed in the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses mainly consist of prepaid insurance expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reduction of the amounts in the category &#8220;others&#8221; primarily relate to credit notes issued to the Company by CROs, which were
still outstanding as of December 31, 2022 and were paid in 2023.</span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt">&#160;</p><div>

</div><div><a id="k_013"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and financial liabilities</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30,
2023 and December 31, 2022:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:continuation id="_DisclosureOfFinancialLiabilitiesExplanatory-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssets" scale="0" unitRef="usd">18,951,267</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssets" scale="0" unitRef="usd">2,900,902</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:FinancialAssetsFromGovernmentGrants" scale="0" unitRef="usd">5,193,245</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:FinancialAssetsFromGovernmentGrants" scale="0" unitRef="usd">732,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="usd">77,601,286</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="0" unitRef="usd">64,791,088</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="0" unitRef="usd">801,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:GovernmentGrants" scale="0" unitRef="usd">6,209,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="usd">5,200,809</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:TradeAndOtherPayables" scale="0" unitRef="usd">4,987,538</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to &#8364;<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" scale="6" unitRef="eur">100.7</ix:nonFraction>
million (Level 1). The Group&#8217;s debt instruments at amortized cost consist solely of quoted securities that are graded highly by
credit rating agencies such as S&amp;P Global and, therefore, are considered low credit risk investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, liabilities from government grants amounted to &#8364;<ix:nonFraction contextRef="c4" decimals="-5" format="ixt:num-dot-decimal" name="infrx:AssetsFromGovernmentGrants" scale="6" unitRef="eur">0.8</ix:nonFraction> million. Liabilities from government grants partly comprise
funds received for advance payments to third parties. If goods or services from such third parties have not been received, corresponding
amounts are not recognized as other income. The Company&#8217;s right to retain these funds is contingent on meeting all grant conditions.</span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_014"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="c0" escape="true" name="infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> June 30, 2023 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term deposits</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" scale="0" unitRef="eur">7,825,926</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" scale="0" unitRef="eur">3,422</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Deposits held in euros</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" scale="0" unitRef="eur">6,100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" scale="0" unitRef="eur">13,925,926</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" scale="0" unitRef="eur">3,422</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">3,340,889</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">8,645,014</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Cash held in euros</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">2,249,144</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">7,616,918</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">5,590,033</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="infrx:CashAtBankstotal" scale="0" unitRef="eur">16,261,932</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="0" unitRef="eur">19,515,959</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:OtherCashAndCashEquivalents" scale="0" unitRef="eur">16,265,354</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p><div>

</div><div><a id="k_015"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company issued <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="infrx:CommonSharesSaleAgreement" scale="0" unitRef="shares">3,235,723</ix:nonFraction> ordinary shares under its ATM program resulting in $<ix:nonFraction contextRef="c48" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:Equity" scale="6" unitRef="usd">15.7</ix:nonFraction> million (or &#8364;<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromIssuingOtherEquityInstruments" scale="6" unitRef="eur">14.4</ix:nonFraction> million) in
net proceeds. The existing ATM program expired in July 2023 and no more shares are issuable under this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
an underwritten public offering in April 2023, the Company sold and issued an aggregate of <ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="infrx:SoldCommonSharesThroughAPublicOffering" scale="0" unitRef="shares">10,823,529</ix:nonFraction> ordinary shares, of which <ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="infrx:ShareBasedPaymentTransactions" scale="0" unitRef="shares">1,411,764</ix:nonFraction>
were sold pursuant to the exercise of an overallotment option by the underwriters. The ordinary shares were sold at a price of $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="infrx:SaleOfPricePerShare" scale="0" unitRef="usdPershares">4.25</ix:nonFraction>
per share and have a nominal value of &#8364;<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="infrx:NominalValuePerShare" scale="0" unitRef="eurPershares">0.12</ix:nonFraction> per share. Proceeds of this offering after deducting &#8364;<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromSalesOfInvestmentProperty" scale="6" unitRef="eur">2.5</ix:nonFraction> million ($<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:ProceedsFromSalesOfInvestmentProperty" scale="6" unitRef="usd">2.8</ix:nonFraction> million)
in underwriting discounts amounted to &#8364;<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="eur">39.1</ix:nonFraction> million ($<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:CurrentInvestments" scale="6" unitRef="usd">43.2</ix:nonFraction> million). Other offering expenses amounted to &#8364;<ix:nonFraction contextRef="c49" decimals="-5" format="ixt:num-dot-decimal" name="ifrs-full:OtherExpenseByNature" scale="6" unitRef="eur">0.4</ix:nonFraction> million, resulting
in a total of &#8364;<ix:nonFraction contextRef="c47" decimals="-5" format="ixt:num-dot-decimal" name="infrx:OtherOfferingExpensesTotal" scale="6" unitRef="eur">38.7</ix:nonFraction> million in net proceeds from this offering.</span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt">&#160;</p><div>



</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt"></p><div>

</div><div><a id="k_016"></a></div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1" escape="true" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
payments</span></td>
</tr></table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
settled share-based payment arrangements</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_1" escape="true" name="infrx:SchdeuleOfStockOptionActivityTableTextBlock">Prior
to 2016, InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary
shares of InflaRx N.V. at the time of its IPO in November 2017</ix:nonNumeric>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<ix:continuation continuedAt="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_2" id="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised during the six months ended June 30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c58" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c59" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0pt; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c57" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">148,433</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><div><a id="k_017"></a></div><ix:continuation continuedAt="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2" id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH&#8217;s ordinary shares
to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx
N.V. at the time of its IPO in November 2017:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<ix:continuation continuedAt="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_3" id="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding: 0pt; font-weight: bold">&#160;</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; width: 76%; font-weight: bold">Outstanding as of January 1,</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-indent: 0in">Exercised during the six months ended June 30</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">&#8212;</td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Outstanding as of June 30,</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right"><ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-style: italic; text-align: left">thereof vested</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right"><ix:nonFraction contextRef="c65" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">888,632</ix:nonFraction></td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
also granted share options under the 2017 LTIP subsequently to its IPO in November 2017. <ix:nonNumeric contextRef="c0" name="infrx:CommonSharesDescription">The total number of share options granted during
the six months ended June 30, 2023 under the 2017 LTIP was as follows:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<ix:continuation id="infrx_SchdeuleOfStockOptionActivityTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0in">Total number of options outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c66" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">4,985,523</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c67" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">3,170,046</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Granted during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" scale="0" unitRef="shares">1,567,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" scale="0" unitRef="shares">1,561,666</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in">Exercised during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:num-dot-decimal" name="infrx:ExercisedNumberOfShares" scale="0" unitRef="shares">105,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Forfeited during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="infrx:ForfeitedShares" scale="0" sign="-" unitRef="shares">117,259</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0in">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c70" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">6,447,446</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c71" decimals="INF" format="ixt:num-dot-decimal" name="infrx:OutstandingBalance" scale="0" unitRef="shares">4,614,453</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c68" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">4,788,759</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right"><ix:nonFraction contextRef="c69" decimals="INF" format="ixt:num-dot-decimal" name="infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" scale="0" unitRef="shares">3,306,162</ix:nonFraction></td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock-c0_cont_1" escape="true" name="infrx:ScheduleOfFairValueOfOptionsGrantedTableTextBlock">The
number of share options granted during the six months ended June 30, 2023 under the 2017 LTIP was as follows</ix:nonNumeric>:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<ix:continuation id="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share options
granted 2023</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share price at grant date /</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risk-free rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(interpolated, U.S. sovereign strips curve)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">January 24</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,454,250</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="infrx:FairValuePerOption" scale="0" unitRef="usdPershares">2.11</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="4" format="ixt:num-dot-decimal" name="infrx:FXRateAsOfGrantDate" scale="0" unitRef="usdPershares">0.9008</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="infrx:FairValuePerOptions" scale="0" unitRef="usdPershares">1.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="infrx:SharePriceAtGrantDateExercisePrice" scale="0" unitRef="usdPershares">2.37</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">1.35</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="2" format="ixt:num-dot-decimal" name="infrx:ExpectedLifemidpointBased" scale="0" unitRef="usdPershares">5.30</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c72" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">3.571</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>January 24</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="pure">52,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="infrx:FairValuePerOption" scale="0" unitRef="usdPershares">2.13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="4" format="ixt:num-dot-decimal" name="infrx:FXRateAsOfGrantDate" scale="0" unitRef="usdPershares">0.9008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="infrx:FairValuePerOptions" scale="0" unitRef="usdPershares">1.92</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="infrx:SharePriceAtGrantDateExercisePrice" scale="0" unitRef="usdPershares">2.37</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">1.35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="2" format="ixt:num-dot-decimal" name="infrx:ExpectedLifemidpointBased" scale="0" unitRef="usdPershares">5.50</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c73" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">3.565</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="pure">60,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">3,61</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="4" format="ixt:num-dot-decimal" name="infrx:FXRateAsOfGrantDate" scale="0" unitRef="usdPershares">0.9203</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="infrx:FairValuePerOptions" scale="0" unitRef="usdPershares">3.32</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="infrx:SharePriceAtGrantDateExercisePrice" scale="0" unitRef="usdPershares">4.19</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="4" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" unitRef="pure">1.35</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="2" format="ixt:num-dot-decimal" name="infrx:ExpectedLifemidpointBased" scale="0" unitRef="usdPershares">4.50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c74" decimals="5" format="ixt:num-dot-decimal" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" unitRef="pure">3.820</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,567,250</ix:nonFraction></b></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the <ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,567,250</ix:nonFraction> options granted in the six months ended June 30, 2023 (ended June 30, 2022: <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,561,666</ix:nonFraction>), <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,246,000</ix:nonFraction> options (June 30, 2022: <ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" unitRef="pure">1,362,500</ix:nonFraction>) were granted to members of the executive management or Board of Directors.</span> &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">Expected dividends are nil for all share options listed above. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: justify"><b><i>Share-based payment expense recognized</i></b></td>
</tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, the Company has recognized &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="infrx:SharebasedPaymentExpense" scale="6" unitRef="eur">2.2</ix:nonFraction> million (ended June 30, 2022: &#8364;<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="infrx:ValuationPastGrantAmount" scale="6" unitRef="eur">4.7</ix:nonFraction> million) of share-based
payment expense/(benefit) in the statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the share-based payment awards were dilutive in determining earnings per share due to the Group&#8217;s loss position.</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.95pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.95pt; text-indent: -17.85pt"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></span></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.95pt; text-indent: -17.85pt"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="k_018"></a></div><ix:continuation id="_DisclosureOfSharebasedPaymentArrangementsExplanatory-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
                                            options exercised</i></b></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="pure">105,327</ix:nonFraction> shares (ended June 30, 2022: <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" unitRef="pure">0</ix:nonFraction>) were issued upon the exercise of share options, resulting
in proceeds to the Company in the amount of &#8364;<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="3" unitRef="pure">98</ix:nonFraction> thousand (ended June 30, 2022: <ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="3" unitRef="pure">0</ix:nonFraction>). All share options exercised during the six months
ended June 30, 2023 were granted under the 2017 LTIP.</span></p></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_019"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="infrx:DisclosureOfProtectiveFoundationExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protective
foundation</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Articles of Association of the Company, up to <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:AuthorisedCapitalCommonSharesone" scale="0" unitRef="shares">110,000,000</ix:nonFraction> ordinary shares and up to <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="infrx:AuthorisdCapitalPreferenceSharesone" scale="0" unitRef="shares">110,000,000</ix:nonFraction> preferred shares with a nominal
value of &#8364;<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="infrx:PricePerShares" scale="0" unitRef="eurPershares">0.12</ix:nonFraction> per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to deter acquisition bids, the Company`s shareholders approved the right of an independent foundation under Dutch law, or protective
foundation, to exercise a call option on preferred shares. Pursuant to the call option agreement, the Company shall issue an amount of
preferred shares to the protective foundation, amounting to up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="infrx:PercentageOfIssuedCapital" scale="-2" unitRef="pure">100</ix:nonFraction>% of the Company&#8217;s issued capital held by others than the
protective foundation, minus one share. In order to exercise its right to such share issue, the protective foundation is expected to
enter into a finance arrangement with a bank, or subject to applicable restrictions under Dutch law, the protective foundation may request
the Company to provide, or cause the Company&#8217;s subsidiaries to provide, sufficient funding to the protective foundation to enable
it to satisfy its payment obligation under the call option agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
preferred shares will have both a liquidation and dividend preference over the Company`s ordinary shares and will accrue cash dividends
at a pre-determined rate. The protective foundation would be expected to require us to cancel its preferred shares once the perceived
threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. We believe that the call option
does not represent a significant fair value based on a Level 3 valuation, since the preference shares are restricted in use and can be
canceled by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company expensed &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="eur">45</ix:nonFraction> thousand (2022: &#8364;<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="ifrs-full:EmployeeBenefitsExpense" scale="3" unitRef="eur">30</ix:nonFraction> thousand) of ongoing costs to reimburse expenses
incurred by the protective foundation.</span></p></ix:nonNumeric><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 14.2pt; text-indent: -14.2pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="k_020"></a></div><ix:nonNumeric contextRef="c0" escape="true" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
events</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 1, 2023, Dr. Camilla Chong was appointed the Company&#8217;s Chief Medical Officer.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-13</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c2" id="hidden-fact-0" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-1" name="ifrs-full:SalesAndMarketingExpense" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-4" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="2" id="hidden-fact-6" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="eurPershares">0.01</ix:nonFraction>
<ix:nonFraction contextRef="c1" decimals="2" id="hidden-fact-7" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">0.14</ix:nonFraction>
<ix:nonFraction contextRef="c3" decimals="2" id="hidden-fact-8" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">0.31</ix:nonFraction>
<ix:nonFraction contextRef="c0" decimals="2" id="hidden-fact-9" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" unitRef="eurPershares">0.38</ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-10" name="ifrs-full:Inventories" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-11" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-13" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-14" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-16" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-17" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-18" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-19" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-20" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-21" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-22" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-23" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-24" name="ifrs-full:IssueOfEquity" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-25" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-26" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-27" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-28" name="ifrs-full:ShareIssueRelatedCost" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-29" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-30" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-31" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-32" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-33" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-34" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c16" id="hidden-fact-35" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-36" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-37" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-38" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-39" name="ifrs-full:ProfitLoss" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-40" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-41" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-42" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-43" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-44" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-45" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-46" name="ifrs-full:ComprehensiveIncome" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-47" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-48" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-49" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-50" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-51" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-52" name="infrx:ProceedsFromIssuanceOfCommonShares" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-53" name="ifrs-full:PaymentsForShareIssueCosts" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-54" name="ifrs-full:ProceedsFromExerciseOfOptions" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-55" name="ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-56" name="infrx:UnfinishedGoods" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="ifrs-full:FinishedGoods" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-58" name="ifrs-full:CurrentFinancialAssets" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c46" id="hidden-fact-59" name="infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal" unitRef="eur" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-60" name="infrx:ExercisedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-61" name="infrx:ExercisedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-62" name="infrx:ExercisedNumberOfShares" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" decimals="0" id="hidden-fact-63" name="infrx:FairValuePerOption" unitRef="usdPershares">361</ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentPeriodEndDate">2023-06-30</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001708688</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="infrx-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources><ix:relationship fromRefs="ix_0_fact ix_1_fact ix_2_fact ix_3_fact ix_4_fact ix_5_fact ix_6_fact ix_7_fact ix_8_fact ix_9_fact ix_10_fact ix_11_fact ix_12_fact ix_13_fact" toRefs="ix_0_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nw3T9YnDj9JC1lF36Nwa1F4Kl/bjH2p4Mk=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInEurosMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInEurosMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-04-01</xbrli:startDate>
    <xbrli:endDate>2023-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">infrx:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">infrx:BoardOfDirectorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">infrx:OptionLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">infrx:OptionLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708688</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:MayThirtyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="eurPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea183075ex99-2_inflarxnv.htm
<DESCRIPTION>INFLARX N.V. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 99.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS<BR>
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This management&rsquo;s discussion and analysis
is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read
this discussion together with our unaudited interim condensed consolidated financial statements, including the notes thereto, for the
three- and six- months ended June 30, 2023 and 2022, respectively, included as Exhibit 99.1 to the Report on Form 6-K to which this discussion
is attached as Exhibit 99.2. We also recommend that you read our &ldquo;ITEM 5. Operating and Financial Review and Prospects&rdquo; and
our audited consolidated financial statements for fiscal year 2022, and the notes thereto, which appear in our Annual Report on Form 20-F
for the year ended December 31, 2022 (the &ldquo;Annual Report&rdquo;) filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;).
In addition, we recommend that you read any public announcements made by InflaRx N.V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion is based on our financial
information prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting
principles in the United States and other jurisdictions. We maintain our books and records in euros. Unless otherwise indicated, all references
to currency amounts in this discussion are in euros. We have made rounding adjustments to some of the figures included in this discussion
and analysis. Accordingly, numerical figures shown as totals in some tables may not be arithmetic aggregations of the figures that precede
them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following discussion includes forward-looking
statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these
forward-looking statements as a result of many factors, including but not limited to those described under &ldquo;ITEM 3. Key Information&ndash;&ndash;Risk
factors&rdquo; in the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Unless otherwise indicated or the context otherwise
requires, all references to &ldquo;InflaRx&rdquo; or the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;ours,&rdquo;
&ldquo;us&rdquo; or similar terms refer to InflaRx N.V. and its subsidiaries InflaRx GmbH and InflaRx Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are a biopharmaceutical company focused on
applying our proprietary anti-C5a and C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors
of the complement activation factor known as C5a and its receptor known as C5aR. C5a is a powerful inflammatory mediator involved in the
progression of a wide variety of autoimmune and other inflammatory diseases. Our lead product candidate, vilobelimab, is a novel intravenously
delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical
activity and tolerability in multiple clinical settings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Gohibic (vilobelimab) for the treatment
of critically ill COVID-19 patients</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In April 2023, we received an Emergency Use Authorization
(EUA) from the U.S. Food and Drug Administration (FDA) for Gohibic (vilobelimab) for the treatment of critically ill, invasively mechanically
ventilated COVID-19 patients. Specifically, we received an EUA for the treatment of COVID-19 in hospitalized adults when initiated within
48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO). Gohibic (vilobelimab) is not
FDA-approved for any indication, including for the treatment of COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The EUA is supported by the previously announced
results of the multicenter Phase III PANAMO trial. PANAMO is one of the largest 1:1 randomized, double-blind placebo-controlled trials
in IMV COVID-19 patients in intensive care units. A total of 369 patients were randomly assigned to the vilobelimab treatment group (six
800 mg infusions) or the placebo group. Both groups also received standard of care, which included treatment with anticoagulants, corticosteroids
like dexamethasone and other immunomodulators. The data showed that the vilobelimab treatment improved survival with a relative reduction
in 28-day all-cause mortality by 23.9% compared to the placebo in the global data set. The data were published in The Lancet Respiratory
Medicine in September 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June 2023, we began the commercialization
of Gohibic (vilobelimab) in the United States for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving
IMV or ECMO. For this, we have hired and are continuing to hire U.S. experts with relevant experience in the commercialization of medical
products in the hospital market, including in the areas of sales, sales operations, marketing, market access, distribution and others.
Notably, we hired Dr. Camilla Chong as our Chief Medical Officer, who will also be supporting the commercialization efforts in the United
States through her responsibility for medical affairs. In addition, we are building the necessary infrastructure, including IT systems,
supply chain, financial reporting systems and inventory management systems both, internally and with the assistance of external service
providers. In June 2023, we announced that Gohibic (vilobelimab) was available in the United States. In connection with such announcement,
we entered into agreements with certain subsidiaries of AmerisourceBergen Corp., which will act as our U.S. distributor and make Gohibic
(vilobelimab) available for order by U.S. hospital customers under the EUA. AmerisourceBergen Corp. will provide cold storage, cold-chain
distribution services, inventory management and secondary labeling/packaging, among other services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In parallel, as part of our launch plan, we are
finalizing our commercial strategic plan, building our sales force and medical affairs teams, preparing relevant promotional and medical
education materials to target healthcare providers and other stakeholders, refining our medical affairs strategy to increase scientific
awareness of the EUA within the target customers, and implementing a commercial strategy to allow for first revenues from sales of Gohibic
(vilobelimab) in the United States from Q3 onwards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To achieve full commercial scale and successfully
exploit the full market potential of the product in the future, we also aspire to obtain full market approval for Gohibic (vilobelimab).
We are therefore continuing discussions with the FDA related to a submission of a Biologics License Applications (BLA) for full approval
of Gohibic (vilobelimab) in our COVID-19 indication and potentially, in the future, in similar indications that may apply to other virally
induced acute respiratory distress conditions. We are also advancing our plans to prepare a submission for regulatory approval of Gohibic
(vilobelimab) with the European Medicines Agency&rsquo;s (EMA) Committee for Medicinal Products for Human Use (CHMP), which we anticipate
being submitted soon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2021, we announced that we received
a grant of up to &euro;43.7 million from the German Ministry of Education and Research and the German Ministry of Health to support our
development of vilobelimab for the treatment of severe COVID-19 patients. Due to subsequent changes in our research and development plan
and fewer costs projected within the timeframe of the grant, we were notified that the amount available to us is &euro;41.4 million. The
grant is structured as a reimbursement of 80% of certain pre-specified expenses related to the clinical development and manufacturing
of vilobelimab. The grant period ended on June 30, 2023. We expect to receive approximately &euro;5.2 million of the remaining grant amount
during the third quarter. In total, during the duration of the grant period, we were able to claim an amount of &euro; 32.7 million to
support our activities regarding the development of vilobelimab for the treatment of critically ill COVID-19 patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Vilobelimab for the treatment of Pyoderma
Gangrenosum </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing vilobelimab for the treatment
of&nbsp;pyoderma gangraenosum&nbsp;(PG). PG is a rare chronic inflammatory form of neutrophilic dermatosis characterized by accumulation
of neutrophils in the affected skin areas. The exact pathophysiology is not fully understood, but it is postulated that inflammatory cytokine
production, as well as neutrophil activation and dysfunction contribute to a sterile inflammation in the skin. PG often presents as painful
pustules or papules, mainly on the lower extremities, which can rapidly progress to an extremely painful enlarging ulcers. Associated
symptoms include fever, malaise, weight loss and myalgia. PG has a devastating impact on a patient&rsquo;s life due to the severe pain
and induction of significant movement impairment depending on lesions&rsquo; locations. The exact prevalence of PG is not yet known, but
it is estimated that up to 51,000 patients in the United States and Europe are affected by this disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In&nbsp;April 2021,&nbsp;we completed an open-label,
multicenter Phase&nbsp;IIa&nbsp;exploratory study enrolling 19 patients with moderate to severe PG in Canada, the United States and Poland.
The main objectives of this study were to evaluate the safety and efficacy of vilobelimab in three different doses and to determine the
appropriate dose for the future development of vilobelimab in registrational Phase III studies for the treatment of PG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The reported final results showed a dose-dependent
treatment effect, whereby in the highest dose cohort of 2,400 mg, six out of seven patients showed a clinical remission (PGA score &le;
1) and closure of the target ulcer. The seventh patient showed a slight improvement (PGA score 4), with a decrease of the target ulcer
area of over 50%. During the follow-up period, ulcers remained closed two months after treatment completion in all but one patient, and
a sustained suppression of C5a was observed for up to 20 days after the last dosing. Final results&nbsp;from all patients&nbsp;were presented
at the American Academy of Dermatology Association (AAD) Annual Meeting in March 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">With these results, vilobelimab was granted orphan
drug designation for the treatment of PG by both the FDA in the United States and the EMA in Europe, as well as fast-track designation
by the FDA. In January 2023, we announced details related to the design of our pivotal Phase III study with vilobelimab in ulcerative
PG. The design is based on detailed feedback and recommendations from the FDA Division of Dermatology and Dentistry and was developed
in close collaboration with the Company&acute;s medical advisors from the United States, Europe and other regions. The randomized, double-blinded
controlled study will comprise an active arm of 2,400&nbsp;mg of vilobelimab versus its passive arm that will receive a placebo every
other week for a treatment period of 26 weeks. Both arms will be initiated with a low-dose corticosteroid treatment, which will be tapered
off during the first 8 weeks of the treatment period. The study will be conducted with an adaptive trial design, providing for a planned
interim analysis after enrollment of 30 patients (15 per arm). At least 48 patients and up to 90 patients will be enrolled in the trial
and be treated for a period of 26 weeks. Patients dropping out of the treatment will be considered as non-responders to the treatment.
The interim analysis by an independent data safety monitoring committee (blinded for the sponsor and investigators) will consider the
then-observed difference in complete target ulcer closure between the two arms based on a set of predefined rules, and accordingly, the
trial sample size will be continued with a 2:1 randomization in favor of vilobelimab, adapted in size, or the trial will be stopped due
to futility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have submitted a Phase III clinical trial
protocol to the FDA and initiated the preparatory activities for the study, including selection of clinical trial sites, obtaining regulatory
and ethics approvals to conduct the study and expect to start the trial by enrolling patients in the United States, Europe and selected
other regions in Q3 2023. The total enrollment period is projected to be at least two years, depending on the trial size after potential
sample size adaptation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Vilobelimab for the treatment of cutaneous
squamous cell carcinoma (cSCC)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are also developing vilobelimab for the treatment
of PD-1 / PD-L1 inhibitor resistant / refractory, locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). cSCC is the
second most common skin cancer. The incidence of cSCC increases with cumulative sun exposure and age, and individuals with fair skin and
hair are more often affected. The potential for local recurrence or metastasis of cSCC varies with the pathologic variant and localization
of the primary lesion, and the risk for metastasis in cSCC is approximately 2%-5%. Advanced cSCC 10-year survival rates are less than
20% with regional lymph node involvement and less than 10% with distant metastases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the study, which was initiated in April 2021,
we recruted patients in two independent arms, vilobelimab alone (Arm A) and vilobelimab in combination with pembrolizumab (Arm B). The
main objectives of the trial are to assess the safety and antitumor activity of vilobelimab monotherapy, to determine the maximum tolerated
or recommended dose in combination with pembrolizumab, as well as to evaluate the safety and antitumor activity in the combination treatment
arm in cSCC patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date hereof, 10 patients were enrolled
in Arm A, in which they received a run-in dose of 800 mg of vilobelimab on days 1, 4, 8 and 15, followed by a dose of 1,600 mg vilobelimab
every two weeks starting on day 22. An interim analysis in Arm A of the 10 patients was conducted in July 2023 and the treatment responses
in Arm A were evaluated. &#9;The interim efficacy analysis shows that 1 patient showed a complete response and one patient showed stable
disease according to the protocol. One additional patient demonstrated stable disease per &ldquo;Response Evaluation Criteria In Solid
Tumors&rdquo; (RECIST) only. Two of ten patients are still on treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In Arm B, as of the date hereof, three patients
have been treated in the first dosing cohort of the study (400 mg intravenous infusions of vilobelimab on days 1, 4, 8 and 15 and 800
mg from day 22 and every two weeks thereafter, in addition to 400 mg of pembrolizumab on day 8 and every six weeks thereafter). Six patients
were treated at the next higher dose (600 mg intravenous infusions of vilobelimab on days 1, 4, 8 and 15 and 1,200 mg from day 22 and
every two weeks thereafter, in addition to 400 mg of pembrolizumab on day 8 and every six weeks thereafter). In the third dosing cohort,
an additional six patients were treated at the highest planned dose per protocol (800 mg intravenous infusions of vilobelimab on days
1, 4, 8 and 15 and 1,600 mg from day 22 and every two weeks thereafter, in addition to 400 mg of pembrolizumab on day 8 and every six
weeks thereafter). Each dose escalation was done per recommendation and after review of the safety data by an independent study monitoring
committee comprised of external clinical advisors. In total, as of the date hereof, 15 patients were enrolled in Arm B (3+6+6 in the three
dosing cohorts). Before proceeding with the second stage of the study in Arm B, we plan to perform an efficacy interim analysis in Arm
B. We plan to conduct such analysis once all ten patients treated with the maximum tolerated dose identified in stage one, are evaluable
for the response assessment. We expect these data to be available in the first half of 2024. The decision on whether to progress to stage
2 of the study in arms A and/or B will be taken once the efficacy analysis in Arm B has been completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Anti-C5aR inhibitor INF904 </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are developing INF904, an oral small-molecule
drug candidate that targets the C5aR receptor. We plan on targeting complement-mediated, chronic autoimmune and inflammatory conditions
for which an oral small molecule is the preferred route of administration for patients. In our investigational new drug (IND)-enabling
preclinical studies we demonstrated the absence of any obvious toxicological findings even in the highest dose groups in required GLP
toxicity analyses. In these preclinical studies, oral INF904 showed higher plasma exposure in animals, including non-human primates, and
improved inhibitory activity in a hamster neutropenia model compared to the marketed C5aR inhibitor avacopan. Anti-inflammatory therapeutic
effects in several preclinical disease models were also demonstrated by INF904. Further, in contrast to the marketed C5aR inhibitor avacopan,
in vitro experiments showed that INF904 has substantially less inhibition of the cytochrome P450 3A4/5 (CYP3A4/5) enzymes, which play
an important role in the metabolism of a variety of drugs, including glucocorticoids. We are currently conducting a Phase I single (SAD)
and multiple ascending dose (MAD) study in healthy volunteers with the goal of confirming the safety of INF904 and to establish the pharmacokinetic
and pharmacodynamic profile of this development candidate. We plan to show the effect of INF904 on C5a-induced downstream activity and
to generate data in a format comparable with other published data on C5aR inhibitory molecules like avacopan. Results from the SAD part
of the study are expected for Q3 2023 and results from the MAD part of the study are expected in Q4 of 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Anti-C5a antibody IFX002</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To expand the breadth of our anti-C5a technology,
we are also developing IFX002 for the treatment of chronic inflammatory indications. IFX002 shares the same mechanism of action as vilobelimab,
blocking C5a with high specificity, but is designed to have a dosing regimen that may be more suitable for chronic therapy through a potentially
less frequent necessity to administer the product. IFX002 is currently in pre-clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Management changes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Effective April 26, 2023, Ms. Hege Hellstrom
was appointed to the Board of Directos of InflaRx N.V. Mrs. Hellstrom has more than 30 years&rsquo; experience in sales, marketing, strategy
development, commercialization, partner alliances and executive management. Since December 2021, Ms. Hellstrom has been serving as the
Chief Commercial Officer at Advicenne Pharma SA, a French pharmaceutical company specializing in the development of innovative treatments
in Nephrology. In addition, Ms. Hellstrom has been a non-executive board member and audit committee member of Vivesto AB since 2019 and
of Camurus AB since 2020; both are public biopharmaceutical Swedish companies. Ms. Hellstrom has also been the founder and managing director
of Belnor BV, an investment and consulting company, since 2019. From 2013 to 2018, she worked as President for Europe, Middle East, North
Africa and Russia at Sobi, a Swedish biopharmaceutical company, where she led several launches for drugs that threat rare diseases, such
as hemophilia and metabolic diseases. Ms. Hellstrom holds a&nbsp;B.Sc. in biomedical laboratory science from Oslo Metropolitan University,
Norway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">Effective July 1, 2023, we appointed Dr. Camilla
Chong as our Chief Medical Officer. Dr. Chong is a medical doctor with 25 years of experience in the global pharmaceutical industry. She
has successfully led clinical development, medical affairs, clinical operations, regulatory and pharmacovigilance teams and has managed
global clinical development programs. She has extensive experience in the launch of many new pharmaceutical products in multiple geographies.
She joined InflaRx from Kyowa Kirin Corporation, where she was vice president and global medical affairs therapy area head for immunology.
Her previous senior management roles have spanned multiple therapeutic areas, including cardiology, immunology, respiratory, dermatology
and orphan diseases at Pfizer, GlaxoSmithKline and Teva. Dr. Chong received her M.D. degree from the Royal Free Hospital School of Medicine,
University College London, UK. She holds a diploma in pharmaceutical medicine and is a member of the faculty of pharmaceutical medicine
(MFPM).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Financial highlights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2023, we had cash and cash equivalents
of &euro;19.5 million and marketable securities of &euro;95.7 million. We believe that our current funds on hand will be sufficient to
fund our planned operations into 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We anticipate that our expenses might increase
if and as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD>continue to expand the commercialization efforts for Gohibic (vilobelimab) in the United States by investing in our commercial infrastructure
and seek partners to support commercialization of our other products;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>continue to develop and conduct clinical trials with respect to our lead product candidate, vilobelimab;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>continue research, preclinical and clinical development efforts for any future product candidates, including IFX002 and INF904;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>invest in our working capital;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>actively seek to identify additional research programs and additional product candidates;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>pursue full BLA and centralised marketing authorisation applications (MAA) approvals for Gohibic (vilobelimab);</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various products for which
we may obtain marketing approval, if any;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>require the scale-up and validation of the manufacturing process for the commercialization of Gohibic (vilobelimab) including the
manufacturing of larger quantities for the completion of the development activities towards the establishment of a commercial manufacturing
process and for further clinical development;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>collaborate with strategic partners to optimize the manufacturing process for vilobelimab, IFX002, INF904 and other pipeline products;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>maintain, expand and protect our intellectual property portfolio;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>hire and retain additional personnel, such as commercial, administrative, clinical, quality control and scientific personnel; and</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>add operational, financial and management information systems and personnel, including personnel to support our product development
and help us comply with our obligations as a public company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ability to become and remain profitable depends
on our ability to generate revenue. Historically, we had no products or services from which we could generate revenues. In April 2023,
the FDA issued an EUA for the emergency use of Gohibic (vilobelimab) for the treatment of COVID-19 in hospitalized adults. Gohibic (vilobelimab)
is not FDA-approved for any indication, including for the treatment of COVID-19. Subsequently to obtaining the EUA in this indication,
in June 2023 we launched Gohibic (vilobelimab) into the U.S. market by making it available through the ordering channels for hospitals.
In the future, as long as the product is still authorized under the EUA, we may be able to generate limited revenues through sales of
Gohibic (vilobelimab) to U.S. hospitals under the EUA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For this, we are hiring experts with relevant
experience in the commercialization of medical products and are building the necessary commercial and logistical infrastructure internally
and/or with the potential assistance of external partners or service providers. However, in order to achieve full commercial scale and
successfully exploit the full market potential of our products in the future, we or our collaborators will need to obtain full market
approval for Gohibic (vilobelimab) and for our other product candidates in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Successful commercialization of our products and
product candidates will require achievement of key milestones, including successfully completing clinical trials; obtaining marketing
approval for these product candidates; manufacturing, marketing and selling those products for which we, or any of our future collaborators,
may obtain marketing approval; satisfying any post-marketing requirements of the FDA and other regulatory agencies and obtaining reimbursement
for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities,
we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve profitability. We and any future
collaborators may never succeed in these activities, and even if we do, or any future collaborators do, we may never generate revenue
that is large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability
on a quarterly or annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our expenses in any quarter may not be indicative
of our expenses in future periods, and in particular we expect that our expenses, and therefore our net losses, could vary depending on
the going-forward strategy relating to the full regulatory approval of vilobelimab for the treatment of critically ill COVID-19 patients,
our development plans in PG, cSCC and additional indications, as well as for other product candidates like INF904 or any potential addition
of a technology platform or assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accordingly, we may seek to further fund our
operations through public or private equity or debt financings or other sources, including strategic collaborations. We may, however,
be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise
capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability
to develop vilobelimab or any additional product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt">Research and development expenses have consisted
principally of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>expenses incurred under agreements with contract research organizations,
or CROs, and contract manufacturing organizations, or CMOs, consultants and independent contractors that conduct research and development,
preclinical and clinical activities on our behalf;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>employee-related expenses, including salaries, benefits and
stock-based compensation expenses based upon employees&rsquo; roles within the organization; and</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>professional fees for lawyers related to the protection and
maintenance of our intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0pt">Our research and development expenses primarily
relate to the following key programs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left"><B><I>Vilobelimab</I></B>.
We expect our expenses associated with&nbsp;vilobelimab&nbsp;to increase in&nbsp;2023&nbsp;compared to&nbsp;2022,&nbsp;as we&nbsp;are&nbsp;initiating&nbsp;the
Phase III clinical&nbsp;study&nbsp;in&nbsp;PG and conducting&nbsp;our Phase II&nbsp;clinical program in cSCC. In addition, we are incurring,
and expect to further incur, expenses in conjunction with filing market authorizations for vilobelimab in the United States and elsewhere,
including expenses to obtain full BLA and MAA approval for Gohibic (vilobelimab). We might also potentially consider development of vilobelimab
in&nbsp;additional indications. In addition, we are also incurring expenses related to the manufacturing of clinical trial material and&nbsp;by&nbsp;establishing
a commercial scale production process.</TD>
</TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B><I>INF904</I></B><I>. </I>We are also developing INF904,
a product candidate that targets the C5aR receptor. We have been conducting a Phase I single and multiple ascending dose clinical study
since November 2022 and expect to incur additional costs by advancing the development of INF904. We plan to study INF904 in complement-mediated,
chronic autoimmune and inflammatory conditions for which an oral low molecular weight compound might have advantages or is needed for
patients and for which oral delivery is the medically preferred route of administration.</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B><I>IFX002</I></B>.&nbsp;We are also developing IFX002 for
the treatment of chronic inflammatory indications. IFX002 is a highly potent anti-complement C5a antibody with a higher humanization
grade and altered pharmacokinetic properties compared to vilobelimab and is currently in preclinical development. Expenses for this program
mainly consist of salaries, costs for preclinical testing conducted by CROs and costs&nbsp;to produce&nbsp;preclinical material.&nbsp;</TD></TR></TABLE>


<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: left"><B><I>Other development programs</I></B>. Our other research
and development expenses relate to our preclinical studies of other product candidates and discovery activities, expenses for which mainly
consist of salaries, costs for production of preclinical compounds and costs paid to CROs.&nbsp;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2022, we incurred &euro;37.5 million in research
and development expenses. For the six months ended June 30, 2023 and 2022, we incurred research and development expenses of &euro;25.7
million and &euro;21.7 million, respectively. The increase in our research and development expenses was attributable to the completion
of the development activities for vilobelimab for the treatment of critically ill COVID-19 patients, for which the FDA granted an EUA
in April 2023. These expenses comprised of costs attributable to the establishment of a commercial scale manufacturing process for vilobelimab
and regulatory expenses in conjunction with the EUA filing and other regulatory activities, as well as for the manufacturing of clinical
trial-related material. Our research and development expenses may vary substantially from period to period based on the timing of our
research and development activities, including due to timing of clinical trial initiation and enrollment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expense research and development costs as
incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation
of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical
site activations for services received and efforts expended. Research and development activities are central to our business model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The successful development of our product candidates
is highly uncertain. We cannot reasonably and accurately predict the nature, timing and estimated costs of the efforts that will be necessary
to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates.
For a discussion of our other key financial statement line items, please see &ldquo;ITEM 5. Operating and Financial Review and Prospects&mdash;Operating
results&rdquo; in the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>General and administrative expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect that our general and administrative
expenses will increase in the future as our business expands, we initiate commercial operations in conjunction with the recently granted
EUA for Gohibic (vilobelimab), this will not only result in sales and marketing costs, but we believe will also result in an increase
in general and administrative costs. There will also be additional costs associated with operating as a public company. It is expected
that the costs of commercialization will also result in additional personnel, additional consulting costs in the connection of the expansion
of our ERP system and internal and external reporting. Public company-related costs relate primarily to additional personnel, additional
professional and legal fees, audit fees, directors&rsquo; and officers&rsquo; liability insurance premiums and costs associated with investor
relations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2022, we incurred &euro;14.9 million in general
and administrative expenses. For the six months ended June 30, 2023 and 2022, we incurred general and administrative expenses of &euro;7.1
million and &euro;8.7 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Sales and marketing expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the three- and six-months ended June 30, 2023,
we report marketing and sales expenses for the first time. These expenses amounted to &euro;0.3 million in the three- and six-months ended
June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Results of operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information below was derived from our unaudited
interim condensed consolidated financial statements included elsewhere herein. The discussion below should be read along with these unaudited
interim condensed consolidated financial statements and our Annual Report.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.2pt; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">Comparison of the three months ended June 30, 2023 and 2022</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(10,919,595</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(11,180,958</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">261,363</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,540,805</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,346,965</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">806,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Sales and marketing expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(276,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(276,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(14,736,451</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(15,527,923</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">791,472</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,882,908</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,441,541</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,558,633</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,624</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(279</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,345</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating result</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(9,856,168</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,086,661</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,769,507</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,087,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,004,610</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,052</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,945</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,893</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange result</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">767,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(795,934</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other financial result</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(195,567</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(86,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(109,567</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income (loss) for the period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,202,130</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">465,376</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,667,506</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(330</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,408,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,409,270</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive income (loss)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(8,202,460</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,874,316</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(13,076,776</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.85pt; text-indent: -17pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.85pt; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Sales and marketing expenses</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left">Third-party expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">124,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">124,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Legal and consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,051</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,051</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the three-months ended June 30, 2023, we incurred
&euro;0.3 million of sales and marketing espenses. These expenses are primarily comprised of &euro;0.1 million personnel costs and &euro;0.1
external services for distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Research and development expenses</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left">Third-party expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,096,874</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,694,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(597,470</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,798,930</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,117,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(319,045</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Legal and consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">542,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">277,274</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">264,741</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">481,776</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">91,364</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">390,412</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total research and development expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">10,919,596</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,180,958</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(261,362</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We use our employee and infrastructure resources
across multiple research and development programs directed toward developing vilobelimab in different indications and in our pre-clinical
programs. We manage certain activities such as contract research and manufacturing of vilobelimab and our discovery programs through our
third-party vendors. Research and development expenses incurred for the three months ended June 30, 2023 decreased slightly by &euro;0.3
million compared to the three months ended June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 17pt">c)</TD><TD>General and administrative expenses</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Personnel expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,386,945</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,052,710</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(665,765</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal, consulting and audit fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,085,521</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,141,416</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(55,895</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,068,338</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,152,838</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(84,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total general and administrative expense</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,540,805</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,346,965</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(806,160</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses decreased
by &euro;0.8 million to &euro;3.5 million for the three months ended June 30, 2023, from &euro;4.3 million for the three months ended
June 30, 2022. This decrease is attributable to lower expenses associated with equity-settled share-based compensation recognized in personnel
expenses of &euro;0.6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Other income</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Income from government grants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,874,934</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14,415,368</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(9,540,434</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,974</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,173</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,199</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total other income</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,882,908</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,441,541</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(9,558,633</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other income decreased by &euro;9.6 million to
&euro;4.9 million for the three months ended June 30, 2023, from &euro;14.4 million for the three months ended June 30, 2022. The decrease
in income from government grants is primarily due to a non-recurring catch-up effect of costs incurred in preceding periods for which
income recognition was deferred until the three months ended June 30, 2022, when the recognition criteria were met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other income is primarily attributable to income
recognized from the grant payments received from the German federal government for the development of Gohibic (vilobelimab) in severe
COVID-19 cases, including our expenses related to clinical development and manufacturing process development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">e)</TD><TD STYLE="text-align: justify">Net financial result</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Interest income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,087,011</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">82,401</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,004,610</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(363</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,243</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,880</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Interest on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,689</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,702</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Finance result</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,081,959</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">74,456</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,007,503</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,090,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,947,221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(856,227</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Foreign exchange expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,323,348</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,383,641</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">60,293</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Foreign exchange result</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">767,646</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,563,580</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(795,934</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other financial result</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(195,567</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(86,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(109,567</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,654,038</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,552,036</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">102,002</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net financial result increased by &euro;0.1 million
to a gain of &euro;1.7 million for the three months ended June 30, 2023 from a gain of &euro;1.6 million for the three months ended June
30, 2022. This increase is mainly attributable to an increase of interest income on marketable securities by &euro;1.0, which was partially
offset by &euro;0.8 million lower foreign exchange result. Other financial result consists of an adjustment for expected credit losses
on marketable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Comparison of the six months ended June 30, 2023 and 2022</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating expenses</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(25,651,503</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21,652,881</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(3,998,622</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,149,359</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,734,408</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,585,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Sales and marketing expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(276,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(276,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(33,076,914</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(30,387,289</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,689,625</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,629,096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,443,135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,814,039</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,190</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(844</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,346</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating result</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(20,451,007</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(15,944,999</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(4,506,008</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,543,047</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,362</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,432,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,531</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange result</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(369,664</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,291,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,661,177</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other financial result</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,241</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">39,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(36,759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Income (loss) for the period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(19,285,963</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(13,536,654</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(5,749,309</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Exchange differences on translation of foreign currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,718,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,735,931</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total comprehensive income (Loss)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(19,303,079</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(7,817,839</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(11,485,240</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a)</TD><TD STYLE="text-align: justify">Sales and marketing expenses</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold; text-align: left">Third-party expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">124,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">124,930</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,884</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">104,884</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Legal and consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42,891</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,347</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total sales and marketing expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,051</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">276,051</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal">In the
six months ended June 30, 2023 we had incurred &euro;0.3 million of sales and marketing expenses. These expenses are mainly composed of
&euro;0.1 million personnel costs and &euro;0.1 external services for distribution.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b)</TD><TD STYLE="text-align: justify">Research and development expenses</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Third-party expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">20,500,002</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16,782,955</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,717,047</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Personnel expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,410,009</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,225,598</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(815,589</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Legal and consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,087,166</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">471,361</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">615,805</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">654,327</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">172,967</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">481,360</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total research and development expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">25,651,503</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">21,652,881</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,998,622</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We use our employee and infrastructure resources
across multiple research and development programs directed toward developing vilobelimab and our pre-clinical programs. We manage certain
activities such as contract research and manufacturing of vilobelimab and our discovery programs through our third-party vendors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Research and development expenses incurred for
the six months ended June 30, 2023 increased compared to the corresponding period in 2022 by &euro;4.0 million. This increase was primarily
due to higher expenses in conjunction with our EUA application of vilobelimab in COVID-19. The main driver were costs related to manufacturing
development and regulatory activities and was driven by an overall increase in third-party expenses of &euro;3.7 million. The &euro;0.8
million decrease in personnel expenses was mainly related to equity-settled share-based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c)</TD><TD STYLE="text-align: justify">General and administrative expenses</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Personnel expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,992,950</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,529,727</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,536,777</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal, consulting and audit fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,071,433</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,911,707</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,084,976</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,292,974</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(207,998</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total general and administrative expense</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,149,359</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">8,734,408</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,585,049</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">General and administrative expenses decreased
by &euro;1.6 million to &euro;7.1 million for the six months ended June 30, 2023, from &euro;8.7 million for the six months ended June
30, 2022. This decrease is primarily attributable to a decrease in expenses associated with equity-settled share-based compensation recognized
in personnel expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d)</TD><TD STYLE="text-align: justify">Other income</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Income from government grants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">12,609,789</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">14,415,368</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(1,805,579</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Other</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">19,307</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,767</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,460</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Total other income</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,629,096</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,443,135</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,814,039</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other income decreased by &euro;1.8 million to
&euro;12.6 million for the six months ended June 30, 2023, from &euro;14.4 million for the six months ended June 30, 2022. The decrease
in income from government grants is primarily due to a non-recurring catch-up effect of costs incurred in preceding periods for which
income recognition was deferred until the three months ended June 30, 2022 when the recognition criteria were met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Other income is primarily attributable to income
recognized from the grant payments received from the German federal government for the development of Gohibic (vilobelimab) in severe
COVID-19 cases, including our expenses related to clinical development and manufacturing process development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">e)</TD><TD STYLE="text-align: justify">Net financial result</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Interest income</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,543,047</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">110,362</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,432,685</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(782</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,102</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,320</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Interest on lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,798</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,429</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">631</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Finance Result</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,532,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">77,831</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,454,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Foreign exchange income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,381,519</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,057,629</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,676,110</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Foreign exchange expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,751,183</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,766,116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(985,067</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Foreign exchange result</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(369,664</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,291,513</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,661,177</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Other financial result</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,241</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">39,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(36,759</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net financial result</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,165,044</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,408,344</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(1,243,300</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net financial result decreased by &euro;1.2 million
to &euro;1.2 million for the six months ended June 30, 2023, from &euro;2.4 million for the six months ended June 30, 2022. This decrease
was mainly attributable to lower foreign exchange results which decreased by &euro;2.7 million, partly compensated by the increase in
interest income of &euro;1.4&nbsp;million due to increased interest payments from marketable securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Liquidity and capital resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Since inception, we have incurred significant
operating losses. For the six months ended June 30, 2023, we incurred a net loss of &euro;19.3 million. To date, we have financed our
operations primarily through the sale of our securities. As of June 30, 2023, we had cash, cash equivalents in the amount of &euro;19.5
million and financial assets in the amount of &euro;101.7 million, comprised of marketable securities in the amount of &euro;95.7 million
and other financial assets amounting to &euro;6.1 million, including receivables from our governmental grant. Our cash and cash equivalents
primarily consist of bank deposit accounts and fixed U.S. dollar term deposits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Cash flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The table below summarizes our consolidated statement
of cash flows for the six months ended June 30, 2023 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">six months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21,685,642</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(25,359,081</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash from investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,893,346</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,554,101</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash from/ (used in) financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,175,455</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(182,014</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash and cash equivalents at the beginning of the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,265,355</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,249,995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Exchange gains on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(345,862</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,153,152</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at the end of the period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,515,959</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,416,152</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Net cash used in operating activities</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The use of cash in all periods resulted primarily
from our net losses, adjusted for noncash charges and changes in components of working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash used in operating activities decreased
to &euro;21.7 million in the six months ended June 30, 2023, from &euro;25.4 million in the six months ended June 30, 2022.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.2pt; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">Net cash from/used in investing activities</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash from investing activities decreased
by &euro;40.4 million in the six months ended June 30, 2023, mainly due to higher investments in marketable securities in the three months
ended June 30, 2023 compared to the three months ended June 30, 2022.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.2pt; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">Net cash from/used in financing activities</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Net cash from financing activities increased
by &euro;53.5 million in the six months ended June 30, 2023, compared to the six months ended June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the six months ended June 30, 2023, we issued
an additional 3,235,723 ordinary shares under our at-the-market program (refer to Note 8 &ldquo;Equity&rdquo;), resulting in &euro;14.4
million in net proceeds. The existing ATM program expired in July 2023 and no more shares are issuable under this program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Through an underwritten public offering in April
2023, the Company sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764 were sold pursuant to the exercise of
an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25 per share and have a nominal value of &euro;0.12
per share. Proceeds of this offering after deducting &euro;2.5 million ($2.8 million) in underwriting discounts amounted to &euro;39.1
million ($43.2 million). Other offering expenses amounted to &euro;0.4 million, resulting in a total of &euro;38.7 million in net proceeds
from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Funding requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We expect our expenses associated with&nbsp;vilobelimab&nbsp;to
increase in&nbsp;2023 compared to&nbsp;2022,&nbsp;as we continue discussion with the FDA related to submission of a BLA for full approval
of Gohibic (vilobelimab) in severe COVID-19, pursue commercialization of Gohibic (vilobelimab) under the EUA for emergency use as granted
by the FDA, complete developing vilobelimab in other indications, including PG in our Phase III trial, and&nbsp;continue the Phase II
clinical program in cSCC. In addition, we are also incurring expenses related to the manufacturing of clinical trial material and by validating
our manufacturing process for vilobelimab to meet regulatory standards for approval as a commercial grade manufacturing process. Furthermore,
we also have established commercial scale production options and are initiating manufacturing campaigns to be able to serve the market
needs in the United States under the granted the EUA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We also plan to advance the development of INF904
by completing the ongoing Phase I clinical program consisting of a SAD and a MAD arm in H2 2023. In parallel, we are also continuing with
non-clinical development activities in relation to CMC and additional non-clinical animal studies in order to prepare for the future initiation
of a Phase II clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If clinical data is supportive, we may seek marketing
approval for any product candidates that we successfully develop. Additionally, we will validate and further develop the manufacturing
process of our products to be able to apply for marketing authorization and to be able to provide a commercial-grade product. If we obtain
marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing
sales, marketing, distribution, and other commercial infrastructure to commercialize such products. We will need to obtain substantial
additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms,
we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. We believe
that our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure
requirements under our current business plan into 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Until such time, if ever, that we can generate
substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty-based
financings, future collaborations, strategic alliances, licensing arrangements and revenues from product sales. To the extent that we
raise additional capital through the sale of equity or convertible debt securities, the interest of our current shareholders will be diluted,
and the terms of these securities may include voting or other rights that adversely affect your rights as a common shareholder. Debt financing,
if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures, or declaring dividends. If we raise funds through additional collaborations, strategic alliances
or licensing arrangements with third parties, we may have to relinquish rights to our technologies, future revenue streams, research programs
or product candidates, or grant licenses on terms that may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For more information as to the risks associated
with our future funding needs, see &ldquo;ITEM 3. Key Information&ndash;&ndash;Risk factors&rdquo; in our Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Off-balance sheet arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of June 30, 2023, and during the periods presented,
we did not have any off-balance sheet arrangements other as described under &ldquo;ITEM 5. Operating and financial review and prospects&mdash;off-balance
sheet arrangements&rdquo; in our Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Contractual obligations and commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of the date of this discussion and analysis,
we do not have any, and during the periods presented we did not have any, contractual obligations and commitments other than as described
under &ldquo;ITEM 5. Operating and Financial Review and Prospects&mdash;Liquidity and capital resources&ndash;&ndash;Contractual obligations
and commitments&rdquo; in the Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Quantitative and qualitative disclosures about
market risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the six months ended June 30, 2023, there
were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in &ldquo;ITEM 11. Quantitative
and Qualitative Disclosures About Market Risk&rdquo; in the Annual Report <FONT STYLE="font-size: 10pt">and our quarterly report for the
three months ended March 31, 2023 included as Exhibit 99.1 and 99.2 to the Report on Form 6-K, filed on May 11, 2023</FONT>, except as
set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>The manufacturing and distribution of Gohibic
(vilobelimab) is subject to a number of risks that could harm our reputation, business, financial condition and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.25in">The manufacturing and distribution
of Gohibic (vilobelimab) is subject to a number of risks that could harm our reputation, business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Manufacturing: The manufacturing processes of Gohibic (vilobelimab)
is complex. We may encounter manufacturing difficulties, including difficulties related to product storage and shelf life. Such difficulties
could result from the complexities of manufacturing product batches at a larger scale, equipment failure, availability of excipients
and other product components/ingredients (including related to choice and quality of raw materials), analytical testing technology and
product instability. Specifically, insufficient product stability or shelf life of Gohibic (vilobelimab) or its components could materially
limit or delay our or our collaborators&rsquo; ability to distribute and commercialize Gohibic (vilobelimab) at the current price or
at all. Further, if Gohibic (vilobelimab) becomes subject to a product recall, including as the result of manufacturing errors, design/labeling
defects or other deficiencies, our reputation would be adversely affected.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: left">Distribution: Gohibic (vilobelimab) is a &ldquo;cold-chain product&rdquo;
that must be shipped and stored at cold temperatures. We could lose supply of Gohibic (vilobelimab) due to distribution difficulties,
including generally related supply chain management (e.g., shelf-life expiration) and specifically related to shipping and storing Gohibic
(vilobelimab) at cold temperatures. If so, we could incur additional manufacturing costs in order to supply required quantities to U.S.
hospitals under the EUA.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Any such manufacturing and distribution difficulties
may harm our reputation, business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>Our ability to successfully commercialize
and generate revenue from sales of Gohibic (vilobelimab) is subject to a number of risks that could harm our business, financial condition
and operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our ability to successfully commercialize Gohibic
(vilobelimab) is subject to a number of risks that could impact our business, financial condition and operating results. Specifically,
our ability to generate revenue from sales of Gohibic (vilobelimab) is uncertain, including due to the market opportunity for, and interest
and perception in, Gohibic (vilobelimab). In particular, given fluctuations in the number of patients developing severe symptoms from
COVID-19 infections, the size of the addressable patient population and, thus, the market opportunity for Gohibic (vilobelimab) is uncertain
and may shrink over time. In addition, since Gohibic (vilobelimab) has an EUA, but not FDA approval, sales of Gohibic (vilobelimab) depend
on whether healthcare providers at U.S. hospitals are interested in and receptive to providing Gohibic (vilobelimab) as a treatment for
COVID-19. If we are unable to successfully commercialize and generate revenue from sales of Gohibic (vilobelimab), our business, financial
condition and operating results could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Critical judgments and accounting estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There have been no material changes to the significant
accounting policies and estimates described in &ldquo;ITEM 5. Operating and Financial Review and Prospects&mdash;Critical judgments and
accounting estimates&rdquo; in the Annual Report other than a change in the functional currency of the InflaRx N.V. entity from the U.S.
dollar to the euro. Refer to our unaudited interim condensed consolidated financial statements and notes as of June 30, 2023 for additional
information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Cautionary statement regarding forward looking
statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This discussion contains forward-looking statements
that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo;
&ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;believe,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo;
or &ldquo;continue&rdquo; or the negative of these terms or other similar expressions intended to identify statements about the future.
These statements speak only as of the date of this discussion and involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements
expressed or implied by the forward-looking statements. We have based these forward-looking statements largely on our current expectations
and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.
These forward-looking statements include, without limitation, statements about the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the receptiveness of Gohibic (vilobelimab) as a treatment for
COVID-19 by COVID-19 patients and U.S. hospitals;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to commercialize Gohibic (vilobelimab) and our other product candidates;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding the size of the patient populations for, market opportunity
for, estimated returns and return accruals for, coverage and reimbursement for and clinical utility of Gohibic (vilobelimab) in its approved
or authorized indication or for vilobelimab and any other product candidates, under the EUA and in the future if approved for commercial
use in the United States or elsewhere;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the success of our future clinical trials for vilobelimab and any other product
candidates and whether such clinical results will reflect results seen in previously conducted preclinical studies and clinical trials&#894;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>the timing, progress and results of clinical trials of our product candidates,
and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during
which the results of the trials will become available, the costs of such trials and our research and development programs generally;</TD></TR></TABLE>


<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our interactions with regulators regarding the results of clinical trials and
potential regulatory approval pathways, including related to our biologics license application, or BLA, submission for Gohibic (vilobelimab),
and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for any indication;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>whether the FDA, the EMA, or any comparable foreign regulatory authority will
accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary
endpoints for such trials&#894;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our expectations regarding the scope of any approved indication for vilobelimab;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to leverage our proprietary anti-C5a and C5aR technologies to discover and develop therapies to treat complement-mediated
autoimmune and inflammatory diseases;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to protect, maintain and enforce our intellectual property protection
for vilobelimab and any other product candidates, and the scope of such protection;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our manufacturing capabilities and strategy, including the scalability and cost
of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue
to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future
clinical trials and for commercial supply of vilobelimab and for the finished product Gohibic (vilobelimab);</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our estimates of our expenses, ongoing losses, future revenue, capital requirements
and our needs for or ability to obtain additional financing&#894;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to defend against liability claims resulting from the testing of
our product candidates in the clinic or, if, approved, any commercial sales;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>if any of our product candidates obtain regulatory approval, our ability to comply
with and satisfy ongoing obligations and continued regulatory overview&#894;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our ability to comply with enacted and future legislation in seeking marketing
approval and commercialization&#894;</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our future growth and ability to compete, which depends on our retaining key
personnel and recruiting additional qualified personnel&#894; and</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-indent: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>our competitive position and the development of and projections relating to our
competitors in the development of C5a and C5aR inhibitors or our industry.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should
not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking
statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.
You should refer to the &ldquo;ITEM 3. Key Information&ndash;&ndash;Risk factors&rdquo; section of our Annual Report for a discussion
of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.
Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking
statements in this discussion or in our Annual Report will prove to be accurate. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events,
changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports
we will file from time to time with the SEC after the date of this discussion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">15</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ea183075ex99-3_inflarxnv.htm
<DESCRIPTION>INFLARX N.V. PRESS RELEASE DATED AUGUST 10, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit 99.3</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: left; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
Reports Second Quarter 2023<BR>
Financial Results &amp; Operating Update</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-indent: -17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Quarter
                                            highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab)
                                            in the United States</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Oral
                                            C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending dose
                                            (MAD) Phase I trial</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Progress
                                            in clinical development of vilobelimab in other indications, including cutaneous squamous
                                            cell carcinoma (cSCC) and pyoderma gangrenosum (PG)</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Strong
                                            addition to management team as Camilla Chong, M.D., joins as Chief Medical Officer</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 17.85pt; text-indent: -17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Cash,
                                            cash equivalents and marketable securities of &euro;115.2 million, expected to fund operations
                                            at least into 2026</I></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Jena,&nbsp;Germany,&nbsp;August&nbsp;10,&nbsp;2023&nbsp;</B>&ndash;&nbsp;InflaRx&nbsp;N.V.
(Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing and commercializing anti-inflammatory therapeutics by
targeting the complement system, announced today financial results for the three and six months ended June 30, 2023 and provided an
operating update.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&ldquo;It
was truly thrilling to launch Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in the United States
and to be in the position of making our drug available for patients in U.S. hospitals,&rdquo;</I> said Prof. Niels C. Riedemann, Chief
Executive Officer and Founder of InflaRx. <I>&ldquo;Our development work in other disease areas where C5a and C5aR may play a significant
role is progressing well as we strive to make Gohibic (vilobelimab) available to other patients who may benefit from it and to further
our C5aR inhibitor INF904 into research in additional disease areas. Today, we also announced first data from an ongoing clinical trial
in cutaneous squamous cell carcinoma.&rdquo;</I> He continued: <I>&ldquo;With all the important work ahead, I am very pleased that Dr.
Camilla Chong has joined the team to drive our future clinical development work with both vilobelimab and our oral C5aR inhibitor INF904.
With her impressive background in the pharmaceutical industry, including her experience in launching new pharmaceutical products, she
will be instrumental in advancing our complement-targeting therapies through the clinic and ultimately </I>i<I>nto the market.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recent
Highlights and Business Update</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Camilla
Chong, M.D. joins InflaRx as Chief Medical Officer:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
Camilla Chong was appointed as Chief Medical Officer, effective July 1, 2023. She is a medical doctor with 25 years of experience in
the global pharmaceutical industry. Dr. Chong has successfully led clinical development, medical affairs, clinical operations, regulatory
and pharmacovigilance teams and has managed global clinical development programs. She has extensive experience in the launch of many
new pharmaceutical products in multiple geographies. She joined InflaRx from Kyowa Kirin Corporation, where she was Vice President and
Global Medical Affairs Therapy Area Head - Immunology. Dr. Chong is leading all clinical development activities at InflaRx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Commercial
Launch of Gohibic (vilobelimab) for the Treatment of Critically ill COVID-19 Patients following the EUA in the United States:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April 2023, the U.S. Food and Drug Administration (FDA) issued an EUA for Gohibic (vilobelimab) for the treatment of COVID-19 in hospitalized
adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).
Gohibic (vilobelimab) has been commercially available to hospitals across the United States since late Q2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
is building an experienced and highly focused commercial team to support the drug&rsquo;s launch and distribution to hospitals. At the
same time, the Company has set up a robust supply chain to allow for uninterrupted supply of Gohibic to the U.S. market. Lastly, InflaRx
is raising awareness for this treatment option in the medical community through dedicated medical information campaigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further,
the Company is continuing discussions with the FDA related to the submission of a Biologics License Application (BLA) for a potential
future full approval of Gohibic (vilobelimab) in the United States. InflaRx has also completed encouraging meetings with the rapporteur
and co-rapporteur member state teams of the European Committee for Medicinal Products for Human Use (CHMP) related to a planned Marketing
Authorization Application with the European Medicines Agency (EMA). The Company will provide updates on the status of regulatory submissions
in the United States and elsewhere once available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Development
of Vilobelimab in Pyoderma Gangrenosum (PG):</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
January 2023, InflaRx presented details related to the design of its planned pivotal Phase III study with vilobelimab in ulcerative PG,
following compelling Phase II results for the treatment of this rare neutrophilic and inflammatory skin disease with destructive, painful
cutaneous ulcers. The multi-national, randomized, double-blind, placebo-controlled trial has an adaptive design with an interim analysis
that will determine the planned total patient number. InflaRx submitted a Phase III clinical trial protocol to the FDA, initiated the
preparatory activities and expects the first patient to be enrolled in Q3 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><IMG SRC="ex99-3_001.jpg" ALT=""></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>INF904
&ndash; Low Molecular Weight, Oral C5aR Inhibitor:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
is currently conducting a single (SAD) and multiple ascending dose (MAD) Phase I clinical trial in healthy volunteers to assess the safety,
tolerability and pharmacokinetic / pharmacodynamic properties of InflaRx&rsquo; new and proprietary low molecular weight C5aR inhibitor
INF904. The Company plans to show the effect of INF904 on C5a-induced downstream activity and to generate data in a format comparable
with other published data on C5aR inhibitory molecules like avacopan. Results from the SAD part of the study are expected for Q3 2023
and results from the MAD part of the study are expected in Q4 2023. In the future, InflaRx plans to develop INF904 for complement-mediated,
chronic autoimmune and inflammatory diseases where oral administration is the preferred choice for patients.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Initial
Results for Development of Vilobelimab in Cutaneous Squamous Cell Carcinoma:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
is conducting an open-label, multicenter Phase II study, evaluating vilobelimab in two study arms - as stand-alone therapy (Arm A) and
in combination with pembrolizumab (Arm B) - in patients with programmed cell death protein 1 (PD1) or programmed cell death ligand 1
(PDL1) inhibitor resistant/refractory, locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). The main objectives of
this trial are to assess the safety and antitumor activity of vilobelimab in the monotherapy arm and to assess the maximum tolerated
or recommended dose of vilobelimab and the safety and antitumor activity of this drug pair in the combination arm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">An
interim analysis of ten evaluable patients in the monotherapy Arm A, which was not powered for significance due to the small number of
patients in this cohort, showed first evaluable signals of efficacy: one patient had a complete response and another patient displayed
overall stable disease; and a third patient showed stable disease of the target lesion according to &ldquo;Response Evaluation Criteria
In Solid Tumors&rdquo; (RECIST) criteria. Vilobelimab treatment did not result in signals of concern related to safety or tolerability
in these patients with advanced cSCC, who typically are of higher age and frequently suffer from multiple comorbidities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
Arm B, patients are currently being enrolled and treated in the highest dose cohort. An interim analysis is planned to be performed once
ten patients in the highest dose cohort are evaluable for response assessment. So far, six patients have been enrolled, and the interim
results are expected to be available in H1 2024. The decision on whether to progress to stage two of the study in arms A and/or B will
be taken once the efficacy analysis in Arm B has been completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Although
generally, cSCC patients can be effectively treated, some patients become resistant or refractory to current treatment options. Those
patients have very high fatality rates and currently no approved treatment options. Based on these first encouraging activity signals
in this difficult to treat patient population, the Company will decide on next development steps once more results of the combination
arm where patients receive a PD-1 inhibitor in addition to vilobelimab become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Financing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
April 2023, the Company issued 3,235,723 ordinary shares under its ATM program, resulting in &euro;14.4 million in net proceeds. Also
in April 2023, the Company completed an underwritten public offering of an aggregate of 10,823,529 ordinary shares, of which 1,411,764
were sold pursuant to the full exercise of an overallotment option granted to the underwriters. The ordinary shares were sold at a price
of $4.25 per share and have a nominal value of &euro;0.12 per share. Aggregate proceeds from these equity offerings amounted to &euro;53.5
million after deducting underwriting discounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July 12, 2023, InflaRx filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC) in order
to replace its expiring shelf registration statement and to authorize the issuance of up to $250 million in securities in registered
offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
Thomas Taapken, Chief Financial Officer of InflaRx, said: &ldquo;<I>It is an exciting time for InflaRx as we evolve into a commercial-stage
company and build a strong team to support the commercialization of Gohibic. However, with the lower numbers of severe COVID-19 cases,
which we are grateful for, we are expecting moderate demand and first revenues in H2 2023. Thanks to our recent successful financing
activities, we are well positioned to invest in the necessary infrastructure to make Gohibic available to hospitals across the United
States, in addition to supporting our clinical development activities, including the Phase III trial with vilobelimab in pyoderma gangrenosum
and the future development of our promising C5aR inhibitor INF904. Despite a financial market environment that has remained highly challenging,
we are well funded to support our operations well into 2026.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Financial
Highlights &ndash; Q2 2023&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Research
and Development Expenses&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
and development expenses incurred in H1 2023 increased compared to the corresponding period in 2022 by &euro;4.0 million. This increase
was primarily due to higher third-party expenses of &euro;3.7 million related to manufacturing, development and regulatory activities
in conjunction with the EUA application for vilobelimab in COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
and Administrative Expenses&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
and administrative expenses in H1 2023 decreased by &euro;1.6 million to &euro;7.1 million from &euro;8.7 million in H1 2022. This decrease
was primarily attributable to decreasing expenses associated with equity-settled share-based compensation recognized in personnel expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Sales
and Marketing Expenses&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
H1 2023, InflaRx reported sales and marketing expenses for the first time, which amounted to &euro;0.3 million, as a result of the initiation
of the commercialization of Gohibic (vilobelimab). These expenses were mainly comprised of &euro;0.1 million in personnel costs and &euro;0.1
million in external distribution services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Other
Income</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
income, which was primarily derived from income from government grants, decreased by &euro;1.8 million to &euro;12.6 million for the
first half of 2023, from &euro;14.4 million for the comparable period in 2022. The decrease was primarily due to the absence of a non-recurring
catch-up effect of costs incurred in periods before Q2 2022, for which income recognition was deferred until Q3 2022, when the recognition
criteria were considered to be met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Net
Financial Result&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
financial result decreased by &euro;1.2 million to &euro;1.2 million for the six months ended June 30, 2023, from &euro;2.4 million in
the same period of 2022. This decrease was mainly attributable to lower foreign exchange results which decreased by &euro;2.7 million,
partly compensated by the increase in interest income of &euro;1.4&nbsp;million due to increased interest payments from marketable securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Net
Loss&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
loss in H1 2023 amounted to &euro;19.3 million, compared to &euro;13.5 million in H1 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><IMG SRC="ex99-3_001.jpg" ALT=""></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Net
Cash Used in Operating Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
cash used in operating activities in H1 2023 decreased to &euro;21.7 from &euro;25.4 million in H1 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Liquidity
and Capital Resources</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of June 30, 2023, the Company&rsquo;s total available funds were approximately &euro;115.2 million, composed of &euro;19.5 million in
cash and cash equivalents and &euro;95.7 million in marketable securities. These funds are expected to finance operations at least into
2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Additional
Financial Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
information regarding these results and other relevant information is included in the notes to the unaudited interim condensed consolidated
financial statements as of June 30, 2023, and the three and six months ended June 30, 2023, and 2022, as well as the consolidated financial
statements as of and for the year ended December 31, 2022, in &ldquo;ITEM 18. Financial Statements,&rdquo; in InflaRx&rsquo;s Annual
Report on Form 20-F for the year ended December 31, 2022, as filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>InflaRx
N.V. and subsidiaries</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited
Condensed Consolidated Statements of Operations and Comprehensive Loss<BR>
 for the three and six months ended June 30, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For the three months </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ended June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For the six months </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ended June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2023</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2022</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2023</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2022</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center">(in &euro;, except for share data)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(10,919,595</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(11,180,958</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(25,651,503</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(21,652,881</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,540,805</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,346,965</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,149,359</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,734,408</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Sales and marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">(276,051</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">(276,051</TD><TD STYLE="text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left"></TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,882,908</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,441,541</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,629,096</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,443,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,624</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(279</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,190</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(844</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operating Result</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(9,856,168</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,086,661</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(20,451,007</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(15,944,999</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,087,011</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,543,047</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Finance expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,052</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,945</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,580</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,531</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Foreign exchange result</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">767,646</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,563,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(369,664</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,291,513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other financial result</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(195,567</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(86,000</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,241</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Income Taxes</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Income (Loss) for the Period</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(8,202,130</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">465,376</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(19,285,963</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(13,536,654</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Share Information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Weighted average number of shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,985,734</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,203,763</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,912,459</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,203,763</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Income (Loss) per share (basic/diluted)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.14</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.01</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.38</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.31</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exchange differences on translation of foreign currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(330</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,408,940</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,718,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Total Comprehensive Income (Loss)</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(8,202,460</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,874,316</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(19,303,079</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(7,817,839</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>




<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex99-3_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>InflaRx
N.V. and subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited
Condensed Consolidated Statements of Financial Position <BR>
as of June 30, 2023 and December 31, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>June
30,<BR>
2023<BR>
(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Non-current assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Property and equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">296,382</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">328,920</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Right-of-use assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,122,183</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,311,809</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">138,905</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">283,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">308,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Financial assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,951,267</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,900,902</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total non-current assets</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,744,405</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,988,602</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">578,705</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,405,867</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,170,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,925,037</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,732,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financial assets from government grants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,193,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">732,971</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,601,286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,810,135</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,515,959</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,265,355</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total current assets</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">112,220,100</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">97,411,058</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">132,964,505</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">102,399,660</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">EQUITY AND LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issued capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,065,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,364,452</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Share premium</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">334,211,338</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,552,633</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other capital reserves</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,874,961</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,635,564</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(262,746,253</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(243,460,290</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other components of equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,239,965</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,257,081</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">124,646,004</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88,349,440</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">814,560</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">987,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">36,877</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">851,437</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,024,184</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,200,809</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,987,538</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Liabilities from government grants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">801,632</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,209,266</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Lease liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">356,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,376</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Employee benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">900,474</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,312,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">208,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">147,608</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,467,065</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,026,036</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">8,318,502</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">14,050,220</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">TOTAL EQUITY AND LIABILITIES</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">132,964,505</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">102,399,660</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex99-3_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>InflaRx
N.V. and subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited
Condensed Consolidated Statements of Changes in Shareholders&rsquo; Equity <BR>
for the six months ended June 30, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.25in; margin: 0pt 0 0pt 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(in &euro;)</B></FONT></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Issued capital</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>premium</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other capital reserves</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Other</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.9pt; text-align: center; text-indent: -1.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>components</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>of equity</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <BR> equity</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; width: 28%; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balance as of January 1, 2023</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">5,364,452</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">282,552,633</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">36,635,564</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">(243,460,290</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">7,257,081</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">88,349,440</TD><TD STYLE="padding-bottom: 1.5pt; width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,285,963</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(19,285,963</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exchange differences on translation of foreign currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(17,116</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><B>Total comprehensive loss</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>(19,285,963</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>(17,116</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>(19,303,079</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,687,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">54,796,819</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,483,929</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Transaction costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,360,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,360,626</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity-settled share-based payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,239,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,239,397</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">Share options exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14,431</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">222,512</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">236,943</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balance as of June 30, 2023</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,065,993</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">334,211,338</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">38,874,961</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(262,746,253</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">7,239,965</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">124,646,004</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-indent: -0.125in; padding-left: 0.125in">Balance as of January 1, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,304,452</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">280,310,744</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">30,591,209</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(213,975,679</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,050,271</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">105,280,996</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss for the period</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,536,654</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,536,654</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Exchange differences on translation of foreign currency</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,718,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5,718,815</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><B>Total comprehensive loss</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>(13,536,654</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>)</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>5,718,815</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><B>&nbsp;</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><B>(7,817,839</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><B>)</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Equity-settled share-based payments</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,668,481</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,668,481</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Balance as of June 30, 2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,304,452</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">280,310,744</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">35,259,689</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(227,512,333</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,769,086</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">102,131,638</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex99-3_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>InflaRx
N.V. and subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Unaudited
Condensed Consolidated Statements of Cash Flows<BR>
 for the six months ended June 30, 2023 and 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months ended<BR> June 30,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2023</B></FONT></P> <P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2022</B></FONT></P> <P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(unaudited)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">(in &euro;)</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Loss for the period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">(19,285,963</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right">(13,536,654</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Adjustments for:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">293,328</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,870</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net finance income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,165,044</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,408,345</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Share-based payment expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,239,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,668,481</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Net foreign exchange differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,953</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">130,347</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Changes in:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Financial assets from government grants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,460,274</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,260,503</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,295,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">611,843</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Employee benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(411,774</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(640,112</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Other liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,869</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Liabilities from government grants received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,407,634</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,154,865</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Trade and other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,270</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(661,741</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(578,705</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Interest received</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">556,068</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">631,504</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Interest paid</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,777</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(32,039</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(21,685,642</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(25,359,081</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Purchase of intangible assets, property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(24,673</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,728</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Purchase of current financial assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(83,071,163</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(47,031,216</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Proceeds from the maturity of financial assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,202,491</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59,595,044</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net cash from/(used in) investing activities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(27,893,346</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">12,554,101</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Proceeds from issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,483,929</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Transaction costs from issuance of common shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,360,626</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Proceeds from exercise of share options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">236,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Repayment of lease liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(184,791</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(182,014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net cash from/(used in) financing activities</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">53,175,455</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(182,014</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Net increase/(decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,596,467</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,986,995</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Effect of exchange rate changes on cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(345,862</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,153,152</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash and cash equivalents at beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">16,265,355</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">26,249,995</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash and cash equivalents at end of period</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,515,959</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">15,416,152</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ex99-3_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>About
InflaRx</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">InflaRx
(Nasdaq: IFRX) is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover and develop
and commercialize first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known
as C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases.
InflaRx&rsquo; lead product candidate, vilobelimab, is a novel intravenously delivered, first-in-class anti-C5a monoclonal antibody that
selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For
further information, please visit <FONT STYLE="text-decoration: none">www.inflarx.de</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
COVID-19 related work described herein is partly funded by the German Federal Government through grant number 16LW0113 (VILO-COVID).
All responsibility for the content of this work lies with InflaRx.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Contacts:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>InflaRx N.V.</B></FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MC Services AG</B></FONT></TD>
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: <FONT STYLE="text-decoration: none">IR@inflarx.de</FONT></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Katja Arnold, Laurie Doyle, Dr. Regina Lutz</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: <FONT STYLE="text-decoration: none">inflarx@mc-services.eu</FONT></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Europe: +49 89-210 2280</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.: +1-339-832-0752</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><IMG SRC="ex99-3_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.95pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORWARD-LOOKING
STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements,
which are often indicated by terms such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo; or &ldquo;continue,&rdquo; among others. Forward-looking statements
appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things, our ability to commercialize and the receptiveness of Gohibic (vilobelimab)
as a treatment for COVID-19 by COVID-19 patients and U.S. hospitals or our other product candidates; our expectations regarding the size
of the patient populations for, market opportunity for, coverage and reimbursement for, estimated returns and return accruals for, and
clinical utility of Gohibic (vilobelimab) in its approved or authorized indication or for vilobelimab and any other product candidates,
under an EUA and in the future if approved for commercial use in the United States or elsewhere; the success of our future clinical trials
for vilobelimab and any other product candidates and whether such clinical results will reflect results seen in previously conducted
preclinical studies and clinical trials; the timing, progress and results of clinical trials of our product candidates, and statements
regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results
of the trials will become available, the costs of such trials and our research and development programs generally; our interactions with
regulators regarding the results of clinical trials and potential regulatory approval pathways, including related to our BLA submission
for Gohibic (vilobelimab), and our ability to obtain and maintain full regulatory approval of vilobelimab or Gohibic (vilobelimab) for
any indication; whether the FDA, the EMA, or any comparable foreign regulatory authority will accept or agree with the number, design,
size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials; our expectations
regarding the scope of any approved indication for vilobelimab; our ability to leverage our proprietary anti-C5a and C5aR technologies
to discover and develop therapies to treat complement-mediated autoimmune and inflammatory diseases; our ability to protect, maintain
and enforce our intellectual property protection for vilobelimab and any other product candidates, and the scope of such protection;
our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization
of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability
to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of vilobelimab and for
the finished product Gohibic (vilobelimab); our estimates of our expenses, ongoing losses, future revenue, capital requirements and our
needs for or ability to obtain additional financing; our ability to defend against liability claims resulting from the testing of our
product candidates in the clinic or, if approved, any commercial sales; if any of our product candidates obtain regulatory approval,
our ability to comply with and satisfy ongoing obligations and continued regulatory overview; our ability to comply with enacted and
future legislation in seeking marketing approval and commercialization; our future growth and ability to compete, which depends on our
retaining key personnel and recruiting additional qualified personnel; and our competitive position and the development of and projections
relating to our competitors in the development of C5a and C5aR inhibitors or our industry; and the risks, uncertainties and other factors
described under the heading &ldquo;Risk Factors&rdquo; in our periodic filings with the SEC. These statements speak only as of the date
of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results,
performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the
future, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-3_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-3_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  S )\# 2(  A$! Q$!_\0
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M\(W7BG3+9K%E^U6K,51S@.IQD9['@5P_A?X5ZI+JL,^M1+;V<3!F0L&:3';
MZ#WK"?,W9'VF35,MH83VU6W.KWOJ_)),].\%V$FG>$-.AFSYS1>;(6/.YOFY
M_/%;]1M-#&=C21J1V+ 4IEC6/S#(HCQG<3QCZULE96/D*U1U:DJCW;;^\?15
M:#4+.YD,<%U#*X_A1P31J%Q]DTZYN,X\N-F'U IF1R7B/QI)9W;V6G!2T9VO
M*PSSZ"L"#Q3X@,R,+IF#,  R+@_I6=I%NE_KMM#.04DE!<DXR.IKU^);5D$<
M0A*KT5<$"F!S/BWQ!>Z-]CCMG022(6D)4'T_^O5WPEJ=[JVG2W-XP)\S:F%
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M0@HJEJVK6.AZ;-J&HW"P6L(R[M^0'N:YS3?B=X6UB^2RTZ]EN;EP2L<<#DD
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2=& &1G\0*^GJ** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>infrx-20230630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<xs:schema xmlns:infrx="http://www.inflarx.de.com/20230630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.inflarx.de.com/20230630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="infrx-20230630_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="infrx-20230630_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="infrx-20230630_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="infrx-20230630_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome" id="infrx_r_ConsolidatedComprehensiveIncome">
        <link:definition>001 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals" id="infrx_r_ConsolidatedComprehensiveIncome_Parentheticals">
        <link:definition>002 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet" id="infrx_r_ConsolidatedBalanceSheet">
        <link:definition>003 - Statement - Unaudited Condensed Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3" id="infrx_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow" id="infrx_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures" id="infrx_r_SummaryofSignificantAccountingPoliciesandOtherDisclosures">
        <link:definition>006 - Disclosure - Summary of Significant Accounting Policies and Other Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherIncome" id="infrx_r_OtherIncome">
        <link:definition>007 - Disclosure - Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/NetFinancialResult" id="infrx_r_NetFinancialResult">
        <link:definition>008 - Disclosure - Net Financial Result</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/Inventories" id="infrx_r_Inventories">
        <link:definition>009 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherAssets" id="infrx_r_OtherAssets">
        <link:definition>010 - Disclosure - Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities" id="infrx_r_FinancialAssetsandFinancialLiabilities">
        <link:definition>011 - Disclosure - Financial Assets and Financial Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CashandCashEquivalents" id="infrx_r_CashandCashEquivalents">
        <link:definition>012 - Disclosure - Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/Equity" id="infrx_r_Equity">
        <link:definition>013 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ShareBasedPayments" id="infrx_r_ShareBasedPayments">
        <link:definition>014 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ProtectiveFoundation" id="infrx_r_ProtectiveFoundation">
        <link:definition>015 - Disclosure - Protective Foundation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/SubsequentEvents" id="infrx_r_SubsequentEvents">
        <link:definition>016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy" id="infrx_r_AccountingPoliciesByPolicy">
        <link:definition>017 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherIncomeTables" id="infrx_r_OtherIncomeTables">
        <link:definition>018 - Disclosure - Other Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/NetFinancialResultTables" id="infrx_r_NetFinancialResultTables">
        <link:definition>019 - Disclosure - Net Financial Result (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/InventoriesTables" id="infrx_r_InventoriesTables">
        <link:definition>020 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherAssetsTables" id="infrx_r_OtherAssetsTables">
        <link:definition>021 - Disclosure - Other Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables" id="infrx_r_FinancialAssetsandFinancialLiabilitiesTables">
        <link:definition>022 - Disclosure - Financial Assets and Financial Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/CashandCashEquivalentsTables" id="infrx_r_CashandCashEquivalentsTables">
        <link:definition>023 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsTables" id="infrx_r_ShareBasedPaymentsTables">
        <link:definition>024 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherIncomeDetails" id="infrx_r_OtherIncomeDetails">
        <link:definition>025 - Disclosure - Other Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable" id="infrx_r_ScheduleofOtherIncomeTable">
        <link:definition>026 - Disclosure - Other Income (Details) - Schedule of Other Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable" id="infrx_r_ScheduleofNetFinancialResultTable">
        <link:definition>027 - Disclosure - Net Financial Result (Details) - Schedule of Net Financial Result</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable" id="infrx_r_ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable">
        <link:definition>028 - Disclosure - Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable" id="infrx_r_ScheduleofForeignExchangeIncomeandExpenseTable">
        <link:definition>029 - Disclosure - Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/InventoriesDetails" id="infrx_r_InventoriesDetails">
        <link:definition>030 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleInventoriesTable" id="infrx_r_ScheduleInventoriesTable">
        <link:definition>031 - Disclosure - Inventories (Details) - Schedule Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/OtherAssetsDetails" id="infrx_r_OtherAssetsDetails">
        <link:definition>032 - Disclosure - Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nzpqoV921k7GFN39I2H3XAZoC2OuoZDe9M=] CSR-->
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable" id="infrx_r_ScheduleofOtherAssetsTable">
        <link:definition>033 - Disclosure - Other Assets (Details) - Schedule of Other Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails" id="infrx_r_FinancialAssetsandFinancialLiabilitiesDetails">
        <link:definition>034 - Disclosure - Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable" id="infrx_r_ScheduleofFinancialAssetsandliabilitiesTable">
        <link:definition>035 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable" id="infrx_r_ScheduleofCashandCashEquivalentsTable">
        <link:definition>036 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/EquityDetails" id="infrx_r_EquityDetails">
        <link:definition>037 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsDetails" id="infrx_r_ShareBasedPaymentsDetails">
        <link:definition>038 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable" id="infrx_r_ScheduleofStockOptionActivityTable">
        <link:definition>039 - Disclosure - Share-Based Payments (Details) - Schedule of Stock Option Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable" id="infrx_r_ScheduleofFairValueofOptionsGrantedTable">
        <link:definition>040 - Disclosure - Share-Based Payments (Details) - Schedule of Fair Value of Options Granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/ProtectiveFoundationDetails" id="infrx_r_ProtectiveFoundationDetails">
        <link:definition>041 - Disclosure - Protective Foundation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
  <xs:element name="UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
  <xs:element name="ScheduleOfOtherIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfOtherIncomeAbstract"/>
  <xs:element name="ScheduleOfNetFinancialResultAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfNetFinancialResultAbstract"/>
  <xs:element name="ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract"/>
  <xs:element name="ScheduleOfForeignExchangeIncomeAndExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract"/>
  <xs:element name="ScheduleInventoriesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleInventoriesAbstract"/>
  <xs:element name="ScheduleOfOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfOtherAssetsAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
  <xs:element name="DisclosureOfCashAndCashEquivalentsTextBlockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
  <xs:element name="ScheduleOfCashAndCashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueOfOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
  <xs:element name="UnlabeledAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnlabeledAbstract"/>
  <xs:element name="UnlabeledAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnlabeledAbstract0"/>
  <xs:element name="UnlabeledAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnlabeledAbstract1"/>
  <xs:element name="InAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract"/>
  <xs:element name="FinancialIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialIncomeAbstract"/>
  <xs:element name="FinancialExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialExpensesAbstract"/>
  <xs:element name="InAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract0"/>
  <xs:element name="ForeignExchangeResultAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ForeignExchangeResultAbstract"/>
  <xs:element name="InAbstract1" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract1"/>
  <xs:element name="InAbstract2" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract2"/>
  <xs:element name="InAbstract3" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract3"/>
  <xs:element name="NonCurrentOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NonCurrentOtherAssetsAbstract"/>
  <xs:element name="CurrentOtherAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_CurrentOtherAssetsAbstract"/>
  <xs:element name="InAbstract4" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract4"/>
  <xs:element name="FinancialAssetsAtAmortizedCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialAssetsAtAmortizedCostAbstract"/>
  <xs:element name="FinancialLiabilitiesAtAmortizedCostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
  <xs:element name="InAbstract5" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_InAbstract5"/>
  <xs:element name="ShortTermDepositsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShortTermDepositsAbstract"/>
  <xs:element name="CashAtBanksAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_CashAtBanksAbstract"/>
  <xs:element name="ExchangeDifferencesOnTranslationOfForeignCurrency1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1"/>
  <xs:element name="IssuanceOfCommonSharesAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_IssuanceOfCommonSharesAndWarrants"/>
  <xs:element name="ShareOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareOptionsExercised"/>
  <xs:element name="NetFinanceIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_NetFinanceIncome"/>
  <xs:element name="NetForeignExchangeDifferences" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_NetForeignExchangeDifferences"/>
  <xs:element name="AdjustmentsForDecreaseIncreaseInFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets"/>
  <xs:element name="LiabilitiesFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_LiabilitiesFromGovernmentGrants"/>
  <xs:element name="ProceedsFromTheMaturityOfFinancialAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ProceedsFromTheMaturityOfFinancialAssets"/>
  <xs:element name="ProceedsFromIssuanceOfCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ProceedsFromIssuanceOfCommonShares"/>
  <xs:element name="RepaymentOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_RepaymentOfLeaseLiabilities"/>
  <xs:element name="DisclosureOfSummaryOfSignificantAccountingPolicy" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy"/>
  <xs:element name="DisclosureOfOtherIncomeTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfOtherIncomeTextBlock"/>
  <xs:element name="DisclosureOfNetFinancialResult" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfNetFinancialResult"/>
  <xs:element name="DisclosureOfOtherAssets" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfOtherAssets"/>
  <xs:element name="DisclosureOfProtectiveFoundationExplanatory" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfProtectiveFoundationExplanatory"/>
  <xs:element name="DisclosureOfReportingEntityAndGroupsStructure" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfReportingEntityAndGroupsStructure"/>
  <xs:element name="SummaryofotherIncometableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SummaryofotherIncometableTextBlock"/>
  <xs:element name="OtherIncomeTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_OtherIncomeTablesTable"/>
  <xs:element name="OtherIncomeTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherIncomeTablesLineItems"/>
  <xs:element name="ScheduleOfNetFinancialResultTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfNetFinancialResultTableTextBlock"/>
  <xs:element name="ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock"/>
  <xs:element name="ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock"/>
  <xs:element name="DisclosureOfCashAndCashEquivalentsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock"/>
  <xs:element name="SchdeuleOfStockOptionActivityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SchdeuleOfStockOptionActivityTableTextBlock"/>
  <xs:element name="ScheduleOfFairValueOfOptionsGrantedTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock"/>
  <xs:element name="OtherIncomeDetailsScheduleofOtherIncomeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable"/>
  <xs:element name="IncomeFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_IncomeFromGovernmentGrants"/>
  <xs:element name="OtherIncomeTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherIncomeTotal"/>
  <xs:element name="NetFinancialResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_NetFinancialResult"/>
  <xs:element name="ForeignExchangeIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ForeignExchangeIncome"/>
  <xs:element name="ForeignExchangeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ForeignExchangeExpense"/>
  <xs:element name="NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable"/>
  <xs:element name="OtherFinancialResult" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherFinancialResult"/>
  <xs:element name="InventoriesDetailsScheduleInventoriesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_InventoriesDetailsScheduleInventoriesTable"/>
  <xs:element name="UnfinishedGoods" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_UnfinishedGoods"/>
  <xs:element name="NonPrepaidExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_NonPrepaidExpenses"/>
  <xs:element name="PrepaymentsOnResearchDevelopmentProjects" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_PrepaymentsOnResearchDevelopmentProjects"/>
  <xs:element name="CurrentOtherAssetsTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_CurrentOtherAssetsTotal"/>
  <xs:element name="FinancialAssetsFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialAssetsFromGovernmentGrants"/>
  <xs:element name="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable"/>
  <xs:element name="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems"/>
  <xs:element name="ShorttermDepositsClassifiedAsCashEquivalentsTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal"/>
  <xs:element name="CashAtBankstotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_CashAtBankstotal"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems"/>
  <xs:element name="OutstandingBalance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_OutstandingBalance"/>
  <xs:element name="ExercisedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ExercisedNumberOfShares"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares"/>
  <xs:element name="ForfeitedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ForfeitedShares"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable"/>
  <xs:element name="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
  <xs:element name="FairValuePerOption" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FairValuePerOption"/>
  <xs:element name="FXRateAsOfGrantDate" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FXRateAsOfGrantDate"/>
  <xs:element name="FairValuePerOptions" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FairValuePerOptions"/>
  <xs:element name="SharePriceAtGrantDateExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SharePriceAtGrantDateExercisePrice"/>
  <xs:element name="ExpectedLifemidpointBased" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ExpectedLifemidpointBased"/>
  <xs:element name="AssetsFromGovernmentGrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="infrx_AssetsFromGovernmentGrants"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_EquityDetailsLineItems"/>
  <xs:element name="CommonSharesSaleAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_CommonSharesSaleAgreement"/>
  <xs:element name="SoldCommonSharesThroughAPublicOffering" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_SoldCommonSharesThroughAPublicOffering"/>
  <xs:element name="ShareBasedPaymentTransactions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareBasedPaymentTransactions"/>
  <xs:element name="SaleOfPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_SaleOfPricePerShare"/>
  <xs:element name="NominalValuePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_NominalValuePerShare"/>
  <xs:element name="OtherOfferingExpensesTotal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherOfferingExpensesTotal"/>
  <xs:element name="ShareBasedPaymentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_ShareBasedPaymentsDetailsTable"/>
  <xs:element name="ShareBasedPaymentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareBasedPaymentsDetailsLineItems"/>
  <xs:element name="CommonSharesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_CommonSharesDescription"/>
  <xs:element name="SharebasedPaymentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_SharebasedPaymentExpense"/>
  <xs:element name="ValuationPastGrantAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="infrx_ValuationPastGrantAmount"/>
  <xs:element name="ProtectiveFoundationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="infrx_ProtectiveFoundationDetailsTable"/>
  <xs:element name="ProtectiveFoundationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ProtectiveFoundationDetailsLineItems"/>
  <xs:element name="AuthorisedCapitalCommonSharesone" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_AuthorisedCapitalCommonSharesone"/>
  <xs:element name="AuthorisdCapitalPreferenceSharesone" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_AuthorisdCapitalPreferenceSharesone"/>
  <xs:element name="PricePerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="infrx_PricePerShares"/>
  <xs:element name="PercentageOfIssuedCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_PercentageOfIssuedCapital"/>
  <xs:element name="BoardOfDirectorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_BoardOfDirectorsMember"/>
  <xs:element name="DepositsHeldInEurosMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DepositsHeldInEurosMember"/>
  <xs:element name="DepositsHeldInUSDollarsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DepositsHeldInUSDollarsMember"/>
  <xs:element name="JanuaryTwentyFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_JanuaryTwentyFourMember"/>
  <xs:element name="JanuaryTwentyFourOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_JanuaryTwentyFourOneMember"/>
  <xs:element name="MayThirtyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_MayThirtyMember"/>
  <xs:element name="NumberOfShareOptionsUnderThe2012PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NumberOfShareOptionsUnderThe2012PlanMember"/>
  <xs:element name="NumberOfShareOptionsUnderThe2016PlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NumberOfShareOptionsUnderThe2016PlanMember"/>
  <xs:element name="NumberOfShareOptionsUnderTheLTIPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NumberOfShareOptionsUnderTheLTIPMember"/>
  <xs:element name="OptionLTIPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_OptionLTIPMember"/>
  <xs:element name="ChangesInCashFlowAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ChangesInCashFlowAbstract"/>
  <xs:element name="FinancialAssetsAndFinancialLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
  <xs:element name="NetFinancialResultAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NetFinancialResultAbstract"/>
  <xs:element name="NetFinancialResultLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_NetFinancialResultLineItems"/>
  <xs:element name="OtherAssetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherAssetAbstract"/>
  <xs:element name="OtherIncomesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherIncomesAbstract"/>
  <xs:element name="OtherIncomesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_OtherIncomesLineItems"/>
  <xs:element name="ProtectiveFoundationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ProtectiveFoundationAbstract"/>
  <xs:element name="ScheduleOfInventoriesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ScheduleOfInventoriesLineItems"/>
  <xs:element name="ShareBasedPaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareBasedPaymentsAbstract"/>
  <xs:element name="ShareInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_ShareInformationAbstract"/>
  <xs:element name="SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="infrx_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>infrx-20230630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedComprehensiveIncome" roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_OtherIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_SalesAndMarketingExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceCosts" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:href="infrx-20230630.xsd#infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_RightofuseAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssets" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_FinancialAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherFinancialAssets" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_SharePremium" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherReserves" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_RetainedEarnings" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEquityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_OtherEquityInterest" order="5" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nwamwBWh+H+116tig0PATeN11JDIMItMec=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_LeaseLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_OtherLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentNonfinancialLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinanceIncome" xlink:href="infrx-20230630.xsd#infrx_NetFinanceIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="infrx_NetFinanceIncome" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="infrx_NetForeignExchangeDifferences" xlink:href="infrx-20230630.xsd#infrx_NetForeignExchangeDifferences"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="infrx_NetForeignExchangeDifferences" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="infrx_LiabilitiesFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_LiabilitiesFromGovernmentGrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="infrx_LiabilitiesFromGovernmentGrants" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="13" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromTheMaturityOfFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="infrx_ProceedsFromTheMaturityOfFinancialAssets" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromIssuanceOfCommonShares"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="infrx_ProceedsFromIssuanceOfCommonShares" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="infrx_RepaymentOfLeaseLiabilities" xlink:href="infrx-20230630.xsd#infrx_RepaymentOfLeaseLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="infrx_RepaymentOfLeaseLiabilities" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>infrx-20230630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedComprehensiveIncome" roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareholdersEquityType2or3" roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_SummaryofSignificantAccountingPoliciesandOtherDisclosures" roleURI="http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncome" roleURI="http://www.inflarx.de.com/role/OtherIncome"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_NetFinancialResult" roleURI="http://www.inflarx.de.com/role/NetFinancialResult"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_Inventories" roleURI="http://www.inflarx.de.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssets" roleURI="http://www.inflarx.de.com/role/OtherAssets"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilities" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_CashandCashEquivalents" roleURI="http://www.inflarx.de.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_Equity" roleURI="http://www.inflarx.de.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPayments" roleURI="http://www.inflarx.de.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ProtectiveFoundation" roleURI="http://www.inflarx.de.com/role/ProtectiveFoundation"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_SubsequentEvents" roleURI="http://www.inflarx.de.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_AccountingPoliciesByPolicy" roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncomeTables" roleURI="http://www.inflarx.de.com/role/OtherIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_NetFinancialResultTables" roleURI="http://www.inflarx.de.com/role/NetFinancialResultTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_InventoriesTables" roleURI="http://www.inflarx.de.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssetsTables" roleURI="http://www.inflarx.de.com/role/OtherAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilitiesTables" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_CashandCashEquivalentsTables" roleURI="http://www.inflarx.de.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPaymentsTables" roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofOtherIncomeTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofNetFinancialResultTable" roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofForeignExchangeIncomeandExpenseTable" roleURI="http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleInventoriesTable" roleURI="http://www.inflarx.de.com/role/ScheduleInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofOtherAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofFinancialAssetsandliabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofStockOptionActivityTable" roleURI="http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofFairValueofOptionsGrantedTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncomeDetails" roleURI="http://www.inflarx.de.com/role/OtherIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_InventoriesDetails" roleURI="http://www.inflarx.de.com/role/InventoriesDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssetsDetails" roleURI="http://www.inflarx.de.com/role/OtherAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilitiesDetails" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_EquityDetails" roleURI="http://www.inflarx.de.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPaymentsDetails" roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ProtectiveFoundationDetails" roleURI="http://www.inflarx.de.com/role/ProtectiveFoundationDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#DocumentAndEntityInformation" roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_OtherIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_FinanceIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_FinanceCosts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_ProfitLoss" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareInformationAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="infrx_ShareInformationAbstract" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareInformationAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareInformationAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareInformationAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:href="infrx-20230630.xsd#infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEquityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentNonfinancialLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_OtherReservesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_IssuanceOfCommonSharesAndWarrants" xlink:href="infrx-20230630.xsd#infrx_IssuanceOfCommonSharesAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="infrx_IssuanceOfCommonSharesAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareOptionsExercised" xlink:href="infrx-20230630.xsd#infrx_ShareOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="infrx_ShareOptionsExercised" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinanceIncome" xlink:href="infrx-20230630.xsd#infrx_NetFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="infrx_NetFinanceIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NetForeignExchangeDifferences" xlink:href="infrx-20230630.xsd#infrx_NetForeignExchangeDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="infrx_NetForeignExchangeDifferences" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ChangesInCashFlowAbstract" xlink:href="infrx-20230630.xsd#infrx_ChangesInCashFlowAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="infrx_ChangesInCashFlowAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_LiabilitiesFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_LiabilitiesFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="infrx_LiabilitiesFromGovernmentGrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromTheMaturityOfFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="infrx_ProceedsFromTheMaturityOfFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromIssuanceOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="infrx_ProceedsFromIssuanceOfCommonShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_RepaymentOfLeaseLiabilities" xlink:href="infrx-20230630.xsd#infrx_RepaymentOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="infrx_RepaymentOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures">
    <loc xlink:type="locator" xlink:label="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:href="infrx-20230630.xsd#infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfSummaryOfSignificantAccountingPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:to="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncome">
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfOtherIncomeTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherIncomeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherIncomesAbstract" xlink:to="infrx_DisclosureOfOtherIncomeTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NetFinancialResult">
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfNetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfNetFinancialResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NetFinancialResultAbstract" xlink:to="infrx_DisclosureOfNetFinancialResult" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssets">
    <loc xlink:type="locator" xlink:label="infrx_OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfOtherAssets" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherAssetAbstract" xlink:to="infrx_DisclosureOfOtherAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities">
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ProtectiveFoundation">
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationAbstract" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfProtectiveFoundationExplanatory" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfProtectiveFoundationExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationAbstract" xlink:to="infrx_DisclosureOfProtectiveFoundationExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfReportingEntityAndGroupsStructure" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfReportingEntityAndGroupsStructure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="infrx_DisclosureOfReportingEntityAndGroupsStructure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncomeTables">
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTablesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTablesTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_OtherIncomeTablesLineItems" xlink:to="infrx_OtherIncomeTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SummaryofotherIncometableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SummaryofotherIncometableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherIncomeTablesLineItems" xlink:to="infrx_SummaryofotherIncometableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NetFinancialResultTables">
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfNetFinancialResultTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NetFinancialResultAbstract" xlink:to="infrx_ScheduleOfNetFinancialResultTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NetFinancialResultAbstract" xlink:to="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nxUE5U7E/OBV/Bd3GiUi85UGqQispjAqO8=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NetFinancialResultAbstract" xlink:to="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssetsTables">
    <loc xlink:type="locator" xlink:label="infrx_OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherAssetAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CashandCashEquivalentsTables">
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:to="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_SchdeuleOfStockOptionActivityTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SchdeuleOfStockOptionActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsAbstract" xlink:to="infrx_SchdeuleOfStockOptionActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsAbstract" xlink:to="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable">
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeDetailsScheduleofOtherIncomeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_OtherIncomesLineItems" xlink:to="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherIncomesLineItems" xlink:to="us-gaap_OtherIncomeAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_IncomeFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_IncomeFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="infrx_IncomeFromGovernmentGrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTotal" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="infrx_OtherIncomeTotal" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable">
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfNetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialIncomeAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfNetFinancialResultAbstract" xlink:to="infrx_FinancialIncomeAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialExpensesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfNetFinancialResultAbstract" xlink:to="infrx_FinancialExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialExpensesAbstract" xlink:to="ifrs-full_InterestExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialExpensesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialExpensesAbstract" xlink:to="infrx_NetFinancialResult" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable">
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeResultAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:to="infrx_ForeignExchangeResultAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeIncome" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ForeignExchangeResultAbstract" xlink:to="infrx_ForeignExchangeIncome" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeExpense" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ForeignExchangeResultAbstract" xlink:to="infrx_ForeignExchangeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ForeignExchangeResultAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable">
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultLineItems" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_NetFinancialResultLineItems" xlink:to="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherFinancialResult" xlink:href="infrx-20230630.xsd#infrx_OtherFinancialResult"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NetFinancialResultLineItems" xlink:to="infrx_OtherFinancialResult" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleInventoriesTable">
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInventoriesLineItems" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInventoriesLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_InventoriesDetailsScheduleInventoriesTable" xlink:href="infrx-20230630.xsd#infrx_InventoriesDetailsScheduleInventoriesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="infrx_InventoriesDetailsScheduleInventoriesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_InventoriesDetailsScheduleInventoriesTable" xlink:to="ifrs-full_SegmentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_UnfinishedGoods" xlink:href="infrx-20230630.xsd#infrx_UnfinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="infrx_UnfinishedGoods" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_FinishedGoods" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_CurrentFinancialAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable">
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_NonCurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_NonCurrentOtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfOtherAssetsAbstract" xlink:to="infrx_NonCurrentOtherAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NonPrepaidExpenses" xlink:href="infrx-20230630.xsd#infrx_NonPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NonCurrentOtherAssetsAbstract" xlink:to="infrx_NonPrepaidExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_NonCurrentOtherAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfOtherAssetsAbstract" xlink:to="infrx_CurrentOtherAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_PrepaymentsOnResearchDevelopmentProjects" xlink:href="infrx-20230630.xsd#infrx_PrepaymentsOnResearchDevelopmentProjects"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="infrx_PrepaymentsOnResearchDevelopmentProjects" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CurrentOtherAssetsTotal" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="infrx_CurrentOtherAssetsTotal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsLiabilities" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAtAmortizedCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="infrx_FinancialAssetsAtAmortizedCostAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="infrx_FinancialAssetsFromGovernmentGrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrs-full_GovernmentGrants" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_DepositsHeldInUSDollarsMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInUSDollarsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="infrx_DepositsHeldInUSDollarsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_DepositsHeldInEurosMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInEurosMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="infrx_DepositsHeldInEurosMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShortTermDepositsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="infrx_ShortTermDepositsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:href="infrx-20230630.xsd#infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShortTermDepositsAbstract" xlink:to="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CashAtBanksAbstract" xlink:href="infrx-20230630.xsd#infrx_CashAtBanksAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="infrx_CashAtBanksAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CashAtBankstotal" xlink:href="infrx-20230630.xsd#infrx_CashAtBankstotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CashAtBanksAbstract" xlink:to="infrx_CashAtBankstotal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable">
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderThe2012PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2012PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2012PlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderThe2016PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2016PlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2016PlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderTheLTIPMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderTheLTIPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="infrx_NumberOfShareOptionsUnderTheLTIPMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_OutstandingBalance" xlink:href="infrx-20230630.xsd#infrx_OutstandingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_OutstandingBalance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ExercisedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_ExercisedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_ExercisedNumberOfShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ForfeitedShares" xlink:href="infrx-20230630.xsd#infrx_ForfeitedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_ForfeitedShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRateregulatedActivitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="ifrs-full_TypesOfRateregulatedActivitiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RateregulatedActivitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RateregulatedActivitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="ifrs-full_RateregulatedActivitiesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RateregulatedActivitiesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RateregulatedActivitiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="ifrs-full_RateregulatedActivitiesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_JanuaryTwentyFourMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RateregulatedActivitiesMember" xlink:to="infrx_JanuaryTwentyFourMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_JanuaryTwentyFourOneMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RateregulatedActivitiesMember" xlink:to="infrx_JanuaryTwentyFourOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_MayThirtyMember" xlink:href="infrx-20230630.xsd#infrx_MayThirtyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RateregulatedActivitiesMember" xlink:to="infrx_MayThirtyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FairValuePerOption" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_FairValuePerOption" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FXRateAsOfGrantDate" xlink:href="infrx-20230630.xsd#infrx_FXRateAsOfGrantDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_FXRateAsOfGrantDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_FairValuePerOptions" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_FairValuePerOptions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SharePriceAtGrantDateExercisePrice" xlink:href="infrx-20230630.xsd#infrx_SharePriceAtGrantDateExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_SharePriceAtGrantDateExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ExpectedLifemidpointBased" xlink:href="infrx-20230630.xsd#infrx_ExpectedLifemidpointBased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_ExpectedLifemidpointBased" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncomeDetails">
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherIncomesAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfInventoryWritedown" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ReversalOfInventoryWritedown" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssetsDetails">
    <loc xlink:type="locator" xlink:label="infrx_OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_OtherAssetAbstract" xlink:to="ifrs-full_NoncurrentPrepayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_AssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_AssetsFromGovernmentGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="infrx_AssetsFromGovernmentGrants" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="infrx_EquityDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_EquityDetailsTable" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CommonSharesSaleAgreement" xlink:href="infrx-20230630.xsd#infrx_CommonSharesSaleAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_CommonSharesSaleAgreement" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="ifrs-full_Equity" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SoldCommonSharesThroughAPublicOffering" xlink:href="infrx-20230630.xsd#infrx_SoldCommonSharesThroughAPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_SoldCommonSharesThroughAPublicOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentTransactions" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_ShareBasedPaymentTransactions" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SaleOfPricePerShare" xlink:href="infrx-20230630.xsd#infrx_SaleOfPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_SaleOfPricePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_NominalValuePerShare" xlink:href="infrx-20230630.xsd#infrx_NominalValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_NominalValuePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentProperty" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherOfferingExpensesTotal" xlink:href="infrx-20230630.xsd#infrx_OtherOfferingExpensesTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_OtherOfferingExpensesTotal" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="infrx_ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_OptionLTIPMember" xlink:href="infrx-20230630.xsd#infrx_OptionLTIPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="infrx_OptionLTIPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_BoardOfDirectorsMember" xlink:href="infrx-20230630.xsd#infrx_BoardOfDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="infrx_BoardOfDirectorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_CommonSharesDescription" xlink:href="infrx-20230630.xsd#infrx_CommonSharesDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="infrx_CommonSharesDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedPaymentExpense" xlink:href="infrx-20230630.xsd#infrx_SharebasedPaymentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="infrx_SharebasedPaymentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_ValuationPastGrantAmount" xlink:href="infrx-20230630.xsd#infrx_ValuationPastGrantAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="infrx_ValuationPastGrantAmount" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ProtectiveFoundationDetails">
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_ProtectiveFoundationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_AuthorisedCapitalCommonSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisedCapitalCommonSharesone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_AuthorisedCapitalCommonSharesone" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_AuthorisdCapitalPreferenceSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisdCapitalPreferenceSharesone"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_AuthorisdCapitalPreferenceSharesone" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_PricePerShares" xlink:href="infrx-20230630.xsd#infrx_PricePerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_PricePerShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="infrx_PercentageOfIssuedCapital" xlink:href="infrx-20230630.xsd#infrx_PercentageOfIssuedCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_PercentageOfIssuedCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="12" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>infrx-20230630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl" xml:lang="en-US">Operating Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US">Income (Loss) for the Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl0" xml:lang="en-US">Loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US">Total Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl0" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US">Total equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Equity_lbl0" xml:lang="en-US">Equity amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US">TOTAL EQUITY AND LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US">Components of equity [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash from/(used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash from/(used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:href="infrx-20230630.xsd#infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies and Other Disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:to="infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomesAbstract_lbl" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomesAbstract" xlink:to="infrx_OtherIncomesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetFinancialResultAbstract_lbl" xml:lang="en-US">Net Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResultAbstract" xlink:to="infrx_NetFinancialResultAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherAssetAbstract_lbl" xml:lang="en-US">Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherAssetAbstract" xlink:to="infrx_OtherAssetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract_lbl" xml:lang="en-US">Financial Assets and Financial Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="infrx_FinancialAssetsAndFinancialLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:to="infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis_lbl" xml:lang="en-US">Currency in which information is displayed [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsAbstract" xlink:to="infrx_ShareBasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OutstandingBalance" xlink:href="infrx-20230630.xsd#infrx_OutstandingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="infrx_OutstandingBalance_lbl" xml:lang="en-US">Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OutstandingBalance" xlink:to="infrx_OutstandingBalance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="infrx_OutstandingBalance_lbl0" xml:lang="en-US">Outstanding Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OutstandingBalance" xlink:to="infrx_OutstandingBalance_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRateregulatedActivitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRateregulatedActivitiesAxis_lbl" xml:lang="en-US">Types of rate-regulated activities [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="ifrs-full_TypesOfRateregulatedActivitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationAbstract" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ProtectiveFoundationAbstract_lbl" xml:lang="en-US">Protective Foundation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProtectiveFoundationAbstract" xlink:to="infrx_ProtectiveFoundationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Other expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US">Foreign exchange result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl" xml:lang="en-US">Other financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_UnlabeledAbstract" xlink:href="infrx-20230630.xsd#infrx_UnlabeledAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_UnlabeledAbstract_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract" xlink:to="infrx_UnlabeledAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareInformationAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ShareInformationAbstract_lbl" xml:lang="en-US">Share Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareInformationAbstract" xlink:to="infrx_ShareInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US">Weighted average number of shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US">Income (Loss) per share (basic) (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US">Income (Loss) per share (diluted)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:href="infrx-20230630.xsd#infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl" xml:lang="en-US">Exchange differences on translation of foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:to="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US">Intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US">Current other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxAssets_lbl" xml:lang="en-US">Current tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssets" xlink:to="ifrs-full_CurrentTaxAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinancialAssets_lbl" xml:lang="en-US">Other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_UnlabeledAbstract0" xlink:href="infrx-20230630.xsd#infrx_UnlabeledAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_UnlabeledAbstract0_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract0" xlink:to="infrx_UnlabeledAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US">EQUITY AND LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US">Other capital reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEquityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherEquityInterest_lbl" xml:lang="en-US">Other components of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities_lbl" xml:lang="en-US">Liabilities from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:to="ifrs-full_OtherCurrentNonfinancialLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl" xml:lang="en-US">Exchange differences on translation of foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US">Issuance of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_IssuanceOfCommonSharesAndWarrants" xlink:href="infrx-20230630.xsd#infrx_IssuanceOfCommonSharesAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_IssuanceOfCommonSharesAndWarrants_lbl" xml:lang="en-US">Issuance of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IssuanceOfCommonSharesAndWarrants" xlink:to="infrx_IssuanceOfCommonSharesAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US">Equity-settled share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US">Share options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareOptionsExercised" xlink:href="infrx-20230630.xsd#infrx_ShareOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ShareOptionsExercised_lbl" xml:lang="en-US">Share options exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareOptionsExercised" xlink:to="infrx_ShareOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_UnlabeledAbstract1" xlink:href="infrx-20230630.xsd#infrx_UnlabeledAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_UnlabeledAbstract1_lbl" xml:lang="en-US"></label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract1" xlink:to="infrx_UnlabeledAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US">Loss for the period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US">Adjustments for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinanceIncome" xlink:href="infrx-20230630.xsd#infrx_NetFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NetFinanceIncome_lbl" xml:lang="en-US">Net finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinanceIncome" xlink:to="infrx_NetFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US">Share-based payment expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetForeignExchangeDifferences" xlink:href="infrx-20230630.xsd#infrx_NetForeignExchangeDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NetForeignExchangeDifferences_lbl" xml:lang="en-US">Net foreign exchange differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetForeignExchangeDifferences" xlink:to="infrx_NetForeignExchangeDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ChangesInCashFlowAbstract" xlink:href="infrx-20230630.xsd#infrx_ChangesInCashFlowAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ChangesInCashFlowAbstract_lbl" xml:lang="en-US">Changes in:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="infrx_ChangesInCashFlowAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:to="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_LiabilitiesFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_LiabilitiesFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_LiabilitiesFromGovernmentGrants_lbl" xml:lang="en-US">Liabilities from government grants received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_LiabilitiesFromGovernmentGrants" xlink:to="infrx_LiabilitiesFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromTheMaturityOfFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl" xml:lang="en-US">Proceeds from the maturity of financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:to="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromIssuanceOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares_lbl" xml:lang="en-US">Proceeds from issuance of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromIssuanceOfCommonShares" xlink:to="infrx_ProceedsFromIssuanceOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl" xml:lang="en-US">Proceeds from exercise of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US">Sales and marketing expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US">Transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US">Purchase of intangible assets, property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl" xml:lang="en-US">Purchase of current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US">Transaction costs from issuance of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_RepaymentOfLeaseLiabilities" xlink:href="infrx-20230630.xsd#infrx_RepaymentOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="infrx_RepaymentOfLeaseLiabilities_lbl" xml:lang="en-US">Repayment of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_RepaymentOfLeaseLiabilities" xlink:to="infrx_RepaymentOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US">Shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl0" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReservesMember_lbl" xml:lang="en-US">Other capital reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl" xml:lang="en-US">Other components of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfSummaryOfSignificantAccountingPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy_lbl" xml:lang="en-US">Summary of significant accounting policies and other disclosures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy" xlink:to="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfOtherIncomeTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherIncomeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfOtherIncomeTextBlock_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfOtherIncomeTextBlock" xlink:to="infrx_DisclosureOfOtherIncomeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SummaryofotherIncometableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SummaryofotherIncometableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SummaryofotherIncometableTextBlock_lbl" xml:lang="en-US">Schedule of Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SummaryofotherIncometableTextBlock" xlink:to="infrx_SummaryofotherIncometableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_IncomeFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_IncomeFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_IncomeFromGovernmentGrants_lbl" xml:lang="en-US">Income from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IncomeFromGovernmentGrants" xlink:to="infrx_IncomeFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:to="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTotal" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_OtherIncomeTotal_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeTotal" xlink:to="infrx_OtherIncomeTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfNetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfNetFinancialResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfNetFinancialResult_lbl" xml:lang="en-US">Net financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfNetFinancialResult" xlink:to="infrx_DisclosureOfNetFinancialResult_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfNetFinancialResultTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ScheduleOfNetFinancialResultTableTextBlock_lbl" xml:lang="en-US">Schedule of Net financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfNetFinancialResultTableTextBlock" xlink:to="infrx_ScheduleOfNetFinancialResultTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract" xlink:href="infrx-20230630.xsd#infrx_InAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract" xlink:to="infrx_InAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialIncomeAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FinancialIncomeAbstract_lbl" xml:lang="en-US">Financial income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialIncomeAbstract" xlink:to="infrx_FinancialIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialExpensesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FinancialExpensesAbstract_lbl" xml:lang="en-US">Financial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialExpensesAbstract" xlink:to="infrx_FinancialExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NetFinancialResult_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResult" xlink:to="infrx_NetFinancialResult_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock_lbl" xml:lang="en-US">Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" xlink:to="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract0" xlink:href="infrx-20230630.xsd#infrx_InAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract0_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract0" xlink:to="infrx_InAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeResultAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ForeignExchangeResultAbstract_lbl" xml:lang="en-US">Foreign exchange result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeResultAbstract" xlink:to="infrx_ForeignExchangeResultAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeIncome" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ForeignExchangeIncome_lbl" xml:lang="en-US">Foreign exchange income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeIncome" xlink:to="infrx_ForeignExchangeIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Foreign Exchange Income and Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" xlink:to="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract1" xlink:href="infrx-20230630.xsd#infrx_InAbstract1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract1_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract1" xlink:to="infrx_InAbstract1_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US">Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US">Schedule Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract2" xlink:href="infrx-20230630.xsd#infrx_InAbstract2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract2_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract2" xlink:to="infrx_InAbstract2_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl" xml:lang="en-US">Raw materials and supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_UnfinishedGoods" xlink:href="infrx-20230630.xsd#infrx_UnfinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_UnfinishedGoods_lbl" xml:lang="en-US">Unfinished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnfinishedGoods" xlink:to="infrx_UnfinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfOtherAssets" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfOtherAssets_lbl" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfOtherAssets" xlink:to="infrx_DisclosureOfOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl" xml:lang="en-US">Schedule Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract3" xlink:href="infrx-20230630.xsd#infrx_InAbstract3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract3_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract3" xlink:to="infrx_InAbstract3_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NonCurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_NonCurrentOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NonCurrentOtherAssetsAbstract_lbl" xml:lang="en-US">Non-current other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NonCurrentOtherAssetsAbstract" xlink:to="infrx_NonCurrentOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NonPrepaidExpenses" xlink:href="infrx-20230630.xsd#infrx_NonPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NonPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NonPrepaidExpenses" xlink:to="infrx_NonPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CurrentOtherAssetsAbstract_lbl" xml:lang="en-US">Current other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="infrx_CurrentOtherAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_PrepaymentsOnResearchDevelopmentProjects" xlink:href="infrx-20230630.xsd#infrx_PrepaymentsOnResearchDevelopmentProjects"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl" xml:lang="en-US">Prepayments on research &amp; development projects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PrepaymentsOnResearchDevelopmentProjects" xlink:to="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xml:lang="en-US">Others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CurrentOtherAssetsTotal" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CurrentOtherAssetsTotal_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CurrentOtherAssetsTotal" xlink:to="infrx_CurrentOtherAssetsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsLiabilities_lbl" xml:lang="en-US">Total other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsLiabilities" xlink:to="ifrs-full_CurrentAssetsLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Financial assets and financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US">Schedule of Financial Assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract4" xlink:href="infrx-20230630.xsd#infrx_InAbstract4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract4_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract4" xlink:to="infrx_InAbstract4_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAtAmortizedCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FinancialAssetsAtAmortizedCostAbstract_lbl" xml:lang="en-US">Financial assets at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="infrx_FinancialAssetsAtAmortizedCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xml:lang="en-US">Non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialAssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FinancialAssetsFromGovernmentGrants_lbl" xml:lang="en-US">Financial assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsFromGovernmentGrants" xlink:to="infrx_FinancialAssetsFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl" xml:lang="en-US">Financial liabilities at amortized cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="infrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US">Liabilities from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:to="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InAbstract5" xlink:href="infrx-20230630.xsd#infrx_InAbstract5"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_InAbstract5_lbl" xml:lang="en-US">(in &#8364;)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract5" xlink:to="infrx_InAbstract5_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShortTermDepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ShortTermDepositsAbstract_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShortTermDepositsAbstract" xlink:to="infrx_ShortTermDepositsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:href="infrx-20230630.xsd#infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl" xml:lang="en-US">Short-term deposits	total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:to="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CashAtBanksAbstract" xlink:href="infrx-20230630.xsd#infrx_CashAtBanksAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CashAtBanksAbstract_lbl" xml:lang="en-US">Cash at banks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashAtBanksAbstract" xlink:to="infrx_CashAtBanksAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CashAtBankstotal" xlink:href="infrx-20230630.xsd#infrx_CashAtBankstotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CashAtBankstotal_lbl" xml:lang="en-US">Cash at banks	total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashAtBankstotal" xlink:to="infrx_CashAtBankstotal_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl" xml:lang="en-US">Total cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SchdeuleOfStockOptionActivityTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SchdeuleOfStockOptionActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SchdeuleOfStockOptionActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SchdeuleOfStockOptionActivityTableTextBlock" xlink:to="infrx_SchdeuleOfStockOptionActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ExercisedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_ExercisedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ExercisedNumberOfShares_lbl" xml:lang="en-US">Exercised during the six months ended June 30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExercisedNumberOfShares" xlink:to="infrx_ExercisedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl" xml:lang="en-US">thereof vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl" xml:lang="en-US">Granted during the six months ended June 30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ForfeitedShares" xlink:href="infrx-20230630.xsd#infrx_ForfeitedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ForfeitedShares_lbl" xml:lang="en-US">Forfeited during the six months ended June 30</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForfeitedShares" xlink:to="infrx_ForfeitedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock" xlink:to="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of Share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FairValuePerOption" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FairValuePerOption_lbl" xml:lang="en-US">Fair value per option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOption" xlink:to="infrx_FairValuePerOption_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FXRateAsOfGrantDate" xlink:href="infrx-20230630.xsd#infrx_FXRateAsOfGrantDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FXRateAsOfGrantDate_lbl" xml:lang="en-US">FX rate as of grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FXRateAsOfGrantDate" xlink:to="infrx_FXRateAsOfGrantDate_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_FairValuePerOptions" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_FairValuePerOptions_lbl" xml:lang="en-US">Fair value per option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOptions" xlink:to="infrx_FairValuePerOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SharePriceAtGrantDateExercisePrice" xlink:href="infrx-20230630.xsd#infrx_SharePriceAtGrantDateExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SharePriceAtGrantDateExercisePrice_lbl" xml:lang="en-US">Share price at grant date / Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharePriceAtGrantDateExercisePrice" xlink:to="infrx_SharePriceAtGrantDateExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ExpectedLifemidpointBased" xlink:href="infrx-20230630.xsd#infrx_ExpectedLifemidpointBased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ExpectedLifemidpointBased_lbl" xml:lang="en-US">Expected life (midpoint based)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExpectedLifemidpointBased" xlink:to="infrx_ExpectedLifemidpointBased_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US">Risk-free rate (interpolated, U.S. sovereign strips curve)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfProtectiveFoundationExplanatory" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfProtectiveFoundationExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfProtectiveFoundationExplanatory_lbl" xml:lang="en-US">Protective foundation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfProtectiveFoundationExplanatory" xlink:to="infrx_DisclosureOfProtectiveFoundationExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US">Subsequent events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ForeignExchangeExpense" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="infrx_ForeignExchangeExpense_lbl" xml:lang="en-US">Foreign exchange expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeExpense" xlink:to="infrx_ForeignExchangeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherFinancialResult" xlink:href="infrx-20230630.xsd#infrx_OtherFinancialResult"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="infrx_OtherFinancialResult_lbl" xml:lang="en-US">Other financial result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherFinancialResult" xlink:to="infrx_OtherFinancialResult_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DepositsHeldInUSDollarsMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInUSDollarsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DepositsHeldInUSDollarsMember_lbl" xml:lang="en-US">Deposits Held in U.S. Dollars [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DepositsHeldInUSDollarsMember" xlink:to="infrx_DepositsHeldInUSDollarsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DepositsHeldInEurosMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInEurosMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DepositsHeldInEurosMember_lbl" xml:lang="en-US">Deposits Held in Euros [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DepositsHeldInEurosMember" xlink:to="infrx_DepositsHeldInEurosMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderThe2012PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2012PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NumberOfShareOptionsUnderThe2012PlanMember_lbl" xml:lang="en-US">Number of share options under the 2012 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderThe2012PlanMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2012PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderThe2016PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2016PlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NumberOfShareOptionsUnderThe2016PlanMember_lbl" xml:lang="en-US">Number of share options under the 2016 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderThe2016PlanMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2016PlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NumberOfShareOptionsUnderTheLTIPMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderTheLTIPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NumberOfShareOptionsUnderTheLTIPMember_lbl" xml:lang="en-US">Number of share options under the LTIP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderTheLTIPMember" xlink:to="infrx_NumberOfShareOptionsUnderTheLTIPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_JanuaryTwentyFourMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_JanuaryTwentyFourMember_lbl" xml:lang="en-US">January Twenty four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_JanuaryTwentyFourMember" xlink:to="infrx_JanuaryTwentyFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_JanuaryTwentyFourOneMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_JanuaryTwentyFourOneMember_lbl" xml:lang="en-US">January twenty four one [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_JanuaryTwentyFourOneMember" xlink:to="infrx_JanuaryTwentyFourOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_MayThirtyMember" xlink:href="infrx-20230630.xsd#infrx_MayThirtyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_MayThirtyMember_lbl" xml:lang="en-US">May thirty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_MayThirtyMember" xlink:to="infrx_MayThirtyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US">Classes of share capital [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US">Classes of ordinary shares [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US">Classes of financial instruments [axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherFinanceIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfInventoryWritedown" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReversalOfInventoryWritedown_lbl" xml:lang="en-US">Write-downs of inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfInventoryWritedown" xlink:to="ifrs-full_ReversalOfInventoryWritedown_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentPrepayments_lbl" xml:lang="en-US">Prepayments on research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPrepayments" xlink:to="ifrs-full_NoncurrentPrepayments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_lbl" xml:lang="en-US">Fair value of current and non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_AssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_AssetsFromGovernmentGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_AssetsFromGovernmentGrants_lbl" xml:lang="en-US">Assets from government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AssetsFromGovernmentGrants" xlink:to="infrx_AssetsFromGovernmentGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CommonSharesSaleAgreement" xlink:href="infrx-20230630.xsd#infrx_CommonSharesSaleAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CommonSharesSaleAgreement_lbl" xml:lang="en-US">Sale of common shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesSaleAgreement" xlink:to="infrx_CommonSharesSaleAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US">Net proceeds from equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SoldCommonSharesThroughAPublicOffering" xlink:href="infrx-20230630.xsd#infrx_SoldCommonSharesThroughAPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SoldCommonSharesThroughAPublicOffering_lbl" xml:lang="en-US">Sold common shares through a public offering (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SoldCommonSharesThroughAPublicOffering" xlink:to="infrx_SoldCommonSharesThroughAPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentTransactions" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ShareBasedPaymentTransactions_lbl" xml:lang="en-US">Share based payment transactions (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentTransactions" xlink:to="infrx_ShareBasedPaymentTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SaleOfPricePerShare" xlink:href="infrx-20230630.xsd#infrx_SaleOfPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SaleOfPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SaleOfPricePerShare" xlink:to="infrx_SaleOfPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NominalValuePerShare" xlink:href="infrx-20230630.xsd#infrx_NominalValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_NominalValuePerShare_lbl" xml:lang="en-US">Nominal value of price per share (in Euro per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NominalValuePerShare" xlink:to="infrx_NominalValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl" xml:lang="en-US">Proceeds from sales of investment property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nzxCtW6Xay/kt3qsY4hTFZQi25kbRTyugY=] CSR-->
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentInvestments_lbl" xml:lang="en-US">Discounts amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherExpenseByNature_lbl" xml:lang="en-US">Other offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherOfferingExpensesTotal" xlink:href="infrx-20230630.xsd#infrx_OtherOfferingExpensesTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_OtherOfferingExpensesTotal_lbl" xml:lang="en-US">Other offering expenses total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherOfferingExpensesTotal" xlink:to="infrx_OtherOfferingExpensesTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CommonSharesDescription" xlink:href="infrx-20230630.xsd#infrx_CommonSharesDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_CommonSharesDescription_lbl" xml:lang="en-US">Common shares, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesDescription" xlink:to="infrx_CommonSharesDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Number of grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_SharebasedPaymentExpense" xlink:href="infrx-20230630.xsd#infrx_SharebasedPaymentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_SharebasedPaymentExpense_lbl" xml:lang="en-US">Share-based payment expense (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedPaymentExpense" xlink:to="infrx_SharebasedPaymentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ValuationPastGrantAmount" xlink:href="infrx-20230630.xsd#infrx_ValuationPastGrantAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_ValuationPastGrantAmount_lbl" xml:lang="en-US">Valuation past grants amount (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ValuationPastGrantAmount" xlink:to="infrx_ValuationPastGrantAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US">Exercise of share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_AuthorisedCapitalCommonSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisedCapitalCommonSharesone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_AuthorisedCapitalCommonSharesone_lbl" xml:lang="en-US">Common shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AuthorisedCapitalCommonSharesone" xlink:to="infrx_AuthorisedCapitalCommonSharesone_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_AuthorisdCapitalPreferenceSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisdCapitalPreferenceSharesone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_AuthorisdCapitalPreferenceSharesone_lbl" xml:lang="en-US">Preferred shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AuthorisdCapitalPreferenceSharesone" xlink:to="infrx_AuthorisdCapitalPreferenceSharesone_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_PricePerShares" xlink:href="infrx-20230630.xsd#infrx_PricePerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_PricePerShares_lbl" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PricePerShares" xlink:to="infrx_PricePerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_PercentageOfIssuedCapital" xlink:href="infrx-20230630.xsd#infrx_PercentageOfIssuedCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_PercentageOfIssuedCapital_lbl" xml:lang="en-US">Percentage of issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PercentageOfIssuedCapital" xlink:to="infrx_PercentageOfIssuedCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US">Reimburse expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_DisclosureOfReportingEntityAndGroupsStructure" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfReportingEntityAndGroupsStructure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_DisclosureOfReportingEntityAndGroupsStructure_lbl" xml:lang="en-US">Reporting entity and the Group&#8217;s structure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfReportingEntityAndGroupsStructure" xlink:to="infrx_DisclosureOfReportingEntityAndGroupsStructure_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US">Basis of preparation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_BoardOfDirectorsMember" xlink:href="infrx-20230630.xsd#infrx_BoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_BoardOfDirectorsMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_BoardOfDirectorsMember" xlink:to="infrx_BoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OptionLTIPMember" xlink:href="infrx-20230630.xsd#infrx_OptionLTIPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="infrx_OptionLTIPMember_lbl" xml:lang="en-US">Option LTIP [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OptionLTIPMember" xlink:to="infrx_OptionLTIPMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US">Equity [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US">Statement of changes in equity [table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US">Statement of changes in equity [line items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTablesTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomeTablesTable_lbl" xml:lang="en-US">Other Income (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeTablesTable" xlink:to="infrx_OtherIncomeTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeTablesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomeTablesLineItems_lbl" xml:lang="en-US">Other income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeTablesLineItems" xlink:to="infrx_OtherIncomeTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeDetailsScheduleofOtherIncomeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable_lbl" xml:lang="en-US">Other Income (Details) - Schedule of Other Income [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:to="infrx_OtherIncomeDetailsScheduleofOtherIncomeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_OtherIncomesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomesLineItems_lbl" xml:lang="en-US">Other Incomes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomesLineItems" xlink:to="infrx_OtherIncomesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable_lbl" xml:lang="en-US">Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:to="infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_NetFinancialResultLineItems" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetFinancialResultLineItems_lbl" xml:lang="en-US">Net Financial Result [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResultLineItems" xlink:to="infrx_NetFinancialResultLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_InventoriesDetailsScheduleInventoriesTable" xlink:href="infrx-20230630.xsd#infrx_InventoriesDetailsScheduleInventoriesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InventoriesDetailsScheduleInventoriesTable_lbl" xml:lang="en-US">Inventories (Details) - Schedule Inventories [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InventoriesDetailsScheduleInventoriesTable" xlink:to="infrx_InventoriesDetailsScheduleInventoriesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInventoriesLineItems" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInventoriesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfInventoriesLineItems_lbl" xml:lang="en-US">Schedule of Inventories [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfInventoriesLineItems" xlink:to="infrx_ScheduleOfInventoriesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember_lbl" xml:lang="en-US">Functional or presentation currency [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable_lbl" xml:lang="en-US">Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:to="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems_lbl" xml:lang="en-US">Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable_lbl" xml:lang="en-US">Share-Based Payments (Details) - Schedule of Stock Option Activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems_lbl" xml:lang="en-US">Share-Based Payments (Details) - Schedule of Stock Option Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RateregulatedActivitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RateregulatedActivitiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RateregulatedActivitiesMember_lbl" xml:lang="en-US">Rate-regulated activities [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RateregulatedActivitiesMember" xlink:to="ifrs-full_RateregulatedActivitiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable_lbl" xml:lang="en-US">Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems_lbl" xml:lang="en-US">Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US">Share capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_EquityDetailsTable" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_EquityDetailsTable" xlink:to="infrx_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_EquityDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_EquityDetailsLineItems" xlink:to="infrx_EquityDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl1" xml:lang="en-US">Ordinary shares [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US">Financial instruments, class [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsTable_lbl" xml:lang="en-US">Share-Based Payments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsTable" xlink:to="infrx_ShareBasedPaymentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ShareBasedPaymentsDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentsDetailsLineItems" xlink:to="infrx_ShareBasedPaymentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ProtectiveFoundationDetailsTable_lbl" xml:lang="en-US">Protective Foundation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProtectiveFoundationDetailsTable" xlink:to="infrx_ProtectiveFoundationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="infrx_ProtectiveFoundationDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ProtectiveFoundationDetailsLineItems_lbl" xml:lang="en-US">Disclosure of Protective Foundation Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProtectiveFoundationDetailsLineItems" xlink:to="infrx_ProtectiveFoundationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl0" xml:lang="en-US">The amount of financial assets adjusted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:to="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_AssetsFromGovernmentGrants_lbl0" xml:lang="en-US">Assets From Government Grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AssetsFromGovernmentGrants" xlink:to="infrx_AssetsFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_CashAtBankstotal_lbl0" xml:lang="en-US">Cash at banks total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashAtBankstotal" xlink:to="infrx_CashAtBankstotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_CommonSharesDescription_lbl0" xml:lang="en-US">Common shares, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesDescription" xlink:to="infrx_CommonSharesDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_CommonSharesSaleAgreement_lbl0" xml:lang="en-US">Sale of common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesSaleAgreement" xlink:to="infrx_CommonSharesSaleAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_CurrentOtherAssetsTotal_lbl0" xml:lang="en-US">The amount of other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CurrentOtherAssetsTotal" xlink:to="infrx_CurrentOtherAssetsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl0" xml:lang="en-US">Exchange differences on translation of foreign currency.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:to="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ExercisedNumberOfShares_lbl0" xml:lang="en-US">Number of exercised shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExercisedNumberOfShares" xlink:to="infrx_ExercisedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ExpectedLifemidpointBased_lbl0" xml:lang="en-US">Description of option life share options granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExpectedLifemidpointBased" xlink:to="infrx_ExpectedLifemidpointBased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_FXRateAsOfGrantDate_lbl0" xml:lang="en-US">Fair value at grant date fx rate as of grant date.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FXRateAsOfGrantDate" xlink:to="infrx_FXRateAsOfGrantDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_FairValuePerOption_lbl0" xml:lang="en-US">Fair value per option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOption" xlink:to="infrx_FairValuePerOption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_FairValuePerOptions_lbl0" xml:lang="en-US">Fair value per option.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOptions" xlink:to="infrx_FairValuePerOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_FinancialAssetsFromGovernmentGrants_lbl0" xml:lang="en-US">The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsFromGovernmentGrants" xlink:to="infrx_FinancialAssetsFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ForeignExchangeExpense_lbl0" xml:lang="en-US">Foreign exchange expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeExpense" xlink:to="infrx_ForeignExchangeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ForeignExchangeIncome_lbl0" xml:lang="en-US">Foreign exchange income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeIncome" xlink:to="infrx_ForeignExchangeIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ForfeitedShares_lbl0" xml:lang="en-US">Number of forfeited shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForfeitedShares" xlink:to="infrx_ForfeitedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_IncomeFromGovernmentGrants_lbl0" xml:lang="en-US">Income from government grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IncomeFromGovernmentGrants" xlink:to="infrx_IncomeFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_IssuanceOfCommonSharesAndWarrants_lbl0" xml:lang="en-US">Issuance of common shares and warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IssuanceOfCommonSharesAndWarrants" xlink:to="infrx_IssuanceOfCommonSharesAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_LiabilitiesFromGovernmentGrants_lbl0" xml:lang="en-US">The amount of liabilities from government grants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_LiabilitiesFromGovernmentGrants" xlink:to="infrx_LiabilitiesFromGovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_NetFinanceIncome_lbl0" xml:lang="en-US">The amount of net finance income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinanceIncome" xlink:to="infrx_NetFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_NetFinancialResult_lbl0" xml:lang="en-US">The net financial total value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResult" xlink:to="infrx_NetFinancialResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_NetForeignExchangeDifferences_lbl0" xml:lang="en-US">The amount of net foriegn exchange difference.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetForeignExchangeDifferences" xlink:to="infrx_NetForeignExchangeDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_NominalValuePerShare_lbl0" xml:lang="en-US">The number of nominal  value of price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NominalValuePerShare" xlink:to="infrx_NominalValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_NonPrepaidExpenses_lbl0" xml:lang="en-US">Prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NonPrepaidExpenses" xlink:to="infrx_NonPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_OtherFinancialResult_lbl0" xml:lang="en-US">Other financial result.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherFinancialResult" xlink:to="infrx_OtherFinancialResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_OtherIncomeTotal_lbl0" xml:lang="en-US">Other income total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeTotal" xlink:to="infrx_OtherIncomeTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_OtherOfferingExpensesTotal_lbl0" xml:lang="en-US">Other offering expenses total.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherOfferingExpensesTotal" xlink:to="infrx_OtherOfferingExpensesTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_OutstandingBalance_lbl1" xml:lang="en-US">Number of shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OutstandingBalance" xlink:to="infrx_OutstandingBalance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_PercentageOfIssuedCapital_lbl0" xml:lang="en-US">Percentage of issued capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PercentageOfIssuedCapital" xlink:to="infrx_PercentageOfIssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl0" xml:lang="en-US">Prepayments on research &amp; development projects.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PrepaymentsOnResearchDevelopmentProjects" xlink:to="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_PricePerShares_lbl0" xml:lang="en-US">The value of price per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PricePerShares" xlink:to="infrx_PricePerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares_lbl0" xml:lang="en-US">The amount of prceeds from issuance of common shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromIssuanceOfCommonShares" xlink:to="infrx_ProceedsFromIssuanceOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl0" xml:lang="en-US">The amount of preceeds from the maturity of financial assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:to="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_RepaymentOfLeaseLiabilities_lbl0" xml:lang="en-US">The amount of repayment of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_RepaymentOfLeaseLiabilities" xlink:to="infrx_RepaymentOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SaleOfPricePerShare_lbl0" xml:lang="en-US">The number of shares sold price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SaleOfPricePerShare" xlink:to="infrx_SaleOfPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ShareBasedPaymentTransactions_lbl0" xml:lang="en-US">Share based payment transactions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentTransactions" xlink:to="infrx_ShareBasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ShareOptionsExercised_lbl0" xml:lang="en-US">Share options exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareOptionsExercised" xlink:to="infrx_ShareOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SharePriceAtGrantDateExercisePrice_lbl0" xml:lang="en-US">Share price at grant date / Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharePriceAtGrantDateExercisePrice" xlink:to="infrx_SharePriceAtGrantDateExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl0" xml:lang="en-US">Number of option granted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl0" xml:lang="en-US">Number of vested shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SharebasedPaymentExpense_lbl0" xml:lang="en-US">The amount of share-based payment expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedPaymentExpense" xlink:to="infrx_SharebasedPaymentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl0" xml:lang="en-US">A total of cash equivalents representing short-term deposits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:to="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_SoldCommonSharesThroughAPublicOffering_lbl0" xml:lang="en-US">The number of shares of public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SoldCommonSharesThroughAPublicOffering" xlink:to="infrx_SoldCommonSharesThroughAPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_UnfinishedGoods_lbl0" xml:lang="en-US">Unfinished goods.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnfinishedGoods" xlink:to="infrx_UnfinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="infrx_ValuationPastGrantAmount_lbl0" xml:lang="en-US">The amount of valuation past grant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ValuationPastGrantAmount" xlink:to="infrx_ValuationPastGrantAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and administrative expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NumberOfShareOptionsUnderThe2012PlanMember_lbl0" xml:lang="en-US">Number Of Share Options Under The2012 Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderThe2012PlanMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2012PlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ForeignExchangeResultAbstract_lbl0" xml:lang="en-US">Foreign Exchange Result Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeResultAbstract" xlink:to="infrx_ForeignExchangeResultAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl1" xml:lang="en-US">Shortterm Deposits Classified As Cash Equivalents Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:to="infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CashAtBankstotal_lbl1" xml:lang="en-US">Cash At Bankstotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashAtBankstotal" xlink:to="infrx_CashAtBankstotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Depreciation, property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherEquityInterest_lbl0" xml:lang="en-US">Other equity interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherEquityInterest" xlink:to="ifrs-full_OtherEquityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfNetFinancialResult_lbl0" xml:lang="en-US">Disclosure Of Net Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfNetFinancialResult" xlink:to="infrx_DisclosureOfNetFinancialResult_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl0" xml:lang="en-US">Trade and other payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of financial position [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0" xml:lang="en-US">Disclosure of other assets [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CurrentOtherAssetsAbstract_lbl0" xml:lang="en-US">Current Other Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CurrentOtherAssetsAbstract" xlink:to="infrx_CurrentOtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_RepaymentOfLeaseLiabilities_lbl1" xml:lang="en-US">Repayment Of Lease Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_RepaymentOfLeaseLiabilities" xlink:to="infrx_RepaymentOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetForeignExchangeDifferences_lbl1" xml:lang="en-US">Net Foreign Exchange Differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetForeignExchangeDifferences" xlink:to="infrx_NetForeignExchangeDifferences_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NominalValuePerShare_lbl1" xml:lang="en-US">Nominal Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NominalValuePerShare" xlink:to="infrx_NominalValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities_lbl0" xml:lang="en-US">Other current non-financial liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:to="ifrs-full_OtherCurrentNonfinancialLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsLiabilities_lbl0" xml:lang="en-US">Current assets (liabilities)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsLiabilities" xlink:to="ifrs-full_CurrentAssetsLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SharebasedPaymentExpense_lbl1" xml:lang="en-US">Sharebased Payment Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedPaymentExpense" xlink:to="infrx_SharebasedPaymentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl0" xml:lang="en-US">Other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions_lbl0" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialAssetsFromGovernmentGrants_lbl1" xml:lang="en-US">Financial Assets From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsFromGovernmentGrants" xlink:to="infrx_FinancialAssetsFromGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ForeignExchangeExpense_lbl1" xml:lang="en-US">Foreign Exchange Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeExpense" xlink:to="infrx_ForeignExchangeExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl0" xml:lang="en-US">Current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Option Vested Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0" xml:lang="en-US">Increase (decrease) through exercise of options, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0" xml:lang="en-US">Tax expense (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfOtherIncomeAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfOtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfOtherIncomeAbstract_lbl" xml:lang="en-US">Schedule Of Other Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfOtherIncomeAbstract" xlink:to="infrx_ScheduleOfOtherIncomeAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0" xml:lang="en-US">Gains (losses) on exchange differences on translation of foreign operations, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SoldCommonSharesThroughAPublicOffering_lbl1" xml:lang="en-US">Sold Common Shares Through APublic Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SoldCommonSharesThroughAPublicOffering" xlink:to="infrx_SoldCommonSharesThroughAPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl0" xml:lang="en-US">Non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options granted in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FairValuePerOption_lbl1" xml:lang="en-US">Fair Value Per Option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOption" xlink:to="infrx_FairValuePerOption_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl0" xml:lang="en-US">Other current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl0" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl0" xml:lang="en-US">Finance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FXRateAsOfGrantDate_lbl1" xml:lang="en-US">FXRate As Of Grant Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FXRateAsOfGrantDate" xlink:to="infrx_FXRateAsOfGrantDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NonPrepaidExpenses_lbl1" xml:lang="en-US">Non Prepaid Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NonPrepaidExpenses" xlink:to="infrx_NonPrepaidExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OutstandingBalance_lbl2" xml:lang="en-US">Outstanding Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OutstandingBalance" xlink:to="infrx_OutstandingBalance_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy_lbl0" xml:lang="en-US">Disclosure Of Summary Of Significant Accounting Policy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy" xlink:to="infrx_DisclosureOfSummaryOfSignificantAccountingPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareBasedPaymentTransactions_lbl1" xml:lang="en-US">Share Based Payment Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareBasedPaymentTransactions" xlink:to="infrx_ShareBasedPaymentTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl0" xml:lang="en-US">Financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CurrentOtherAssetsTotal_lbl1" xml:lang="en-US">Current Other Assets Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CurrentOtherAssetsTotal" xlink:to="infrx_CurrentOtherAssetsTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl0" xml:lang="en-US">Disclosure Of Cash And Cash Equivalents Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:to="infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract_lbl" xml:lang="en-US">Unaudited Condensed Consolidated Statements Of Changes In Shareholders Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:to="infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl0" xml:lang="en-US">Lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Foreign Exchange Income And Expense Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" xlink:to="infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssets_lbl0" xml:lang="en-US">Current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl0" xml:lang="en-US">Intangible assets and goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl0" xml:lang="en-US">Current raw materials and current production supplies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Gains (losses) on financial assets measured at fair value through other comprehensive income, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl0" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncome_lbl0" xml:lang="en-US">Other finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncome" xlink:to="ifrs-full_OtherFinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract3_lbl0" xml:lang="en-US">In Abstract3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract3" xlink:to="infrx_InAbstract3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl0" xml:lang="en-US">Issued capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract2_lbl0" xml:lang="en-US">In Abstract2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract2" xlink:to="infrx_InAbstract2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentPrepayments_lbl0" xml:lang="en-US">Non-current prepayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentPrepayments" xlink:to="ifrs-full_NoncurrentPrepayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract1_lbl0" xml:lang="en-US">In Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract1" xlink:to="infrx_InAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl0" xml:lang="en-US">Government grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract0_lbl0" xml:lang="en-US">In Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract0" xlink:to="infrx_InAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract5_lbl0" xml:lang="en-US">In Abstract5</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract5" xlink:to="infrx_InAbstract5_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract4_lbl0" xml:lang="en-US">In Abstract4</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract4" xlink:to="infrx_InAbstract4_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentInvestments_lbl0" xml:lang="en-US">Current investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentInvestments" xlink:to="ifrs-full_CurrentInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SharePriceAtGrantDateExercisePrice_lbl1" xml:lang="en-US">Share Price At Grant Date Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharePriceAtGrantDateExercisePrice" xlink:to="infrx_SharePriceAtGrantDateExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl0" xml:lang="en-US">Share issue related cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl0" xml:lang="en-US">Current inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl0" xml:lang="en-US">Equity and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0" xml:lang="en-US">Equity attributable to owners of parent [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of offsetting of financial assets and financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_JanuaryTwentyFourMember_lbl0" xml:lang="en-US">January Twenty Four Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_JanuaryTwentyFourMember" xlink:to="infrx_JanuaryTwentyFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DepositsHeldInEurosMember_lbl0" xml:lang="en-US">Deposits Held In Euros Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DepositsHeldInEurosMember" xlink:to="infrx_DepositsHeldInEurosMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl0" xml:lang="en-US">Component of Operating Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ExercisedNumberOfShares_lbl1" xml:lang="en-US">Exercised Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExercisedNumberOfShares" xlink:to="infrx_ExercisedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of cash flows [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FairValuePerOptions_lbl1" xml:lang="en-US">Fair Value Per Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FairValuePerOptions" xlink:to="infrx_FairValuePerOptions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpense_lbl0" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpense" xlink:to="ifrs-full_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl0" xml:lang="en-US">Employee benefits expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetFinanceIncome_lbl1" xml:lang="en-US">Net Finance Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinanceIncome" xlink:to="infrx_NetFinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl1" xml:lang="en-US">Number of shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReversalOfInventoryWritedown_lbl0" xml:lang="en-US">Reversal of inventory write-down</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReversalOfInventoryWritedown" xlink:to="ifrs-full_ReversalOfInventoryWritedown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NumberOfShareOptionsUnderThe2016PlanMember_lbl0" xml:lang="en-US">Number Of Share Options Under The2016 Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderThe2016PlanMember" xlink:to="infrx_NumberOfShareOptionsUnderThe2016PlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfCashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="infrx_ScheduleOfCashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl0" xml:lang="en-US">Right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareInformationAbstract_lbl0" xml:lang="en-US">Share Information Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareInformationAbstract" xlink:to="infrx_ShareInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract_lbl" xml:lang="en-US">Schedule Of Interest Income Is Derived From Marketable Securities And Short Term Deposits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:to="infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ChangesInCashFlowAbstract_lbl0" xml:lang="en-US">Changes In Cash Flow Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ChangesInCashFlowAbstract" xlink:to="infrx_ChangesInCashFlowAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1" xml:lang="en-US">Foreign exchange gain (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialIncomeAbstract_lbl0" xml:lang="en-US">Financial Income Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialIncomeAbstract" xlink:to="infrx_FinancialIncomeAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of Options Granted Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:to="infrx_ScheduleOfFairValueOfOptionsGrantedAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaidExpenses_lbl0" xml:lang="en-US">Current prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaidExpenses" xlink:to="ifrs-full_CurrentPrepaidExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl0" xml:lang="en-US">Share premium [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_PercentageOfIssuedCapital_lbl1" xml:lang="en-US">Percentage Of Issued Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PercentageOfIssuedCapital" xlink:to="infrx_PercentageOfIssuedCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SchdeuleOfStockOptionActivityTableTextBlock_lbl0" xml:lang="en-US">Schdeule Of Stock Option Activity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SchdeuleOfStockOptionActivityTableTextBlock" xlink:to="infrx_SchdeuleOfStockOptionActivityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl" xml:lang="en-US">Unaudited Condensed Consolidated Statements Of Operations And Comprehensive Loss Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0" xml:lang="en-US">Risk free interest rate, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ForeignExchangeIncome_lbl1" xml:lang="en-US">Foreign Exchange Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForeignExchangeIncome" xlink:to="infrx_ForeignExchangeIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherFinancialResult_lbl1" xml:lang="en-US">Other Financial Result</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherFinancialResult" xlink:to="infrx_OtherFinancialResult_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShortTermDepositsAbstract_lbl0" xml:lang="en-US">Short Term Deposits Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShortTermDepositsAbstract" xlink:to="infrx_ShortTermDepositsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinancialAssets_lbl0" xml:lang="en-US">Other financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialAssets" xlink:to="ifrs-full_OtherFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFinanceIncomeCost_lbl0" xml:lang="en-US">Other finance income (cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinanceIncomeCost" xlink:to="ifrs-full_OtherFinanceIncomeCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl0" xml:lang="en-US">Current lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfNetFinancialResultTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Net Financial Result Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfNetFinancialResultTableTextBlock" xlink:to="infrx_ScheduleOfNetFinancialResultTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentReceivables_lbl0" xml:lang="en-US">Other current receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_PricePerShares_lbl1" xml:lang="en-US">Price Per Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PricePerShares" xlink:to="infrx_PricePerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0" xml:lang="en-US">Disclosure of cash and cash equivalents [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl0" xml:lang="en-US">Non-current assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0" xml:lang="en-US">Disclosure of inventories [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_MayThirtyMember_lbl0" xml:lang="en-US">May Thirty Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_MayThirtyMember" xlink:to="infrx_MayThirtyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl0" xml:lang="en-US">Current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl0" xml:lang="en-US">Trade and other current payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets_lbl0" xml:lang="en-US">Other non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentFinancialAssets" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl0" xml:lang="en-US">Equity and liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialAssetsAtAmortizedCostAbstract_lbl0" xml:lang="en-US">Financial Assets At Amortized Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialAssetsAtAmortizedCostAbstract" xlink:to="infrx_FinancialAssetsAtAmortizedCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NetFinancialResult_lbl1" xml:lang="en-US">Net Financial Result [Standard Label]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NetFinancialResult" xlink:to="infrx_NetFinancialResult_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl0" xml:lang="en-US">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0" xml:lang="en-US">Short-term employee benefits accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl0" xml:lang="en-US">Proceeds from sales of investment property</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentProperty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_IssuanceOfCommonSharesAndWarrants_lbl1" xml:lang="en-US">Issuance Of Common Shares And Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IssuanceOfCommonSharesAndWarrants" xlink:to="infrx_IssuanceOfCommonSharesAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxAssets_lbl0" xml:lang="en-US">Current tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssets" xlink:to="ifrs-full_CurrentTaxAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl1" xml:lang="en-US">Prepayments On Research Development Projects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_PrepaymentsOnResearchDevelopmentProjects" xlink:to="infrx_PrepaymentsOnResearchDevelopmentProjects_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options expired in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfOtherIncomeTextBlock_lbl0" xml:lang="en-US">Disclosure Of Other Income Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfOtherIncomeTextBlock" xlink:to="infrx_DisclosureOfOtherIncomeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ProceedsFromIssuanceOfCommonShares_lbl1" xml:lang="en-US">Proceeds From Issuance Of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromIssuanceOfCommonShares" xlink:to="infrx_ProceedsFromIssuanceOfCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0" xml:lang="en-US">Adjustments for decrease (increase) in inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_lbl0" xml:lang="en-US">Other income (expense) from subsidiaries, jointly controlled entities and associates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:to="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl0" xml:lang="en-US">Purchase of available-for-sale financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl0" xml:lang="en-US">Non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl0" xml:lang="en-US">Current finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl0" xml:lang="en-US">Other reserves</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Option Granted Number Of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:to="infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfNetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfNetFinancialResultAbstract_lbl" xml:lang="en-US">Schedule Of Net Financial Result Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfNetFinancialResultAbstract" xlink:to="infrx_ScheduleOfNetFinancialResultAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ExpectedLifemidpointBased_lbl1" xml:lang="en-US">Expected Lifemidpoint Based</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExpectedLifemidpointBased" xlink:to="infrx_ExpectedLifemidpointBased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0" xml:lang="en-US">Expected volatility, share options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnlabeledAbstract1_lbl0" xml:lang="en-US">Unlabeled Abstract1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract1" xlink:to="infrx_UnlabeledAbstract1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnlabeledAbstract0_lbl0" xml:lang="en-US">Unlabeled Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract0" xlink:to="infrx_UnlabeledAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl1" xml:lang="en-US">Proceeds From The Maturity Of Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ProceedsFromTheMaturityOfFinancialAssets" xlink:to="infrx_ProceedsFromTheMaturityOfFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0" xml:lang="en-US">Disclosure of operating segments [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl0" xml:lang="en-US">Payments for share issue costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl0" xml:lang="en-US">Sales and marketing expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl2" xml:lang="en-US">Cash and cash equivalents [Standard Label]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfOtherAssets_lbl0" xml:lang="en-US">Disclosure Of Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfOtherAssets" xlink:to="infrx_DisclosureOfOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherIncomeTotal_lbl1" xml:lang="en-US">Other Income Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherIncomeTotal" xlink:to="infrx_OtherIncomeTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_JanuaryTwentyFourOneMember_lbl0" xml:lang="en-US">January Twenty Four One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_JanuaryTwentyFourOneMember" xlink:to="infrx_JanuaryTwentyFourOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CashAtBanksAbstract_lbl0" xml:lang="en-US">Cash At Banks Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CashAtBanksAbstract" xlink:to="infrx_CashAtBanksAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in employee benefit liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SummaryofotherIncometableTextBlock_lbl0" xml:lang="en-US">Summaryofother Incometable Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SummaryofotherIncometableTextBlock" xlink:to="infrx_SummaryofotherIncometableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DepositsHeldInUSDollarsMember_lbl0" xml:lang="en-US">Deposits Held In USDollars Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DepositsHeldInUSDollarsMember" xlink:to="infrx_DepositsHeldInUSDollarsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_AssetsFromGovernmentGrants_lbl1" xml:lang="en-US">Assets From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AssetsFromGovernmentGrants" xlink:to="infrx_AssetsFromGovernmentGrants_lbl1"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Financial Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCashAndCashEquivalents_lbl0" xml:lang="en-US">Other cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCashAndCashEquivalents" xlink:to="ifrs-full_OtherCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnlabeledAbstract_lbl0" xml:lang="en-US">Unlabeled Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnlabeledAbstract" xlink:to="infrx_UnlabeledAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Non-current financial assets at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_UnfinishedGoods_lbl1" xml:lang="en-US">Unfinished Goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_UnfinishedGoods" xlink:to="infrx_UnfinishedGoods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0" xml:lang="en-US">Non-current liabilities [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl0" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl0" xml:lang="en-US">Share premium</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl0" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_BoardOfDirectorsMember_lbl0" xml:lang="en-US">Board Of Directors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_BoardOfDirectorsMember" xlink:to="infrx_BoardOfDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest paid, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl0" xml:lang="en-US">Diluted earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl0" xml:lang="en-US">Statement of profit or loss and other comprehensive income [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OtherOfferingExpensesTotal_lbl1" xml:lang="en-US">Other Offering Expenses Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OtherOfferingExpensesTotal" xlink:to="infrx_OtherOfferingExpensesTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_lbl0" xml:lang="en-US">Interest income on financial assets designated at fair value through profit or loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl0" xml:lang="en-US">Other liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfReportingEntityAndGroupsStructure_lbl0" xml:lang="en-US">Disclosure Of Reporting Entity And Groups Structure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfReportingEntityAndGroupsStructure" xlink:to="infrx_DisclosureOfReportingEntityAndGroupsStructure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_OptionLTIPMember_lbl0" xml:lang="en-US">Option LTIPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_OptionLTIPMember" xlink:to="infrx_OptionLTIPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_AuthorisedCapitalCommonSharesone_lbl0" xml:lang="en-US">Authorised Capital Common Sharesone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AuthorisedCapitalCommonSharesone" xlink:to="infrx_AuthorisedCapitalCommonSharesone_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Foreign Exchange Income And Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract" xlink:to="infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0" xml:lang="en-US">Adjustments for increase (decrease) in trade accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0" xml:lang="en-US">Adjustments to reconcile profit (loss) [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ForfeitedShares_lbl1" xml:lang="en-US">Forfeited Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ForfeitedShares" xlink:to="infrx_ForfeitedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl0" xml:lang="en-US">Non-current financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl0" xml:lang="en-US">Issue of equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0" xml:lang="en-US">Disclosure of events after reporting period [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0" xml:lang="en-US">Disclosure of financial liabilities [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl1" xml:lang="en-US">Equity attributable to owners of parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0" xml:lang="en-US">Expense from equity-settled share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CommonSharesSaleAgreement_lbl1" xml:lang="en-US">Common Shares Sale Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesSaleAgreement" xlink:to="infrx_CommonSharesSaleAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NumberOfShareOptionsUnderTheLTIPMember_lbl0" xml:lang="en-US">Number Of Share Options Under The LTIPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NumberOfShareOptionsUnderTheLTIPMember" xlink:to="infrx_NumberOfShareOptionsUnderTheLTIPMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl0" xml:lang="en-US">Proceeds from issuing other equity instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfStockOptionActivityAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Stock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfStockOptionActivityAbstract" xlink:to="infrx_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl0" xml:lang="en-US">Retained earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl0" xml:lang="en-US">Basic earnings (loss) per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl1" xml:lang="en-US">Comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl0" xml:lang="en-US">Disclosure of reserves within equity [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl0" xml:lang="en-US">Assets [abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0" xml:lang="en-US">Interest received, classified as operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl0" xml:lang="en-US">Issued capital [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ValuationPastGrantAmount_lbl1" xml:lang="en-US">Valuation Past Grant Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ValuationPastGrantAmount" xlink:to="infrx_ValuationPastGrantAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl1" xml:lang="en-US">Exchange Differences On Translation Of Foreign Currency1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:to="infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Fair Value Of Options Granted Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock" xlink:to="infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReservesMember_lbl0" xml:lang="en-US">Other reserves [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReservesMember" xlink:to="ifrs-full_OtherReservesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0" xml:lang="en-US">Interest expense on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl0" xml:lang="en-US">Current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAndOperatingIncome_lbl0" xml:lang="en-US">Revenue and other operating income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAndOperatingIncome" xlink:to="ifrs-full_RevenueAndOperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialExpensesAbstract_lbl0" xml:lang="en-US">Financial Expenses Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialExpensesAbstract" xlink:to="infrx_FinancialExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_SaleOfPricePerShare_lbl1" xml:lang="en-US">Sale Of Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_SaleOfPricePerShare" xlink:to="infrx_SaleOfPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_NonCurrentOtherAssetsAbstract_lbl0" xml:lang="en-US">Non Current Other Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_NonCurrentOtherAssetsAbstract" xlink:to="infrx_NonCurrentOtherAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl1" xml:lang="en-US">Adjustments For Decrease Increase In Financial Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:to="infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl1" xml:lang="en-US">Profit (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleInventoriesAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleInventoriesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleInventoriesAbstract_lbl" xml:lang="en-US">Schedule Inventories Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleInventoriesAbstract" xlink:to="infrx_ScheduleInventoriesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_DisclosureOfProtectiveFoundationExplanatory_lbl0" xml:lang="en-US">Disclosure Of Protective Foundation Explanatory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_DisclosureOfProtectiveFoundationExplanatory" xlink:to="infrx_DisclosureOfProtectiveFoundationExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_AuthorisdCapitalPreferenceSharesone_lbl0" xml:lang="en-US">Authorisd Capital Preference Sharesone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_AuthorisdCapitalPreferenceSharesone" xlink:to="infrx_AuthorisdCapitalPreferenceSharesone_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_CommonSharesDescription_lbl1" xml:lang="en-US">Common Shares Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_CommonSharesDescription" xlink:to="infrx_CommonSharesDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_IncomeFromGovernmentGrants_lbl1" xml:lang="en-US">Income From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_IncomeFromGovernmentGrants" xlink:to="infrx_IncomeFromGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl1" xml:lang="en-US">Equity [Standard Label]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_InAbstract_lbl0" xml:lang="en-US">In Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_InAbstract" xlink:to="infrx_InAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl0" xml:lang="en-US">Profit (loss) before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ShareOptionsExercised_lbl1" xml:lang="en-US">Share Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ShareOptionsExercised" xlink:to="infrx_ShareOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Interest Income Marketable Securities And Short Term Deposits Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" xlink:to="infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="infrx_ScheduleOfOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfOtherAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_ScheduleOfOtherAssetsAbstract_lbl" xml:lang="en-US">Schedule Of Other Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_ScheduleOfOtherAssetsAbstract" xlink:to="infrx_ScheduleOfOtherAssetsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl0" xml:lang="en-US">Financial Liabilities At Amortized Cost Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="infrx_FinancialLiabilitiesAtAmortizedCostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="infrx_LiabilitiesFromGovernmentGrants_lbl1" xml:lang="en-US">Liabilities From Government Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="infrx_LiabilitiesFromGovernmentGrants" xlink:to="infrx_LiabilitiesFromGovernmentGrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl0" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherExpenseByNature_lbl0" xml:lang="en-US">Other expenses, by nature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherExpenseByNature" xlink:to="ifrs-full_OtherExpenseByNature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained earnings [member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>infrx-20230630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Aug 10 04:34:51 UTC 2023 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedComprehensiveIncome" roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedComprehensiveIncome_Parentheticals" roleURI="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedBalanceSheet" roleURI="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareholdersEquityType2or3" roleURI="http://www.inflarx.de.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ConsolidatedCashFlow" roleURI="http://www.inflarx.de.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_SummaryofSignificantAccountingPoliciesandOtherDisclosures" roleURI="http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncome" roleURI="http://www.inflarx.de.com/role/OtherIncome"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_NetFinancialResult" roleURI="http://www.inflarx.de.com/role/NetFinancialResult"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_Inventories" roleURI="http://www.inflarx.de.com/role/Inventories"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssets" roleURI="http://www.inflarx.de.com/role/OtherAssets"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilities" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_CashandCashEquivalents" roleURI="http://www.inflarx.de.com/role/CashandCashEquivalents"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_Equity" roleURI="http://www.inflarx.de.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPayments" roleURI="http://www.inflarx.de.com/role/ShareBasedPayments"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ProtectiveFoundation" roleURI="http://www.inflarx.de.com/role/ProtectiveFoundation"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_SubsequentEvents" roleURI="http://www.inflarx.de.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_AccountingPoliciesByPolicy" roleURI="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncomeTables" roleURI="http://www.inflarx.de.com/role/OtherIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_NetFinancialResultTables" roleURI="http://www.inflarx.de.com/role/NetFinancialResultTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_InventoriesTables" roleURI="http://www.inflarx.de.com/role/InventoriesTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssetsTables" roleURI="http://www.inflarx.de.com/role/OtherAssetsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilitiesTables" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_CashandCashEquivalentsTables" roleURI="http://www.inflarx.de.com/role/CashandCashEquivalentsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPaymentsTables" roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsTables"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofOtherIncomeTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofNetFinancialResultTable" roleURI="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofForeignExchangeIncomeandExpenseTable" roleURI="http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleInventoriesTable" roleURI="http://www.inflarx.de.com/role/ScheduleInventoriesTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofOtherAssetsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofFinancialAssetsandliabilitiesTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofCashandCashEquivalentsTable" roleURI="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofStockOptionActivityTable" roleURI="http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ScheduleofFairValueofOptionsGrantedTable" roleURI="http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherIncomeDetails" roleURI="http://www.inflarx.de.com/role/OtherIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_InventoriesDetails" roleURI="http://www.inflarx.de.com/role/InventoriesDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_OtherAssetsDetails" roleURI="http://www.inflarx.de.com/role/OtherAssetsDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_FinancialAssetsandFinancialLiabilitiesDetails" roleURI="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_EquityDetails" roleURI="http://www.inflarx.de.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ShareBasedPaymentsDetails" roleURI="http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#infrx_r_ProtectiveFoundationDetails" roleURI="http://www.inflarx.de.com/role/ProtectiveFoundationDetails"/>
  <roleRef xlink:type="simple" xlink:href="infrx-20230630.xsd#DocumentAndEntityInformation" roleURI="http://www.inflarx.de.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SalesAndMarketingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_OtherIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RevenueAndOperatingIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueAndOperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_RevenueAndOperatingIncome" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_FinanceIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinanceCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_FinanceCosts" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncomeCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncomeCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_OtherFinanceIncomeCost" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_ProfitLoss" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ShareInformationAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ShareInformationAbstract" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareInformationAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareInformationAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareInformationAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeDifferencesOnTranslationOfForeignCurrency1" xlink:href="infrx-20230630.xsd#infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ExchangeDifferencesOnTranslationOfForeignCurrency1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals">
    <loc xlink:type="locator" xlink:label="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_RightofuseAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Inventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentTaxAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherFinancialAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremium" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremium"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_SharePremium" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReserves" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReserves"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherReserves" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_RetainedEarnings" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherEquityInterest" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherEquityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_OtherEquityInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentNonfinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentNonfinancialLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentNonfinancialLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShorttermEmployeeBenefitsAccruals" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_ShorttermEmployeeBenefitsAccruals" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:href="infrx-20230630.xsd#infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_IssuedCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharePremiumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_SharePremiumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherReservesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherReservesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_OtherReservesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityAttributableToOwnersOfParentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonSharesAndWarrants" xlink:href="infrx-20230630.xsd#infrx_IssuanceOfCommonSharesAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="IssuanceOfCommonSharesAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="8.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareOptionsExercised" xlink:href="infrx-20230630.xsd#infrx_ShareOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ShareOptionsExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAttributableToOwnersOfParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfSharesOutstanding_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetFinanceIncome" xlink:href="infrx-20230630.xsd#infrx_NetFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="NetFinanceIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetForeignExchangeDifferences" xlink:href="infrx-20230630.xsd#infrx_NetForeignExchangeDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="NetForeignExchangeDifferences" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangesInCashFlowAbstract" xlink:href="infrx-20230630.xsd#infrx_ChangesInCashFlowAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ChangesInCashFlowAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsForDecreaseIncreaseInFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="AdjustmentsForDecreaseIncreaseInFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LiabilitiesFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_LiabilitiesFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="LiabilitiesFromGovernmentGrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangesInCashFlowAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromTheMaturityOfFinancialAssets" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromTheMaturityOfFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromTheMaturityOfFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonShares" xlink:href="infrx-20230630.xsd#infrx_ProceedsFromIssuanceOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsForShareIssueCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RepaymentOfLeaseLiabilities" xlink:href="infrx-20230630.xsd#infrx_RepaymentOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="RepaymentOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CashAndCashEquivalents_0" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures">
    <loc xlink:type="locator" xlink:label="SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:href="infrx-20230630.xsd#infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfSummaryOfSignificantAccountingPolicy" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfSummaryOfSignificantAccountingPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract" xlink:to="DisclosureOfSummaryOfSignificantAccountingPolicy" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncome">
    <loc xlink:type="locator" xlink:label="OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherIncomeTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherIncomeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomesAbstract" xlink:to="DisclosureOfOtherIncomeTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NetFinancialResult">
    <loc xlink:type="locator" xlink:label="NetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfNetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfNetFinancialResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultAbstract" xlink:to="DisclosureOfNetFinancialResult" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Inventories">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssets">
    <loc xlink:type="locator" xlink:label="OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfOtherAssets" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetAbstract" xlink:to="DisclosureOfOtherAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities">
    <loc xlink:type="locator" xlink:label="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CashandCashEquivalents">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:to="ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/Equity">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPayments">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ProtectiveFoundation">
    <loc xlink:type="locator" xlink:label="ProtectiveFoundationAbstract" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfProtectiveFoundationExplanatory" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfProtectiveFoundationExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationAbstract" xlink:to="DisclosureOfProtectiveFoundationExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfReportingEntityAndGroupsStructure" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfReportingEntityAndGroupsStructure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="DisclosureOfReportingEntityAndGroupsStructure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncomeTables">
    <loc xlink:type="locator" xlink:label="OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeTablesTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesTable"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeTablesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomesAbstract" xlink:to="OtherIncomeTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeTablesTable" xlink:to="OtherIncomeTablesLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SummaryofotherIncometableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SummaryofotherIncometableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeTablesLineItems" xlink:to="SummaryofotherIncometableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/NetFinancialResultTables">
    <loc xlink:type="locator" xlink:label="NetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfNetFinancialResultTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultAbstract" xlink:to="ScheduleOfNetFinancialResultTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultAbstract" xlink:to="ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSraHXgFdBfbyxi2dbyBEg+pZWYpvY53es4KyIKzblefiTn6njGG+XZGXxCZ8vk0pzf2BbSbt12y1uVWxY1UC5CHr3HOLa1OtWXDwZEZ8dy+NaSAVQx88kOVP89nO3OxG2AwAKbtTKbWxmPnNSzeDnEh6pOJX1NjD8nwamwBWh+H+10+TOdGnDJZiHdGuWDLfc8s=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultAbstract" xlink:to="ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/InventoriesTables">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssetsTables">
    <loc xlink:type="locator" xlink:label="OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetAbstract" xlink:to="ifrs-full_DisclosureOfOtherAssetsExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables">
    <loc xlink:type="locator" xlink:label="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/CashandCashEquivalentsTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfCashAndCashEquivalentsTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCashAndCashEquivalentsTextBlockAbstract" xlink:to="DisclosureOfCashAndCashEquivalentsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPaymentsTables">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="SchdeuleOfStockOptionActivityTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_SchdeuleOfStockOptionActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsAbstract" xlink:to="SchdeuleOfStockOptionActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfOptionsGrantedTableTextBlock" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsAbstract" xlink:to="ScheduleOfFairValueOfOptionsGrantedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherIncomeAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfOtherIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeDetailsScheduleofOtherIncomeTable"/>
    <loc xlink:type="locator" xlink:label="OtherIncomesLineItems" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherIncomeAbstract" xlink:to="OtherIncomeDetailsScheduleofOtherIncomeTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomeDetailsScheduleofOtherIncomeTable" xlink:to="OtherIncomesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomesLineItems" xlink:to="us-gaap_OtherIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncomeFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_IncomeFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="IncomeFromGovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherIncomeTotal" xlink:href="infrx-20230630.xsd#infrx_OtherIncomeTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="OtherIncomeTotal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetFinancialResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfNetFinancialResultAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialIncomeAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="FinancialIncomeAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialIncomeAbstract" xlink:to="ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialExpensesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetFinancialResultAbstract" xlink:to="FinancialExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="ifrs-full_InterestExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="NetFinancialResult" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialExpensesAbstract" xlink:to="NetFinancialResult" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeResultAbstract" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeResultAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract" xlink:to="ForeignExchangeResultAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeIncome" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForeignExchangeResultAbstract" xlink:to="ForeignExchangeIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignExchangeExpense" xlink:href="infrx-20230630.xsd#infrx_ForeignExchangeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForeignExchangeResultAbstract" xlink:to="ForeignExchangeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForeignExchangeResultAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfForeignExchangeIncomeAndExpenseAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable"/>
    <loc xlink:type="locator" xlink:label="NetFinancialResultLineItems" xlink:href="infrx-20230630.xsd#infrx_NetFinancialResultLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfForeignExchangeIncomeAndExpenseAbstract" xlink:to="NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable" xlink:to="NetFinancialResultLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OtherFinancialResult" xlink:href="infrx-20230630.xsd#infrx_OtherFinancialResult"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetFinancialResultLineItems" xlink:to="OtherFinancialResult" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleInventoriesTable">
    <loc xlink:type="locator" xlink:label="ScheduleInventoriesAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="InventoriesDetailsScheduleInventoriesTable" xlink:href="infrx-20230630.xsd#infrx_InventoriesDetailsScheduleInventoriesTable"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoriesLineItems" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfInventoriesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleInventoriesAbstract" xlink:to="InventoriesDetailsScheduleInventoriesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleInventoriesTable" xlink:to="ifrs-full_SegmentsAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_SegmentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SegmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SegmentsAxis" xlink:to="ifrs-full_SegmentsMember" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoriesDetailsScheduleInventoriesTable" xlink:to="ScheduleOfInventoriesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnfinishedGoods" xlink:href="infrx-20230630.xsd#infrx_UnfinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesLineItems" xlink:to="UnfinishedGoods" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FinishedGoods" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_FinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoriesLineItems" xlink:to="ifrs-full_CurrentFinancialAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfOtherAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="NonCurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_NonCurrentOtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="NonCurrentOtherAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonPrepaidExpenses" xlink:href="infrx-20230630.xsd#infrx_NonPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentOtherAssetsAbstract" xlink:to="NonPrepaidExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherNoncurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonCurrentOtherAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentOtherAssetsAbstract" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAssetsAbstract" xlink:to="CurrentOtherAssetsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentsOnResearchDevelopmentProjects" xlink:href="infrx-20230630.xsd#infrx_PrepaymentsOnResearchDevelopmentProjects"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="PrepaymentsOnResearchDevelopmentProjects" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentPrepaidExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CurrentOtherAssetsTotal" xlink:href="infrx-20230630.xsd#infrx_CurrentOtherAssetsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="CurrentOtherAssetsTotal" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentAssetsLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentOtherAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAtAmortizedCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialAssetsAtAmortizedCostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAtAmortizedCostAbstract" xlink:to="FinancialAssetsFromGovernmentGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAtAmortizedCostAbstract" xlink:to="ifrs-full_OtherCurrentFinancialAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialLiabilitiesAtAmortizedCostAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialLiabilitiesAtAmortizedCostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesAbstract" xlink:to="FinancialLiabilitiesAtAmortizedCostAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_GovernmentGrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrs-full_GovernmentGrants" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherPayables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialLiabilitiesAtAmortizedCostAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfCashAndCashEquivalentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfCashAndCashEquivalentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable"/>
    <loc xlink:type="locator" xlink:label="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:href="infrx-20230630.xsd#infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCashAndCashEquivalentsAbstract" xlink:to="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyInWhichInformationIsDisplayedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:to="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_FunctionalOrPresentationCurrencyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FunctionalOrPresentationCurrencyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="ifrs-full_FunctionalOrPresentationCurrencyMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="DepositsHeldInUSDollarsMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInUSDollarsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="DepositsHeldInUSDollarsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DepositsHeldInEurosMember" xlink:href="infrx-20230630.xsd#infrx_DepositsHeldInEurosMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrencyInWhichInformationIsDisplayedAxis" xlink:to="DepositsHeldInEurosMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable" xlink:to="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ShortTermDepositsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShortTermDepositsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ShortTermDepositsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShorttermDepositsClassifiedAsCashEquivalentsTotal" xlink:href="infrx-20230630.xsd#infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermDepositsAbstract" xlink:to="ShorttermDepositsClassifiedAsCashEquivalentsTotal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAtBanksAbstract" xlink:href="infrx-20230630.xsd#infrx_CashAtBanksAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="CashAtBanksAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAtBankstotal" xlink:href="infrx-20230630.xsd#infrx_CashAtBankstotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAtBanksAbstract" xlink:to="CashAtBankstotal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems" xlink:to="ifrs-full_OtherCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsUnderThe2012PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2012PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="NumberOfShareOptionsUnderThe2012PlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsUnderThe2016PlanMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderThe2016PlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="NumberOfShareOptionsUnderThe2016PlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfShareOptionsUnderTheLTIPMember" xlink:href="infrx-20230630.xsd#infrx_NumberOfShareOptionsUnderTheLTIPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="NumberOfShareOptionsUnderTheLTIPMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable" xlink:to="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="OutstandingBalance" xlink:href="infrx-20230630.xsd#infrx_OutstandingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="OutstandingBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_ExercisedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="ExercisedNumberOfShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForfeitedShares" xlink:href="infrx-20230630.xsd#infrx_ForfeitedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="ForfeitedShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingBalance_0" xlink:href="infrx-20230630.xsd#infrx_OutstandingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="OutstandingBalance_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" xlink:href="infrx-20230630.xsd#infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:href="infrx-20230630.xsd#infrx_ScheduleOfFairValueOfOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfOptionsGrantedAbstract" xlink:to="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRateregulatedActivitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="ifrs-full_TypesOfRateregulatedActivitiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_RateregulatedActivitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RateregulatedActivitiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="ifrs-full_RateregulatedActivitiesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="JanuaryTwentyFourMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="JanuaryTwentyFourMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JanuaryTwentyFourOneMember" xlink:href="infrx-20230630.xsd#infrx_JanuaryTwentyFourOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="JanuaryTwentyFourOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MayThirtyMember" xlink:href="infrx-20230630.xsd#infrx_MayThirtyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRateregulatedActivitiesAxis" xlink:to="MayThirtyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable" xlink:to="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuePerOption" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="FairValuePerOption" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FXRateAsOfGrantDate" xlink:href="infrx-20230630.xsd#infrx_FXRateAsOfGrantDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="FXRateAsOfGrantDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValuePerOptions" xlink:href="infrx-20230630.xsd#infrx_FairValuePerOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="FairValuePerOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceAtGrantDateExercisePrice" xlink:href="infrx-20230630.xsd#infrx_SharePriceAtGrantDateExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="SharePriceAtGrantDateExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpectedLifemidpointBased" xlink:href="infrx-20230630.xsd#infrx_ExpectedLifemidpointBased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ExpectedLifemidpointBased" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherIncomeDetails">
    <loc xlink:type="locator" xlink:label="OtherIncomesAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherIncomesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherFinanceIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherFinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherIncomesAbstract" xlink:to="ifrs-full_OtherFinanceIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/InventoriesDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ReversalOfInventoryWritedown" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReversalOfInventoryWritedown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ReversalOfInventoryWritedown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/OtherAssetsDetails">
    <loc xlink:type="locator" xlink:label="OtherAssetAbstract" xlink:href="infrx-20230630.xsd#infrx_OtherAssetAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentPrepayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAssetAbstract" xlink:to="ifrs-full_NoncurrentPrepayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails">
    <loc xlink:type="locator" xlink:label="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:href="infrx-20230630.xsd#infrx_FinancialAssetsAndFinancialLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AssetsFromGovernmentGrants" xlink:href="infrx-20230630.xsd#infrx_AssetsFromGovernmentGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAndFinancialLiabilitiesAbstract" xlink:to="AssetsFromGovernmentGrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="EquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CommonSharesSaleAgreement" xlink:href="infrx-20230630.xsd#infrx_CommonSharesSaleAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonSharesSaleAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_Equity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SoldCommonSharesThroughAPublicOffering" xlink:href="infrx-20230630.xsd#infrx_SoldCommonSharesThroughAPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SoldCommonSharesThroughAPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactions" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ShareBasedPaymentTransactions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SaleOfPricePerShare" xlink:href="infrx-20230630.xsd#infrx_SaleOfPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SaleOfPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NominalValuePerShare" xlink:href="infrx-20230630.xsd#infrx_NominalValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="NominalValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentProperty" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentProperty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentProperty" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_CurrentInvestments" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OtherExpenseByNature" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherExpenseByNature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ifrs-full_OtherExpenseByNature" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOfferingExpensesTotal" xlink:href="infrx-20230630.xsd#infrx_OtherOfferingExpensesTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="OtherOfferingExpensesTotal" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ShareBasedPaymentsDetails">
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsAbstract" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentsDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ShareBasedPaymentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsAbstract" xlink:to="ShareBasedPaymentsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfOrdinarySharesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_OrdinarySharesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BoardOfDirectorsMember" xlink:href="infrx-20230630.xsd#infrx_BoardOfDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="BoardOfDirectorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OptionLTIPMember" xlink:href="infrx-20230630.xsd#infrx_OptionLTIPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="OptionLTIPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsTable" xlink:to="ShareBasedPaymentsDetailsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CommonSharesDescription" xlink:href="infrx-20230630.xsd#infrx_CommonSharesDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="CommonSharesDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentExpense" xlink:href="infrx-20230630.xsd#infrx_SharebasedPaymentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="SharebasedPaymentExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationPastGrantAmount" xlink:href="infrx-20230630.xsd#infrx_ValuationPastGrantAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ValuationPastGrantAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentsDetailsLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/ProtectiveFoundationDetails">
    <loc xlink:type="locator" xlink:label="ProtectiveFoundationAbstract" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationAbstract"/>
    <loc xlink:type="locator" xlink:label="ProtectiveFoundationDetailsTable" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ProtectiveFoundationDetailsLineItems" xlink:href="infrx-20230630.xsd#infrx_ProtectiveFoundationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationAbstract" xlink:to="ProtectiveFoundationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsTable" xlink:to="ProtectiveFoundationDetailsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AuthorisedCapitalCommonSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisedCapitalCommonSharesone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsLineItems" xlink:to="AuthorisedCapitalCommonSharesone" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AuthorisdCapitalPreferenceSharesone" xlink:href="infrx-20230630.xsd#infrx_AuthorisdCapitalPreferenceSharesone"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsLineItems" xlink:to="AuthorisdCapitalPreferenceSharesone" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PricePerShares" xlink:href="infrx-20230630.xsd#infrx_PricePerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsLineItems" xlink:to="PricePerShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedCapital" xlink:href="infrx-20230630.xsd#infrx_PercentageOfIssuedCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsLineItems" xlink:to="PercentageOfIssuedCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProtectiveFoundationDetailsLineItems" xlink:to="ifrs-full_EmployeeBenefitsExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.inflarx.de.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="infrx-20230630.xsd#infrx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720489904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">InflaRx
N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Winzerlaer Str. 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jena<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719769216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract', window );"><strong>Unaudited Condensed Consolidated Statements Of Operations And Comprehensive Loss Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">&#8364; (10,919,595)<span></span>
</td>
<td class="num">&#8364; (11,180,958)<span></span>
</td>
<td class="num">&#8364; (25,651,503)<span></span>
</td>
<td class="num">&#8364; (21,652,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(3,540,805)<span></span>
</td>
<td class="num">(4,346,965)<span></span>
</td>
<td class="num">(7,149,359)<span></span>
</td>
<td class="num">(8,734,408)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="num">(276,051)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(276,051)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income</a></td>
<td class="nump">4,882,908<span></span>
</td>
<td class="nump">14,441,541<span></span>
</td>
<td class="nump">12,629,096<span></span>
</td>
<td class="nump">14,443,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax', window );">Other expenses</a></td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(3,190)<span></span>
</td>
<td class="num">(844)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAndOperatingIncome', window );">Operating Result</a></td>
<td class="num">(9,856,168)<span></span>
</td>
<td class="num">(1,086,661)<span></span>
</td>
<td class="num">(20,451,007)<span></span>
</td>
<td class="num">(15,944,999)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">1,087,011<span></span>
</td>
<td class="nump">82,401<span></span>
</td>
<td class="nump">1,543,047<span></span>
</td>
<td class="nump">110,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(5,052)<span></span>
</td>
<td class="num">(7,945)<span></span>
</td>
<td class="num">(10,580)<span></span>
</td>
<td class="num">(32,531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange result</a></td>
<td class="nump">767,646<span></span>
</td>
<td class="nump">1,563,580<span></span>
</td>
<td class="num">(369,664)<span></span>
</td>
<td class="nump">2,291,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncomeCost', window );">Other financial result</a></td>
<td class="num">(195,567)<span></span>
</td>
<td class="num">(86,000)<span></span>
</td>
<td class="nump">2,241<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Income (Loss) for the Period</a></td>
<td class="num">&#8364; (8,202,130)<span></span>
</td>
<td class="nump">&#8364; 465,376<span></span>
</td>
<td class="num">&#8364; (19,285,963)<span></span>
</td>
<td class="num">&#8364; (13,536,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareInformationAbstract', window );"><strong>Share Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares outstanding (in Shares)</a></td>
<td class="nump">56,985,734<span></span>
</td>
<td class="nump">44,203,763<span></span>
</td>
<td class="nump">50,912,459<span></span>
</td>
<td class="nump">44,203,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Income (Loss) per share (basic) (in Euro per share)</a></td>
<td class="num">&#8364; (0.14)<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="num">&#8364; (0.38)<span></span>
</td>
<td class="num">&#8364; (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1', window );">Exchange differences on translation of foreign currency</a></td>
<td class="num">&#8364; (330)<span></span>
</td>
<td class="nump">&#8364; 4,408,940<span></span>
</td>
<td class="num">&#8364; (17,116)<span></span>
</td>
<td class="nump">&#8364; 5,718,815<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total Comprehensive Income (Loss)</a></td>
<td class="num">&#8364; (8,202,460)<span></span>
</td>
<td class="nump">&#8364; 4,874,316<span></span>
</td>
<td class="num">&#8364; (19,303,079)<span></span>
</td>
<td class="num">&#8364; (7,817,839)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on financial assets measured at fair value through other comprehensive income applying paragraph 4.1.2A of IFRS 9, net of tax, before reclassification adjustments. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAndOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAndOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange differences on translation of foreign currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719986864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract', window );"><strong>Unaudited Condensed Consolidated Statements Of Operations And Comprehensive Loss Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Income (Loss) per share (diluted)</a></td>
<td class="num">&#8364; (0.14)<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="num">&#8364; (0.38)<span></span>
</td>
<td class="num">&#8364; (0.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720064272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Financial Position - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">&#8364; 296,382<span></span>
</td>
<td class="nump">&#8364; 328,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1,122,183<span></span>
</td>
<td class="nump">1,311,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">90,789<span></span>
</td>
<td class="nump">138,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">283,784<span></span>
</td>
<td class="nump">308,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">18,951,267<span></span>
</td>
<td class="nump">2,900,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">20,744,405<span></span>
</td>
<td class="nump">4,988,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">578,705<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Current other assets</a></td>
<td class="nump">6,405,867<span></span>
</td>
<td class="nump">14,170,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssets', window );">Current tax assets</a></td>
<td class="nump">2,925,037<span></span>
</td>
<td class="nump">1,432,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets from government grants</a></td>
<td class="nump">5,193,246<span></span>
</td>
<td class="nump">732,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">77,601,286<span></span>
</td>
<td class="nump">64,810,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">19,515,959<span></span>
</td>
<td class="nump">16,265,355<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">112,220,100<span></span>
</td>
<td class="nump">97,411,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">132,964,505<span></span>
</td>
<td class="nump">102,399,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">7,065,993<span></span>
</td>
<td class="nump">5,364,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">334,211,338<span></span>
</td>
<td class="nump">282,552,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other capital reserves</a></td>
<td class="nump">38,874,961<span></span>
</td>
<td class="nump">36,635,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(262,746,253)<span></span>
</td>
<td class="num">(243,460,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEquityInterest', window );">Other components of equity</a></td>
<td class="nump">7,239,965<span></span>
</td>
<td class="nump">7,257,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">124,646,004<span></span>
</td>
<td class="nump">88,349,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">814,560<span></span>
</td>
<td class="nump">987,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">36,877<span></span>
</td>
<td class="nump">36,877<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">851,437<span></span>
</td>
<td class="nump">1,024,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">5,200,809<span></span>
</td>
<td class="nump">4,987,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentNonfinancialLiabilities', window );">Liabilities from government grants</a></td>
<td class="nump">801,632<span></span>
</td>
<td class="nump">6,209,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">356,099<span></span>
</td>
<td class="nump">369,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermEmployeeBenefitsAccruals', window );">Employee benefits</a></td>
<td class="nump">900,474<span></span>
</td>
<td class="nump">1,312,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">208,051<span></span>
</td>
<td class="nump">147,608<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">7,467,065<span></span>
</td>
<td class="nump">13,026,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">8,318,502<span></span>
</td>
<td class="nump">14,050,220<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL EQUITY AND LIABILITIES</a></td>
<td class="nump">&#8364; 132,964,505<span></span>
</td>
<td class="nump">&#8364; 102,399,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentNonfinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentNonfinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermEmployeeBenefitsAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermEmployeeBenefitsAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719055296">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Shares outstanding</div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Share premium</div></th>
<th class="th"><div>Other capital reserves</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Other components of equity</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,304,452<span></span>
</td>
<td class="nump">&#8364; 280,310,744<span></span>
</td>
<td class="nump">&#8364; 30,591,209<span></span>
</td>
<td class="num">&#8364; (213,975,679)<span></span>
</td>
<td class="nump">&#8364; 3,050,271<span></span>
</td>
<td class="nump">&#8364; 105,280,996<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,203,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,536,654)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,536,654)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign currency</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,718,815<span></span>
</td>
<td class="nump">5,718,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13,536,654)<span></span>
</td>
<td class="nump">5,718,815<span></span>
</td>
<td class="num">(7,817,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,668,481<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,668,481<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Balance at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,304,452<span></span>
</td>
<td class="nump">280,310,744<span></span>
</td>
<td class="nump">35,259,689<span></span>
</td>
<td class="num">(227,512,333)<span></span>
</td>
<td class="nump">8,769,086<span></span>
</td>
<td class="nump">102,131,638<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">44,203,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,364,452<span></span>
</td>
<td class="nump">282,552,633<span></span>
</td>
<td class="nump">36,635,564<span></span>
</td>
<td class="num">(243,460,290)<span></span>
</td>
<td class="nump">7,257,081<span></span>
</td>
<td class="nump">88,349,440<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,703,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,285,963)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,285,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax', window );">Exchange differences on translation of foreign currency</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,116)<span></span>
</td>
<td class="num">(17,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(19,285,963)<span></span>
</td>
<td class="num">(17,116)<span></span>
</td>
<td class="num">(19,303,079)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of common shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687,110<span></span>
</td>
<td class="nump">54,796,819<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">56,483,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_IssuanceOfCommonSharesAndWarrants', window );">Issuance of common shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,059,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,360,626)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,360,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share-based payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,239,397<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,239,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Share options exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,431<span></span>
</td>
<td class="nump">222,512<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">236,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareOptionsExercised', window );">Share options exercised (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">120,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAttributableToOwnersOfParent', window );">Balance at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,065,993<span></span>
</td>
<td class="nump">&#8364; 334,211,338<span></span>
</td>
<td class="nump">&#8364; 38,874,961<span></span>
</td>
<td class="num">&#8364; (262,746,253)<span></span>
</td>
<td class="nump">&#8364; 7,239,965<span></span>
</td>
<td class="nump">&#8364; 124,646,004<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">58,883,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unaudited</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph r<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_r&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_IssuanceOfCommonSharesAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common shares and warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_IssuanceOfCommonSharesAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share options exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702716883344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Condensed Consolidated Statements of Cash Flows - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss for the period</a></td>
<td class="num">&#8364; (19,285,963)<span></span>
</td>
<td class="num">&#8364; (13,536,654)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets</a></td>
<td class="nump">293,328<span></span>
</td>
<td class="nump">300,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetFinanceIncome', window );">Net finance income</a></td>
<td class="num">(1,165,044)<span></span>
</td>
<td class="num">(2,408,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based payment expense</a></td>
<td class="nump">2,239,397<span></span>
</td>
<td class="nump">4,668,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetForeignExchangeDifferences', window );">Net foreign exchange differences</a></td>
<td class="num">(23,953)<span></span>
</td>
<td class="nump">130,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ChangesInCashFlowAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets', window );">Financial assets from government grants</a></td>
<td class="num">(4,460,274)<span></span>
</td>
<td class="num">(8,260,503)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">6,295,975<span></span>
</td>
<td class="nump">611,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities', window );">Employee benefits</a></td>
<td class="num">(411,774)<span></span>
</td>
<td class="num">(640,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities', window );">Other liabilities</a></td>
<td class="nump">60,443<span></span>
</td>
<td class="num">(7,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_LiabilitiesFromGovernmentGrants', window );">Liabilities from government grants received</a></td>
<td class="num">(5,407,634)<span></span>
</td>
<td class="num">(6,154,865)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Trade and other payables</a></td>
<td class="nump">213,270<span></span>
</td>
<td class="num">(661,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="num">(578,705)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">556,068<span></span>
</td>
<td class="nump">631,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(10,777)<span></span>
</td>
<td class="num">(32,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,685,642)<span></span>
</td>
<td class="num">(25,359,081)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of intangible assets, property and equipment</a></td>
<td class="num">(24,673)<span></span>
</td>
<td class="num">(9,728)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfAvailableforsaleFinancialAssets', window );">Purchase of current financial assets</a></td>
<td class="num">(83,071,163)<span></span>
</td>
<td class="num">(47,031,216)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ProceedsFromTheMaturityOfFinancialAssets', window );">Proceeds from the maturity of financial assets</a></td>
<td class="nump">55,202,491<span></span>
</td>
<td class="nump">59,595,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash from/(used in) investing activities</a></td>
<td class="num">(27,893,346)<span></span>
</td>
<td class="nump">12,554,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ProceedsFromIssuanceOfCommonShares', window );">Proceeds from issuance of common shares</a></td>
<td class="nump">56,483,929<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Transaction costs from issuance of common shares</a></td>
<td class="num">(3,360,626)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of share options</a></td>
<td class="nump">236,943<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_RepaymentOfLeaseLiabilities', window );">Repayment of lease liabilities</a></td>
<td class="num">(184,791)<span></span>
</td>
<td class="num">(182,014)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash from/(used in) financing activities</a></td>
<td class="nump">53,175,455<span></span>
</td>
<td class="num">(182,014)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Net increase/(decrease) in cash and cash equivalents</a></td>
<td class="nump">3,596,467<span></span>
</td>
<td class="num">(12,986,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(345,862)<span></span>
</td>
<td class="nump">2,153,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,265,355<span></span>
</td>
<td class="nump">26,249,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">&#8364; 19,515,959<span></span>
</td>
<td class="nump">&#8364; 15,416,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2023-01-01<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets adjusted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ChangesInCashFlowAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ChangesInCashFlowAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_LiabilitiesFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities from government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_LiabilitiesFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net finance income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetForeignExchangeDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net foriegn exchange difference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetForeignExchangeDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ProceedsFromIssuanceOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of prceeds from issuance of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ProceedsFromIssuanceOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ProceedsFromTheMaturityOfFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preceeds from the maturity of financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ProceedsFromTheMaturityOfFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_RepaymentOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of repayment of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_RepaymentOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723195312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies and Other Disclosures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract', window );"><strong>Summary of Significant Accounting Policies and Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfSummaryOfSignificantAccountingPolicy', window );">Summary of significant accounting policies and other disclosures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary
of significant accounting policies and other disclosures</span></td>
</tr></table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
entity and the Group&#8217;s structure</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. (the &#8220;Company&#8221; or &#8220;InflaRx&#8221;) is a Dutch public company with limited liability (<i>naamloze vennootschap</i>)
with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company&#8217;s registered office is at Winzerlaer Stra&#223;e 2 in 07745 Jena, Germany.
Since November 10, 2017, InflaRx N.V.&#8217;s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize
first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. On April 4, 2023, the US Food and Drug
Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the Company&#8217;s monoclonal anti-C5a antibody
vilobelimab, under the brand name Gohibic, for the treatment of COVID-19 in hospitalized adults. These consolidated financial statements
of InflaRx comprise the Company and its wholly-owned subsidiaries, InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann
Arbor, Michigan, United States (together referred to as the &#8220;Group&#8221;).</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of preparation</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements for the three- and six-month reporting periods ended June 30, 2023, and 2022 have
been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include
all the information and disclosures required in the annual financial statements. Accordingly, this report is to be read in conjunction
with the financial statements in our annual report for the year ended December 31, 2022 on form 20-F.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the &#8220;Board
of Directors&#8221;) on August 9, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are presented in euros (&#8364;). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional
currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. Effective January 1, 2023, the functional currency of InflaRx N.V. changed
from the U.S. dollar to the euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency
of its underlying transactions. This change in functional currency has been accounted for prospectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial information presented in euros have been rounded. Accordingly, numerical figures shown as totals in some tables may not be
an arithmetic aggregation of the figures that precede them or may deviate from other tables.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies adopted are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial
statements for the year ended December 31, 2022, except for the adoption of new standards effective as of January 1, 2023, as set out
below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following IFRS standards have been applied starting in Q2 2023 for the first time ever, as no transactions in the scope of these IFRS
standards had been previously recognized and are not expected to have a significant impact on the Company&#8217;s consolidated financial
statements in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 Inventories&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of cost or their net realizable value. Cost comprises direct materials and, where
applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and
condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less
all estimated costs of completion and costs to be incurred in marketing, selling and distribution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 Revenue from contracts with customers&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
will be recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer.
An asset is transferred when the customer obtains control of that asset. Revenue will be recognized at the point in time that the control
of the products is transferred to the customer and measured considering return liabilities. As of June 30, 2023, no revenue has been
recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 Insurance Contracts&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting
                                            Estimates&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies -</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group&#8217;s
consolidated financial statements is being assessed:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 Leases: Leases on Sale and Leaseback&#160;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or
                                            Non-current and Non-current Liabilities with Covenants</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfSummaryOfSignificantAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfSummaryOfSignificantAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723195440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherIncomesAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfOtherIncomeTextBlock', window );">Other income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended June
    30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>
ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">Other income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt">Income from government grants</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">4,874,934</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">14,415,368</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">12,609,789</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">14,415,368</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; width: 60%">Other</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">7,974</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">26,173</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">19,307</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">27,767</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,882,908</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,441,541</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,629,096</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,443,135</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income for the three months ended June 30, 2023 amounted to &#8364;4.9 million (PY: &#8364;14.4 million) and for the six months ended June
30, 2023 amounted to &#8364;12.6 million (PY: &#8364;14.4 million), which is primarily attributable to income recognized from grant payments
received from the German federal government for the development of vilobelimab as treatment for critically ill COVID patients, including
expenses related to clinical development and manufacturing process development. The decrease in income from government grants is primarily
due to a non-recurring catch-up effect of costs incurred in preceding periods for which income recognition was deferred until the three
months ended June 30, 2022 when the recognition criteria were met.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfOtherIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfOtherIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherIncomesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherIncomesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723146880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Financial Result<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetFinancialResultAbstract', window );"><strong>Net Financial Result</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfNetFinancialResult', window );">Net financial result</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
financial result</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,087,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">82,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,543,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">110,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,243</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,102</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,689</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,081,959</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">74,456</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,532,467</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,831</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Foreign exchange result</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Foreign exchange income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,090,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,947,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,381,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">4,057,629</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,323,348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,383,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,751,183</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,766,116</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">767,646</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,563,580</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(369,664</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,291,513</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign
exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx
GmbH and InflaRx N.V.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Other financial result</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(195,567</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(86,000</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,241</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">39,000</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
financial result is attributable to the expected credit loss allowance, which is deducted from the Company&#8217;s current and non-current
financial assets.<span style="clear: both; display: block;"><br/></span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfNetFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfNetFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetFinancialResultAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetFinancialResultAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702722812528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,407</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,674</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">578,705</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company valued inventories at manufacturing cost in its consolidated statements of financial position as of June 30, 2023. Inventories
do not include costs relating to production of products before the granting of the EUA for Gohibic (vilobelimab), since those were expensed
in previous reporting periods as research and development expenses in the period incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the three and the six months ended June 30, 2023, there were no write-downs of inventories.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720635440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherAssetAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfOtherAssets', window );">Other assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
assets</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current other assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">283,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">308,066</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">283,784</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,066</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,757,771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,776,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Prepaid expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,146,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,841,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">501,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,552,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,405,867</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,170,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,689,651</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,478,577</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, prepayments on research &amp; development projects amounted to &#8364;4.8 million compared to &#8364;9.8 million as of
December 31, 2022, and consist of prepayments on clinical and R&amp;D material production contracts. The decrease in prepayments results
from manufacturing development activities, which were partly completed in the six months ended June 30, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses mainly consist of prepaid insurance expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reduction of the amounts in the category &#8220;others&#8221; primarily relate to credit notes issued to the Company by CROs, which were
still outstanding as of December 31, 2022 and were paid in 2023.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723041024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract', window );"><strong>Financial Assets and Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Financial assets and financial liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
assets and financial liabilities</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30,
2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,951,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,900,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,193,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">732,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,601,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,791,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,209,266</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,200,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,987,538</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to &#8364;100.7
million (Level 1). The Group&#8217;s debt instruments at amortized cost consist solely of quoted securities that are graded highly by
credit rating agencies such as S&amp;P Global and, therefore, are considered low credit risk investments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2023, liabilities from government grants amounted to &#8364;0.8 million. Liabilities from government grants partly comprise
funds received for advance payments to third parties. If goods or services from such third parties have not been received, corresponding
amounts are not recognized as other income. The Company&#8217;s right to retain these funds is contingent on meeting all grant conditions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Offsetting financial assets and financial liabilities<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F__IFRS07_g13A-13F_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialAssetsAndFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719175424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents</span></td>
</tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> June 30, 2023 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term deposits</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">7,825,926</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Deposits held in euros</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,925,926</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,422</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,340,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,645,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Cash held in euros</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">2,249,144</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">7,616,918</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,590,033</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,261,932</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,515,959</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,265,354</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702721495104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory', window );">Equity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company issued 3,235,723 ordinary shares under its ATM program resulting in $15.7 million (or &#8364;14.4 million) in
net proceeds. The existing ATM program expired in July 2023 and no more shares are issuable under this program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
an underwritten public offering in April 2023, the Company sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764
were sold pursuant to the exercise of an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25
per share and have a nominal value of &#8364;0.12 per share. Proceeds of this offering after deducting &#8364;2.5 million ($2.8 million)
in underwriting discounts amounted to &#8364;39.1 million ($43.2 million). Other offering expenses amounted to &#8364;0.4 million, resulting
in a total of &#8364;38.7 million in net proceeds from this offering.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of reserves within equity. [Refer: Other reserves [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723083136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsAbstract', window );"><strong>Share-Based Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
payments</span></td>
</tr></table>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
settled share-based payment arrangements</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to 2016, InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary
shares of InflaRx N.V. at the time of its IPO in November 2017:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148,433</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised during the six months ended June 30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0pt; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">148,433</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">148,433</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH&#8217;s ordinary shares
to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx
N.V. at the time of its IPO in November 2017:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding: 0pt; font-weight: bold">&#160;</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; width: 76%; font-weight: bold">Outstanding as of January 1,</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right">888,632</td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right">888,632</td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-indent: 0in">Exercised during the six months ended June 30</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">&#8212;</td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Outstanding as of June 30,</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">888,632</td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">888,632</td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-style: italic; text-align: left">thereof vested</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right">888,632</td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right">888,632</td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
also granted share options under the 2017 LTIP subsequently to its IPO in November 2017. The total number of share options granted during
the six months ended June 30, 2023 under the 2017 LTIP was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0in">Total number of options outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,985,523</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,170,046</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Granted during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,561,666</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in">Exercised during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Forfeited during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117,259</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0in">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,447,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,614,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">4,788,759</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">3,306,162</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of share options granted during the six months ended June 30, 2023 under the 2017 LTIP was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share options
granted 2023</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share price at grant date /</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risk-free rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(interpolated, U.S. sovereign strips curve)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">January 24</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,454,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.9008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 6%; text-align: right">1.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">5.30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3.571</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>January 24</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.565</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">60,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">3,61</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">0.9203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">3.820</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,567,250</b></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the 1,567,250 options granted in the six months ended June 30, 2023 (ended June 30, 2022: 1,561,666), 1,246,000 options (June 30, 2022: 1,362,500) were granted to members of the executive management or Board of Directors.</span> &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">Expected dividends are nil for all share options listed above. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">b)</td><td style="text-align: justify"><b><i>Share-based payment expense recognized</i></b></td>
</tr></table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2023, the Company has recognized &#8364;2.2 million (ended June 30, 2022: &#8364;4.7 million) of share-based
payment expense/(benefit) in the statements of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the share-based payment awards were dilutive in determining earnings per share due to the Group&#8217;s loss position.</span></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.95pt; text-indent: -17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">c)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Share
                                            options exercised</i></b></span></td>
</tr></table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, 105,327 shares (ended June 30, 2022: 0) were issued upon the exercise of share options, resulting
in proceeds to the Company in the amount of &#8364;98 thousand (ended June 30, 2022: 0). All share options exercised during the six months
ended June 30, 2023 were granted under the 2017 LTIP.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702722955168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Protective Foundation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ProtectiveFoundationAbstract', window );"><strong>Protective Foundation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfProtectiveFoundationExplanatory', window );">Protective foundation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Protective
foundation</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Articles of Association of the Company, up to 110,000,000 ordinary shares and up to 110,000,000 preferred shares with a nominal
value of &#8364;0.12 per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to deter acquisition bids, the Company`s shareholders approved the right of an independent foundation under Dutch law, or protective
foundation, to exercise a call option on preferred shares. Pursuant to the call option agreement, the Company shall issue an amount of
preferred shares to the protective foundation, amounting to up to 100% of the Company&#8217;s issued capital held by others than the
protective foundation, minus one share. In order to exercise its right to such share issue, the protective foundation is expected to
enter into a finance arrangement with a bank, or subject to applicable restrictions under Dutch law, the protective foundation may request
the Company to provide, or cause the Company&#8217;s subsidiaries to provide, sufficient funding to the protective foundation to enable
it to satisfy its payment obligation under the call option agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
preferred shares will have both a liquidation and dividend preference over the Company`s ordinary shares and will accrue cash dividends
at a pre-determined rate. The protective foundation would be expected to require us to cancel its preferred shares once the perceived
threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. We believe that the call option
does not represent a significant fair value based on a Level 3 valuation, since the preference shares are restricted in use and can be
canceled by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2023, the Company expensed &#8364;45 thousand (2022: &#8364;30 thousand) of ongoing costs to reimburse expenses
incurred by the protective foundation.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfProtectiveFoundationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfProtectiveFoundationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ProtectiveFoundationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ProtectiveFoundationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723079280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent
events</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
July 1, 2023, Dr. Camilla Chong was appointed the Company&#8217;s Chief Medical Officer.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702722962320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfReportingEntityAndGroupsStructure', window );">Reporting entity and the Group&#8217;s structure</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reporting
entity and the Group&#8217;s structure</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
N.V. (the &#8220;Company&#8221; or &#8220;InflaRx&#8221;) is a Dutch public company with limited liability (<i>naamloze vennootschap</i>)
with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company&#8217;s registered office is at Winzerlaer Stra&#223;e 2 in 07745 Jena, Germany.
Since November 10, 2017, InflaRx N.V.&#8217;s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">InflaRx
is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize
first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. On April 4, 2023, the US Food and Drug
Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the Company&#8217;s monoclonal anti-C5a antibody
vilobelimab, under the brand name Gohibic, for the treatment of COVID-19 in hospitalized adults. These consolidated financial statements
of InflaRx comprise the Company and its wholly-owned subsidiaries, InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann
Arbor, Michigan, United States (together referred to as the &#8220;Group&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">b)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
of preparation</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
interim condensed consolidated financial statements for the three- and six-month reporting periods ended June 30, 2023, and 2022 have
been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include
all the information and disclosures required in the annual financial statements. Accordingly, this report is to be read in conjunction
with the financial statements in our annual report for the year ended December 31, 2022 on form 20-F.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the &#8220;Board
of Directors&#8221;) on August 9, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements are presented in euros (&#8364;). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional
currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. Effective January 1, 2023, the functional currency of InflaRx N.V. changed
from the U.S. dollar to the euro due to a change in the Company&#8217;s operational function and, in turn, a change in the primary currency
of its underlying transactions. This change in functional currency has been accounted for prospectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial information presented in euros have been rounded. Accordingly, numerical figures shown as totals in some tables may not be
an arithmetic aggregation of the figures that precede them or may deviate from other tables.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies adopted are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial
statements for the year ended December 31, 2022, except for the adoption of new standards effective as of January 1, 2023, as set out
below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following IFRS standards have been applied starting in Q2 2023 for the first time ever, as no transactions in the scope of these IFRS
standards had been previously recognized and are not expected to have a significant impact on the Company&#8217;s consolidated financial
statements in future periods.</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAS
                                            2 Inventories&#160;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to IAS 2, inventories are stated at the lower amount of cost or their net realizable value. Cost comprises direct materials and, where
applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and
condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less
all estimated costs of completion and costs to be incurred in marketing, selling and distribution.</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            15 Revenue from contracts with customers&#160;</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
will be recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer.
An asset is transferred when the customer obtains control of that asset. Revenue will be recognized at the point in time that the control
of the products is transferred to the customer and measured considering return liabilities. As of June 30, 2023, no revenue has been
recognized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFRS
                                            17 Insurance Contracts&#160;</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting
                                            Estimates&#160;</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction&#160;</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies -</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group&#8217;s
consolidated financial statements is being assessed:&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IFRS 16 Leases: Leases on Sale and Leaseback&#160;</span></td></tr></table><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendments
                                            to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or
                                            Non-current and Non-current Liabilities with Covenants</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfReportingEntityAndGroupsStructure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfReportingEntityAndGroupsStructure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719702800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherIncomeTablesLineItems', window );"><strong>Other income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SummaryofotherIncometableTextBlock', window );">Schedule of Other Income</a></td>
<td class="text">Other
income<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended June
    30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>
ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold">Other income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt">Income from government grants</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">4,874,934</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">14,415,368</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">12,609,789</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">14,415,368</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; width: 60%">Other</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">7,974</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">26,173</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">19,307</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right">27,767</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,882,908</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,441,541</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">12,629,096</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,443,135</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherIncomeTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherIncomeTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SummaryofotherIncometableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SummaryofotherIncometableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702717574448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Financial Result (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetFinancialResultAbstract', window );"><strong>Net Financial Result</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ScheduleOfNetFinancialResultTableTextBlock', window );">Schedule of Net financial result</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial income</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Interest income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,087,011</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">82,401</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">1,543,047</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">110,362</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Financial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Interest expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(363</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,243</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(782</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(22,102</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,689</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,798</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(10,429</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,081,959</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">74,456</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,532,467</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">77,831</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock', window );">Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Foreign exchange result</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 0pt">Foreign exchange income</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,090,994</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,947,221</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">2,381,519</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">4,057,629</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Foreign exchange expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,323,348</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,383,641</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,751,183</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,766,116</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">767,646</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,563,580</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(369,664</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,291,513</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock', window );">Schedule of Foreign Exchange Income and Expense</a></td>
<td class="text">Foreign
exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx
GmbH and InflaRx N.V.<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months <br/>ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the six months <br/>ended June 30</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022 <br/>(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Other financial result</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(195,567</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">(86,000</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,241</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 1%; font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right">39,000</td><td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetFinancialResultAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetFinancialResultAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ScheduleOfNetFinancialResultTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ScheduleOfNetFinancialResultTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702721495104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule Inventories</a></td>
<td class="text">Inventories<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0pt">Raw materials and supplies</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">337,407</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">&#160;&#160;&#160;&#160;&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Unfinished goods</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,674</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">578,705</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">&#8212;</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723010336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherAssetAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Schedule Other Assets</a></td>
<td class="text">Other
assets<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Non-current other assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Prepaid expenses</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">283,784</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">308,066</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">283,784</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">308,066</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Current other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Prepayments on research &amp; development projects</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,757,771</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,776,505</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Prepaid expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,146,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,841,935</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt">Others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">501,422</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,552,071</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">6,405,867</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">14,170,511</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total other assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">6,689,651</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">14,478,577</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723019744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract', window );"><strong>Financial Assets and Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Schedule of Financial Assets and liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30,
2023 and December 31, 2022:</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
June 30,<br/>
2023<br/>
(unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/>
December&#160;31, <br/>
2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Financial assets at amortized cost</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Non-current financial assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,951,267</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,900,902</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Financial assets from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,193,245</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">732,971</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Other current financial assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">77,601,286</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,791,088</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Financial liabilities at amortized cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Liabilities from government grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801,632</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,209,266</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Trade and other payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,200,809</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,987,538</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialAssetsAndFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720624224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> June 30, 2023 (unaudited)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/>December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in &#8364;)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Short-term deposits</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Deposits held in U.S. dollars</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">7,825,926</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">3,422</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Deposits held in euros</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,100,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">13,925,926</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">3,422</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Cash at banks</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Cash held in U.S. dollars</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,340,889</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,645,014</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Cash held in euros</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">2,249,144</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td><td style="font-weight: normal; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right">7,616,918</td><td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">Total</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,590,033</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">16,261,932</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">Total cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">19,515,959</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">16,265,354</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720487696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsAbstract', window );"><strong>Share-Based Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SchdeuleOfStockOptionActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">Prior
to 2016, InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary
shares of InflaRx N.V. at the time of its IPO in November 2017<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148,433</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">148,433</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised during the six months ended June 30</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0pt; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">148,433</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">148,433</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding: 0pt; font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding: 0pt; font-weight: bold">&#160;</td><td style="padding: 0pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding: 0pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; width: 76%; font-weight: bold">Outstanding as of January 1,</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right">888,632</td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 1%">&#160;</td>
    <td style="padding: 0pt; width: 1%; text-align: left">&#160;</td><td style="padding: 0pt; width: 9%; text-align: right">888,632</td><td style="padding: 0pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt; text-indent: 0in">Exercised during the six months ended June 30</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">&#8212;</div></td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">&#8212;</td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0pt; font-weight: bold">Outstanding as of June 30,</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">888,632</td><td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt">&#160;</td>
    <td style="padding: 0pt; text-align: left">&#160;</td><td style="padding: 0pt; text-align: right">888,632</td><td style="padding: 0pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0pt 0pt 0pt 0.125in; font-style: italic; text-align: left">thereof vested</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right">888,632</td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic">&#160;</td>
    <td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td><td style="padding: 0pt; font-style: italic; text-align: right">888,632</td><td style="padding: 0pt; font-style: italic; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Number of share options</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold; text-indent: 0in">Total number of options outstanding as of January 1,</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,985,523</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,170,046</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Granted during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,567,250</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,561,666</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0in">Exercised during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">105,327</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0in">Forfeited during the six months ended June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(117,259</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: 0in">Outstanding as of June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,447,446</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,614,453</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in">thereof vested</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">4,788,759</td><td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic">&#160;</td>
    <td style="font-style: italic; text-align: left">&#160;</td><td style="font-style: italic; text-align: right">3,306,162</td><td style="font-style: italic; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text">The
number of share options granted during the six months ended June 30, 2023 under the 2017 LTIP was as follows<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Share options
granted 2023</b></p></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FX rate as of grant date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Fair value per</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>option</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Share price at grant date /</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expected volatility</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Expected life</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(midpoint based)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Risk-free rate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(interpolated, U.S. sovereign strips curve)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%">January 24</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1,454,250</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2.11</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">0.9008</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#8364;</td><td style="width: 6%; text-align: right">1.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">2.37</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">1.35</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">5.30</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">3.571</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>January 24</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.13</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.9008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">1.92</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2.37</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.50</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.565</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">May 31</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">60,500</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">3,61</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">0.9203</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#8364;</td><td style="text-align: right">3.32</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4.19</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">1.35</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">4.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="text-align: right">3.820</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt"><b>&#160;</b></td><td style="font-weight: bold; padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><b>&#160;</b></td><td style="border-bottom: Black 4pt double; text-align: right"><b>1,567,250</b></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="padding-bottom: 4pt"><b>&#160;</b></td>
    <td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td><td style="text-align: right"><b>&#160;</b></td><td style="padding-bottom: 4pt; text-align: left"><b>&#160;</b></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SchdeuleOfStockOptionActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SchdeuleOfStockOptionActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702718980656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherIncomesAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinanceIncome', window );">Other income</a></td>
<td class="nump">&#8364; 4.9<span></span>
</td>
<td class="nump">&#8364; 14.4<span></span>
</td>
<td class="nump">&#8364; 12.6<span></span>
</td>
<td class="nump">&#8364; 14.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherIncomesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherIncomesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719782048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details) - Schedule of Other Income - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_IncomeFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="nump">&#8364; 4,874,934<span></span>
</td>
<td class="nump">&#8364; 14,415,368<span></span>
</td>
<td class="nump">&#8364; 12,609,789<span></span>
</td>
<td class="nump">&#8364; 14,415,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates', window );">Other</a></td>
<td class="nump">7,974<span></span>
</td>
<td class="nump">26,173<span></span>
</td>
<td class="nump">19,307<span></span>
</td>
<td class="nump">27,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherIncomeTotal', window );">Total</a></td>
<td class="nump">&#8364; 4,882,908<span></span>
</td>
<td class="nump">&#8364; 14,441,541<span></span>
</td>
<td class="nump">&#8364; 12,629,096<span></span>
</td>
<td class="nump">&#8364; 14,443,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense from subsidiaries, jointly controlled entities and associates that the entity does not separately disclose in the same statement or note. [Refer: Associates [member]; Subsidiaries [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_IncomeFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income from government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_IncomeFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherIncomeTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other income total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherIncomeTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702716948528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Financial Result (Details) - Schedule of Net Financial Result - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialIncomeAbstract', window );"><strong>Financial income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss', window );">Interest income</a></td>
<td class="nump">&#8364; 1,087,011<span></span>
</td>
<td class="nump">&#8364; 82,401<span></span>
</td>
<td class="nump">&#8364; 1,543,047<span></span>
</td>
<td class="nump">&#8364; 110,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialExpensesAbstract', window );"><strong>Financial expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpense', window );">Interest expenses</a></td>
<td class="num">(363)<span></span>
</td>
<td class="num">(2,243)<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="num">(22,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="num">(4,689)<span></span>
</td>
<td class="num">(5,702)<span></span>
</td>
<td class="num">(9,798)<span></span>
</td>
<td class="num">(10,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetFinancialResult', window );">Total</a></td>
<td class="nump">&#8364; 1,081,959<span></span>
</td>
<td class="nump">&#8364; 74,456<span></span>
</td>
<td class="nump">&#8364; 1,532,467<span></span>
</td>
<td class="nump">&#8364; 77,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_f&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on financial assets designated at fair value through profit or loss. [Refer: Interest income; Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net financial total value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719872464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ForeignExchangeResultAbstract', window );"><strong>Foreign exchange result</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ForeignExchangeIncome', window );">Foreign exchange income</a></td>
<td class="nump">&#8364; 2,090,994<span></span>
</td>
<td class="nump">&#8364; 2,947,221<span></span>
</td>
<td class="nump">&#8364; 2,381,519<span></span>
</td>
<td class="nump">&#8364; 4,057,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ForeignExchangeExpense', window );">Foreign exchange expense</a></td>
<td class="num">(1,323,348)<span></span>
</td>
<td class="num">(1,383,641)<span></span>
</td>
<td class="num">(2,751,183)<span></span>
</td>
<td class="num">(1,766,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Total</a></td>
<td class="nump">&#8364; 767,646<span></span>
</td>
<td class="nump">&#8364; 1,563,580<span></span>
</td>
<td class="num">&#8364; (369,664)<span></span>
</td>
<td class="nump">&#8364; 2,291,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2022-03-24<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ForeignExchangeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ForeignExchangeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ForeignExchangeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ForeignExchangeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ForeignExchangeResultAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ForeignExchangeResultAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702723632576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NetFinancialResultLineItems', window );"><strong>Net Financial Result [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherFinancialResult', window );">Other financial result</a></td>
<td class="num">&#8364; (195,567)<span></span>
</td>
<td class="num">&#8364; (86,000)<span></span>
</td>
<td class="nump">&#8364; 2,241<span></span>
</td>
<td class="nump">&#8364; 39,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NetFinancialResultLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NetFinancialResultLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherFinancialResult">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other financial result.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherFinancialResult</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702722960608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReversalOfInventoryWritedown', window );">Write-downs of inventories</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReversalOfInventoryWritedown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_f&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReversalOfInventoryWritedown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720270880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - Schedule Inventories - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ScheduleOfInventoriesLineItems', window );"><strong>Schedule of Inventories [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies', window );">Raw materials and supplies</a></td>
<td class="nump">&#8364; 337,407<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_UnfinishedGoods', window );">Unfinished goods</a></td>
<td class="nump">132,624<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">108,674<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Total</a></td>
<td class="nump">&#8364; 578,705<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ScheduleOfInventoriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ScheduleOfInventoriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_UnfinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unfinished goods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_UnfinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720679040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets (Details) - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherAssetAbstract', window );"><strong>Other Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Prepayments on research and development</a></td>
<td class="nump">&#8364; 4.8<span></span>
</td>
<td class="nump">&#8364; 9.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720252864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets (Details) - Schedule of Other Assets - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NonCurrentOtherAssetsAbstract', window );"><strong>Non-current other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NonPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">&#8364; 283,784<span></span>
</td>
<td class="nump">&#8364; 308,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Total</a></td>
<td class="nump">283,784<span></span>
</td>
<td class="nump">308,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CurrentOtherAssetsAbstract', window );"><strong>Current other assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_PrepaymentsOnResearchDevelopmentProjects', window );">Prepayments on research &amp; development projects</a></td>
<td class="nump">4,757,771<span></span>
</td>
<td class="nump">9,776,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Prepaid expense</a></td>
<td class="nump">1,146,674<span></span>
</td>
<td class="nump">1,841,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Others</a></td>
<td class="nump">501,422<span></span>
</td>
<td class="nump">2,552,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CurrentOtherAssetsTotal', window );">Total</a></td>
<td class="nump">6,405,867<span></span>
</td>
<td class="nump">14,170,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsLiabilities', window );">Total other assets</a></td>
<td class="nump">&#8364; 6,689,651<span></span>
</td>
<td class="nump">&#8364; 14,478,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets less the amount of current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CurrentOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CurrentOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CurrentOtherAssetsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CurrentOtherAssetsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NonCurrentOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NonCurrentOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NonPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NonPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_PrepaymentsOnResearchDevelopmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayments on research &amp; development projects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_PrepaymentsOnResearchDevelopmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720312752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract', window );"><strong>Financial Assets and Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss', window );">Fair value of current and non-current financial assets</a></td>
<td class="nump">&#8364; 100.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_AssetsFromGovernmentGrants', window );">Assets from government grants</a></td>
<td class="nump">&#8364; 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 8<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_8_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_AssetsFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets From Government Grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_AssetsFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialAssetsAndFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialAssetsAndFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720076880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialAssetsAtAmortizedCostAbstract', window );"><strong>Financial assets at amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current financial assets</a></td>
<td class="nump">$ 18,951,267<span></span>
</td>
<td class="nump">$ 2,900,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialAssetsFromGovernmentGrants', window );">Financial assets from government grants</a></td>
<td class="nump">5,193,245<span></span>
</td>
<td class="nump">732,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other current financial assets</a></td>
<td class="nump">77,601,286<span></span>
</td>
<td class="nump">64,791,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FinancialLiabilitiesAtAmortizedCostAbstract', window );"><strong>Financial liabilities at amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GovernmentGrants', window );">Liabilities from government grants</a></td>
<td class="nump">801,632<span></span>
</td>
<td class="nump">6,209,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade and other payables</a></td>
<td class="nump">$ 5,200,809<span></span>
</td>
<td class="nump">$ 4,987,538<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialAssetsAtAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialAssetsAtAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialAssetsFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialAssetsFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FinancialLiabilitiesAtAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FinancialLiabilitiesAtAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720519040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents - EUR (&#8364;)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal', window );">Short-term deposits total</a></td>
<td class="nump">&#8364; 13,925,926<span></span>
</td>
<td class="nump">&#8364; 3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBankstotal', window );">Cash at banks total</a></td>
<td class="nump">5,590,033<span></span>
</td>
<td class="nump">16,261,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCashAndCashEquivalents', window );">Total cash and cash equivalents</a></td>
<td class="nump">19,515,959<span></span>
</td>
<td class="nump">16,265,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInUSDollarsMember', window );">Deposits Held in U.S. Dollars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal', window );">Short-term deposits total</a></td>
<td class="nump">7,825,926<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBankstotal', window );">Cash at banks total</a></td>
<td class="nump">3,340,889<span></span>
</td>
<td class="nump">8,645,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInEurosMember', window );">Deposits Held in Euros [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShortTermDepositsAbstract', window );"><strong>Short-term deposits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal', window );">Short-term deposits total</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBanksAbstract', window );"><strong>Cash at banks</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CashAtBankstotal', window );">Cash at banks total</a></td>
<td class="nump">&#8364; 2,249,144<span></span>
</td>
<td class="nump">&#8364; 7,616,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CashAtBanksAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CashAtBanksAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CashAtBankstotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash at banks total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CashAtBankstotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShortTermDepositsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShortTermDepositsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A total of cash equivalents representing short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInUSDollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInUSDollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInEurosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrencyInWhichInformationIsDisplayedAxis=infrx_DepositsHeldInEurosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702716920768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br> &#8364; / shares in Units, $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CommonSharesSaleAgreement', window );">Sale of common shares (in Shares) | shares</a></td>
<td class="nump">3,235,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,235,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 124,646,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 88,349,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments', window );">Net proceeds from equity investments</a></td>
<td class="nump">&#8364; 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SoldCommonSharesThroughAPublicOffering', window );">Sold common shares through a public offering (in Shares) | shares</a></td>
<td class="nump">10,823,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,823,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentTransactions', window );">Share based payment transactions (in Shares) | shares</a></td>
<td class="nump">1,411,764<span></span>
</td>
<td class="nump">1,411,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SaleOfPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_NominalValuePerShare', window );">Nominal value of price per share (in Euro per share) | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentProperty', window );">Proceeds from sales of investment property</a></td>
<td class="nump">&#8364; 2,500,000<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentInvestments', window );">Discounts amount</a></td>
<td class="nump">39,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherExpenseByNature', window );">Other offering expenses</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OtherOfferingExpensesTotal', window );">Other offering expenses total</a></td>
<td class="nump">&#8364; 38,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingOtherEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingOtherEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investment property. [Refer: Investment property]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CommonSharesSaleAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CommonSharesSaleAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_NominalValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of nominal  value of price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_NominalValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OtherOfferingExpensesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other offering expenses total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OtherOfferingExpensesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SaleOfPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares sold price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SaleOfPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based payment transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SoldCommonSharesThroughAPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SoldCommonSharesThroughAPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719900816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_CommonSharesDescription', window );">Common shares, description</a></td>
<td class="text">The total number of share options granted during
the six months ended June 30, 2023 under the 2017 LTIP was as follows:<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of grants</a></td>
<td class="nump">1,246,000<span></span>
</td>
<td class="nump">1,561,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharebasedPaymentExpense', window );">Share-based payment expense (in Euro)</a></td>
<td class="nump">&#8364; 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ValuationPastGrantAmount', window );">Valuation past grants amount (in Euro)</a></td>
<td class="nump">&#8364; 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercise of share options</a></td>
<td class="nump">105,327<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=infrx_OptionLTIPMember', window );">Option LTIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercise of share options</a></td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfOrdinarySharesAxis=infrx_BoardOfDirectorsMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsLineItems', window );"><strong>Share-Based Payments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of grants</a></td>
<td class="nump">1,567,250<span></span>
</td>
<td class="nump">1,362,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_CommonSharesDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common shares, description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_CommonSharesDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SharebasedPaymentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share-based payment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SharebasedPaymentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ValuationPastGrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of valuation past grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ValuationPastGrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=infrx_OptionLTIPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=infrx_OptionLTIPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=infrx_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=infrx_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702719940960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - Schedule of Stock Option Activity - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2012PlanMember', window );">Number of share options under the 2012 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Beginning Balance</a></td>
<td class="nump">148,433<span></span>
</td>
<td class="nump">148,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExercisedNumberOfShares', window );">Exercised during the six months ended June 30</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Ending Balance</a></td>
<td class="nump">148,433<span></span>
</td>
<td class="nump">148,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares', window );">thereof vested</a></td>
<td class="nump">148,433<span></span>
</td>
<td class="nump">148,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2016PlanMember', window );">Number of share options under the 2016 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Beginning Balance</a></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExercisedNumberOfShares', window );">Exercised during the six months ended June 30</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Ending Balance</a></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares', window );">thereof vested</a></td>
<td class="nump">888,632<span></span>
</td>
<td class="nump">888,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderTheLTIPMember', window );">Number of share options under the LTIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Stock Option Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Beginning Balance</a></td>
<td class="nump">4,985,523<span></span>
</td>
<td class="nump">3,170,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares', window );">Granted during the six months ended June 30</a></td>
<td class="nump">1,567,250<span></span>
</td>
<td class="nump">1,561,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExercisedNumberOfShares', window );">Exercised during the six months ended June 30</a></td>
<td class="nump">105,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ForfeitedShares', window );">Forfeited during the six months ended June 30</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_OutstandingBalance', window );">Outstanding Ending Balance</a></td>
<td class="nump">6,447,446<span></span>
</td>
<td class="nump">4,614,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares', window );">thereof vested</a></td>
<td class="nump">4,788,759<span></span>
</td>
<td class="nump">3,306,162<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ExercisedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercised shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ExercisedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ForfeitedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of forfeited shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ForfeitedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_OutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_OutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of option granted shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2012PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2012PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderThe2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderTheLTIPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=infrx_NumberOfShareOptionsUnderTheLTIPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702716993472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of Share options granted</a></td>
<td class="nump">1,567,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourMember', window );">January Twenty four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of Share options granted</a></td>
<td class="nump">1,454,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOption', window );">Fair value per option</a></td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FXRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="nump">0.9008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharePriceAtGrantDateExercisePrice', window );">Share price at grant date / Exercise price</a></td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExpectedLifemidpointBased', window );">Expected life (midpoint based)</a></td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.571%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourOneMember', window );">January twenty four one [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of Share options granted</a></td>
<td class="nump">52,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOption', window );">Fair value per option</a></td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FXRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="nump">0.9008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="nump">1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharePriceAtGrantDateExercisePrice', window );">Share price at grant date / Exercise price</a></td>
<td class="nump">$ 2.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExpectedLifemidpointBased', window );">Expected life (midpoint based)</a></td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.565%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_MayThirtyMember', window );">May thirty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems', window );"><strong>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Number of Share options granted</a></td>
<td class="nump">60,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOption', window );">Fair value per option</a></td>
<td class="nump">$ 361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FXRateAsOfGrantDate', window );">FX rate as of grant date</a></td>
<td class="nump">0.9203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_FairValuePerOptions', window );">Fair value per option</a></td>
<td class="nump">3.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_SharePriceAtGrantDateExercisePrice', window );">Share price at grant date / Exercise price</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ExpectedLifemidpointBased', window );">Expected life (midpoint based)</a></td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free rate (interpolated, U.S. sovereign strips curve)</a></td>
<td class="nump">3.82%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ExpectedLifemidpointBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of option life share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ExpectedLifemidpointBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FXRateAsOfGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at grant date fx rate as of grant date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FXRateAsOfGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FairValuePerOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FairValuePerOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_FairValuePerOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value per option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_FairValuePerOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_SharePriceAtGrantDateExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price at grant date / Exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_SharePriceAtGrantDateExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_JanuaryTwentyFourOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_MayThirtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRateregulatedActivitiesAxis=infrx_MayThirtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140702720074272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Protective Foundation (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_ProtectiveFoundationDetailsLineItems', window );"><strong>Disclosure of Protective Foundation Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_AuthorisedCapitalCommonSharesone', window );">Common shares authorized</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_AuthorisdCapitalPreferenceSharesone', window );">Preferred shares authorized</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_PricePerShares', window );">Price per share</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_infrx_PercentageOfIssuedCapital', window );">Percentage of issued capital</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Reimburse expenses</a></td>
<td class="nump">&#8364; 45<span></span>
</td>
<td class="nump">&#8364; 30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_AuthorisdCapitalPreferenceSharesone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_AuthorisdCapitalPreferenceSharesone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_AuthorisedCapitalCommonSharesone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_AuthorisedCapitalCommonSharesone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_PercentageOfIssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_PercentageOfIssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_PricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of price per shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_PricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_infrx_ProtectiveFoundationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">infrx_ProtectiveFoundationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>infrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>ea183075-6k_inflarxnv_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:infrx="http://www.inflarx.de.com/20230630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="infrx-20230630.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:OtherReservesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:EquityAttributableToOwnersOfParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInUSDollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInEurosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CurrencyInWhichInformationIsDisplayedAxis">infrx:DepositsHeldInEurosMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">infrx:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">infrx:BoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">infrx:OptionLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">infrx:OptionLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2012PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderThe2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">infrx:NumberOfShareOptionsUnderTheLTIPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:JanuaryTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:JanuaryTwentyFourOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708688</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRateregulatedActivitiesAxis">infrx:MayThirtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="eurPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus contextRef="c0">2023</dei:DocumentFiscalYearFocus>
    <dei:EntityRegistrantName contextRef="c0">InflaRx N.V.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c0">Winzerlaer Str. 2</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="c0">07745</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="c0">Jena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c0">DE</dei:EntityAddressCountry>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c1" decimals="0" unitRef="eur">10919595</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c2" decimals="0" unitRef="eur">11180958</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="eur">25651503</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c3" decimals="0" unitRef="eur">21652881</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c1" decimals="0" unitRef="eur">3540805</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c2" decimals="0" unitRef="eur">4346965</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="eur">7149359</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c3" decimals="0" unitRef="eur">8734408</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c1" decimals="0" unitRef="eur">276051</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense contextRef="c0" decimals="0" unitRef="eur">276051</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:OtherIncome contextRef="c1" decimals="0" unitRef="eur">4882908</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c2" decimals="0" unitRef="eur">14441541</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c0" decimals="0" unitRef="eur">12629096</ifrs-full:OtherIncome>
    <ifrs-full:OtherIncome contextRef="c3" decimals="0" unitRef="eur">14443135</ifrs-full:OtherIncome>
    <ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c1" decimals="0" unitRef="eur">-2624</ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c2" decimals="0" unitRef="eur">-279</ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" unitRef="eur">-3190</ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax contextRef="c3" decimals="0" unitRef="eur">-844</ifrs-full:GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c1" decimals="0" unitRef="eur">-9856168</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c2" decimals="0" unitRef="eur">-1086661</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c0" decimals="0" unitRef="eur">-20451007</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:RevenueAndOperatingIncome contextRef="c3" decimals="0" unitRef="eur">-15944999</ifrs-full:RevenueAndOperatingIncome>
    <ifrs-full:FinanceIncome contextRef="c1" decimals="0" unitRef="eur">1087011</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c2" decimals="0" unitRef="eur">82401</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c0" decimals="0" unitRef="eur">1543047</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome contextRef="c3" decimals="0" unitRef="eur">110362</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts contextRef="c1" decimals="0" unitRef="eur">5052</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c2" decimals="0" unitRef="eur">7945</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c0" decimals="0" unitRef="eur">10580</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts contextRef="c3" decimals="0" unitRef="eur">32531</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c1" decimals="0" unitRef="eur">767646</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c2" decimals="0" unitRef="eur">1563580</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="0" unitRef="eur">-369664</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c3" decimals="0" unitRef="eur">2291513</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c1" decimals="0" unitRef="eur">-195567</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c2" decimals="0" unitRef="eur">-86000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c0" decimals="0" unitRef="eur">2241</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:OtherFinanceIncomeCost contextRef="c3" decimals="0" unitRef="eur">39000</ifrs-full:OtherFinanceIncomeCost>
    <ifrs-full:ProfitLoss contextRef="c1" decimals="0" unitRef="eur">-8202130</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c2" decimals="0" unitRef="eur">465376</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" unitRef="eur">-19285963</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" unitRef="eur">-13536654</ifrs-full:ProfitLoss>
    <ifrs-full:WeightedAverageShares contextRef="c1" decimals="INF" unitRef="shares">56985734</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c2" decimals="INF" unitRef="shares">44203763</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c0" decimals="INF" unitRef="shares">50912459</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c3" decimals="INF" unitRef="shares">44203763</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c1" decimals="2" unitRef="eurPershares">-0.14</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c2" decimals="2" unitRef="eurPershares">0.01</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c0" decimals="2" unitRef="eurPershares">-0.38</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare contextRef="c3" decimals="2" unitRef="eurPershares">-0.31</ifrs-full:BasicEarningsLossPerShare>
    <infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1 contextRef="c1" decimals="0" unitRef="eur">-330</infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1>
    <infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1 contextRef="c2" decimals="0" unitRef="eur">4408940</infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1>
    <infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1 contextRef="c0" decimals="0" unitRef="eur">-17116</infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1>
    <infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1 contextRef="c3" decimals="0" unitRef="eur">5718815</infrx:ExchangeDifferencesOnTranslationOfForeignCurrency1>
    <ifrs-full:ComprehensiveIncome contextRef="c1" decimals="0" unitRef="eur">-8202460</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c2" decimals="0" unitRef="eur">4874316</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" unitRef="eur">-19303079</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" unitRef="eur">-7817839</ifrs-full:ComprehensiveIncome>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c4" decimals="0" unitRef="eur">296382</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="eur">328920</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c4" decimals="0" unitRef="eur">1122183</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c5" decimals="0" unitRef="eur">1311809</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c4" decimals="0" unitRef="eur">90789</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill contextRef="c5" decimals="0" unitRef="eur">138905</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:OtherAssets contextRef="c4" decimals="0" unitRef="eur">283784</ifrs-full:OtherAssets>
    <ifrs-full:OtherAssets contextRef="c5" decimals="0" unitRef="eur">308066</ifrs-full:OtherAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c4" decimals="0" unitRef="eur">18951267</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:OtherNoncurrentFinancialAssets contextRef="c5" decimals="0" unitRef="eur">2900902</ifrs-full:OtherNoncurrentFinancialAssets>
    <ifrs-full:NoncurrentAssets contextRef="c4" decimals="0" unitRef="eur">20744405</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets contextRef="c5" decimals="0" unitRef="eur">4988602</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories contextRef="c4" decimals="0" unitRef="eur">578705</ifrs-full:Inventories>
    <ifrs-full:OtherCurrentAssets contextRef="c4" decimals="0" unitRef="eur">6405867</ifrs-full:OtherCurrentAssets>
    <ifrs-full:OtherCurrentAssets contextRef="c5" decimals="0" unitRef="eur">14170510</ifrs-full:OtherCurrentAssets>
    <ifrs-full:CurrentTaxAssets contextRef="c4" decimals="0" unitRef="eur">2925037</ifrs-full:CurrentTaxAssets>
    <ifrs-full:CurrentTaxAssets contextRef="c5" decimals="0" unitRef="eur">1432087</ifrs-full:CurrentTaxAssets>
    <ifrs-full:FinancialAssets contextRef="c4" decimals="0" unitRef="eur">5193246</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets contextRef="c5" decimals="0" unitRef="eur">732971</ifrs-full:FinancialAssets>
    <ifrs-full:OtherFinancialAssets contextRef="c4" decimals="0" unitRef="eur">77601286</ifrs-full:OtherFinancialAssets>
    <ifrs-full:OtherFinancialAssets contextRef="c5" decimals="0" unitRef="eur">64810135</ifrs-full:OtherFinancialAssets>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="0" unitRef="eur">19515959</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" unitRef="eur">16265355</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets contextRef="c4" decimals="0" unitRef="eur">112220100</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c5" decimals="0" unitRef="eur">97411058</ifrs-full:CurrentAssets>
    <ifrs-full:Assets contextRef="c4" decimals="0" unitRef="eur">132964505</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c5" decimals="0" unitRef="eur">102399660</ifrs-full:Assets>
    <ifrs-full:IssuedCapital contextRef="c4" decimals="0" unitRef="eur">7065993</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c5" decimals="0" unitRef="eur">5364452</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium contextRef="c4" decimals="0" unitRef="eur">334211338</ifrs-full:SharePremium>
    <ifrs-full:SharePremium contextRef="c5" decimals="0" unitRef="eur">282552633</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves contextRef="c4" decimals="0" unitRef="eur">38874961</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves contextRef="c5" decimals="0" unitRef="eur">36635564</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings contextRef="c4" decimals="0" unitRef="eur">-262746253</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c5" decimals="0" unitRef="eur">-243460290</ifrs-full:RetainedEarnings>
    <ifrs-full:OtherEquityInterest contextRef="c4" decimals="0" unitRef="eur">7239965</ifrs-full:OtherEquityInterest>
    <ifrs-full:OtherEquityInterest contextRef="c5" decimals="0" unitRef="eur">7257081</ifrs-full:OtherEquityInterest>
    <ifrs-full:Equity contextRef="c4" decimals="0" unitRef="eur">124646004</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c5" decimals="0" unitRef="eur">88349440</ifrs-full:Equity>
    <ifrs-full:LeaseLiabilities contextRef="c4" decimals="0" unitRef="eur">814560</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c5" decimals="0" unitRef="eur">987307</ifrs-full:LeaseLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c4" decimals="0" unitRef="eur">36877</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c5" decimals="0" unitRef="eur">36877</ifrs-full:OtherLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c4" decimals="0" unitRef="eur">851437</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities contextRef="c5" decimals="0" unitRef="eur">1024184</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c4" decimals="0" unitRef="eur">5200809</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c5" decimals="0" unitRef="eur">4987538</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c4" decimals="0" unitRef="eur">801632</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:OtherCurrentNonfinancialLiabilities contextRef="c5" decimals="0" unitRef="eur">6209266</ifrs-full:OtherCurrentNonfinancialLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c4" decimals="0" unitRef="eur">356099</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c5" decimals="0" unitRef="eur">369376</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c4" decimals="0" unitRef="eur">900474</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:ShorttermEmployeeBenefitsAccruals contextRef="c5" decimals="0" unitRef="eur">1312248</ifrs-full:ShorttermEmployeeBenefitsAccruals>
    <ifrs-full:OtherCurrentLiabilities contextRef="c4" decimals="0" unitRef="eur">208051</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c5" decimals="0" unitRef="eur">147608</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c4" decimals="0" unitRef="eur">7467065</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c5" decimals="0" unitRef="eur">13026036</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities contextRef="c4" decimals="0" unitRef="eur">8318502</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c5" decimals="0" unitRef="eur">14050220</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c4" decimals="0" unitRef="eur">132964505</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c5" decimals="0" unitRef="eur">102399660</ifrs-full:EquityAndLiabilities>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c6" decimals="INF" unitRef="shares">44703763</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c7" decimals="0" unitRef="eur">5364452</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c8" decimals="0" unitRef="eur">282552633</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c9" decimals="0" unitRef="eur">36635564</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c10" decimals="0" unitRef="eur">-243460290</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c11" decimals="0" unitRef="eur">7257081</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c5" decimals="0" unitRef="eur">88349440</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss contextRef="c15" decimals="0" unitRef="eur">-19285963</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c0" decimals="0" unitRef="eur">-19285963</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c16" decimals="0" unitRef="eur">-17116</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c0" decimals="0" unitRef="eur">-17116</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c15" decimals="0" unitRef="eur">-19285963</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c16" decimals="0" unitRef="eur">-17116</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c0" decimals="0" unitRef="eur">-19303079</ifrs-full:ComprehensiveIncome>
    <infrx:IssuanceOfCommonSharesAndWarrants contextRef="c17" decimals="INF" unitRef="shares">14059252</infrx:IssuanceOfCommonSharesAndWarrants>
    <ifrs-full:IssueOfEquity contextRef="c12" decimals="0" unitRef="eur">1687110</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c13" decimals="0" unitRef="eur">54796819</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c0" decimals="0" unitRef="eur">56483929</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c13" decimals="0" unitRef="eur">3360626</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c0" decimals="0" unitRef="eur">3360626</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c14" decimals="0" unitRef="eur">2239397</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c0" decimals="0" unitRef="eur">2239397</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <infrx:ShareOptionsExercised contextRef="c17" decimals="INF" unitRef="shares">120257</infrx:ShareOptionsExercised>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c12" decimals="0" unitRef="eur">14431</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c13" decimals="0" unitRef="eur">222512</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c0" decimals="0" unitRef="eur">236943</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ix_0_fact"
      unitRef="shares">58883272</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c19" decimals="0" id="ix_1_fact" unitRef="eur">7065993</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c20" decimals="0" id="ix_2_fact" unitRef="eur">334211338</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c21" decimals="0" id="ix_3_fact" unitRef="eur">38874961</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c22" decimals="0" id="ix_4_fact" unitRef="eur">-262746253</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c23" decimals="0" id="ix_5_fact" unitRef="eur">7239965</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c4" decimals="0" id="ix_6_fact" unitRef="eur">124646004</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:NumberOfSharesOutstanding contextRef="c24" decimals="INF" unitRef="shares">44203763</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c25" decimals="0" unitRef="eur">5304452</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c26" decimals="0" unitRef="eur">280310744</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c27" decimals="0" unitRef="eur">30591209</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c28" decimals="0" unitRef="eur">-213975679</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c29" decimals="0" unitRef="eur">3050271</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c30" decimals="0" unitRef="eur">105280996</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:ProfitLoss contextRef="c34" decimals="0" unitRef="eur">-13536654</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c3" decimals="0" unitRef="eur">-13536654</ifrs-full:ProfitLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c35" decimals="0" unitRef="eur">5718815</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="c3" decimals="0" unitRef="eur">5718815</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
    <ifrs-full:ComprehensiveIncome contextRef="c34" decimals="0" unitRef="eur">-13536654</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c35" decimals="0" unitRef="eur">5718815</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c3" decimals="0" unitRef="eur">-7817839</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c33" decimals="0" unitRef="eur">4668481</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c3" decimals="0" unitRef="eur">4668481</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="c36"
      decimals="INF"
      id="ix_7_fact"
      unitRef="shares">44203763</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c37" decimals="0" id="ix_8_fact" unitRef="eur">5304452</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c38" decimals="0" id="ix_9_fact" unitRef="eur">280310744</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c39" decimals="0" id="ix_10_fact" unitRef="eur">35259689</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c40" decimals="0" id="ix_11_fact" unitRef="eur">-227512333</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c41" decimals="0" id="ix_12_fact" unitRef="eur">8769086</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:EquityAttributableToOwnersOfParent contextRef="c42" decimals="0" id="ix_13_fact" unitRef="eur">102131638</ifrs-full:EquityAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossBeforeTax contextRef="c0" decimals="0" unitRef="eur">-19285963</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c3" decimals="0" unitRef="eur">-13536654</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="eur">293328</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="eur">300870</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <infrx:NetFinanceIncome contextRef="c0" decimals="0" unitRef="eur">-1165044</infrx:NetFinanceIncome>
    <infrx:NetFinanceIncome contextRef="c3" decimals="0" unitRef="eur">-2408345</infrx:NetFinanceIncome>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c0" decimals="0" unitRef="eur">2239397</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c3" decimals="0" unitRef="eur">4668481</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <infrx:NetForeignExchangeDifferences contextRef="c0" decimals="0" unitRef="eur">-23953</infrx:NetForeignExchangeDifferences>
    <infrx:NetForeignExchangeDifferences contextRef="c3" decimals="0" unitRef="eur">130347</infrx:NetForeignExchangeDifferences>
    <infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets contextRef="c0" decimals="0" unitRef="eur">-4460274</infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets>
    <infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets contextRef="c3" decimals="0" unitRef="eur">-8260503</infrx:AdjustmentsForDecreaseIncreaseInFinancialAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c0" decimals="0" unitRef="eur">6295975</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets contextRef="c3" decimals="0" unitRef="eur">611843</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherCurrentAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c0" decimals="0" unitRef="eur">-411774</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities contextRef="c3" decimals="0" unitRef="eur">-640112</ifrs-full:AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c0" decimals="0" unitRef="eur">60443</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities contextRef="c3" decimals="0" unitRef="eur">-7869</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherLiabilities>
    <infrx:LiabilitiesFromGovernmentGrants contextRef="c0" decimals="0" unitRef="eur">-5407634</infrx:LiabilitiesFromGovernmentGrants>
    <infrx:LiabilitiesFromGovernmentGrants contextRef="c3" decimals="0" unitRef="eur">-6154865</infrx:LiabilitiesFromGovernmentGrants>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c0" decimals="0" unitRef="eur">213270</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable contextRef="c3" decimals="0" unitRef="eur">-661741</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="c0" decimals="0" unitRef="eur">-578705</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c0" decimals="0" unitRef="eur">556068</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="c3" decimals="0" unitRef="eur">631504</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c0" decimals="0" unitRef="eur">10777</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="c3" decimals="0" unitRef="eur">32039</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="eur">-21685642</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="c3" decimals="0" unitRef="eur">-25359081</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c0" decimals="0" unitRef="eur">24673</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c3" decimals="0" unitRef="eur">9728</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="c0" decimals="0" unitRef="eur">83071163</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
    <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="c3" decimals="0" unitRef="eur">47031216</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
    <infrx:ProceedsFromTheMaturityOfFinancialAssets contextRef="c0" decimals="0" unitRef="eur">55202491</infrx:ProceedsFromTheMaturityOfFinancialAssets>
    <infrx:ProceedsFromTheMaturityOfFinancialAssets contextRef="c3" decimals="0" unitRef="eur">59595044</infrx:ProceedsFromTheMaturityOfFinancialAssets>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="eur">-27893346</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c3" decimals="0" unitRef="eur">12554101</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <infrx:ProceedsFromIssuanceOfCommonShares contextRef="c0" decimals="0" unitRef="eur">56483929</infrx:ProceedsFromIssuanceOfCommonShares>
    <ifrs-full:PaymentsForShareIssueCosts contextRef="c0" decimals="0" unitRef="eur">3360626</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c0" decimals="0" unitRef="eur">236943</ifrs-full:ProceedsFromExerciseOfOptions>
    <infrx:RepaymentOfLeaseLiabilities contextRef="c0" decimals="0" unitRef="eur">184791</infrx:RepaymentOfLeaseLiabilities>
    <infrx:RepaymentOfLeaseLiabilities contextRef="c3" decimals="0" unitRef="eur">182014</infrx:RepaymentOfLeaseLiabilities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c0" decimals="0" unitRef="eur">53175455</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c3" decimals="0" unitRef="eur">-182014</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c0" decimals="0" unitRef="eur">3596467</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c3" decimals="0" unitRef="eur">-12986995</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c0" decimals="0" unitRef="eur">-345862</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c3" decimals="0" unitRef="eur">2153152</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c5" decimals="0" unitRef="eur">16265355</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c30" decimals="0" unitRef="eur">26249995</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c4" decimals="0" unitRef="eur">19515959</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c42" decimals="0" unitRef="eur">15416152</ifrs-full:CashAndCashEquivalents>
    <infrx:DisclosureOfSummaryOfSignificantAccountingPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summary
of significant accounting policies and other disclosures&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reporting
entity and the Group&#x2019;s structure&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;InflaRx
N.V. (the &#x201c;Company&#x201d; or &#x201c;InflaRx&#x201d;) is a Dutch public company with limited liability (&lt;i&gt;naamloze vennootschap&lt;/i&gt;)
with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company&#x2019;s registered office is at Winzerlaer Stra&#xdf;e 2 in 07745 Jena, Germany.
Since November 10, 2017, InflaRx N.V.&#x2019;s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;InflaRx
is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize
first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. On April 4, 2023, the US Food and Drug
Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the Company&#x2019;s monoclonal anti-C5a antibody
vilobelimab, under the brand name Gohibic, for the treatment of COVID-19 in hospitalized adults. These consolidated financial statements
of InflaRx comprise the Company and its wholly-owned subsidiaries, InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann
Arbor, Michigan, United States (together referred to as the &#x201c;Group&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis
of preparation&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
interim condensed consolidated financial statements for the three- and six-month reporting periods ended June 30, 2023, and 2022 have
been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include
all the information and disclosures required in the annual financial statements. Accordingly, this report is to be read in conjunction
with the financial statements in our annual report for the year ended December 31, 2022 on form 20-F.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the &#x201c;Board
of Directors&#x201d;) on August 9, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements are presented in euros (&#x20ac;). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional
currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. Effective January 1, 2023, the functional currency of InflaRx N.V. changed
from the U.S. dollar to the euro due to a change in the Company&#x2019;s operational function and, in turn, a change in the primary currency
of its underlying transactions. This change in functional currency has been accounted for prospectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
financial information presented in euros have been rounded. Accordingly, numerical figures shown as totals in some tables may not be
an arithmetic aggregation of the figures that precede them or may deviate from other tables.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies adopted are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial
statements for the year ended December 31, 2022, except for the adoption of new standards effective as of January 1, 2023, as set out
below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following IFRS standards have been applied starting in Q2 2023 for the first time ever, as no transactions in the scope of these IFRS
standards had been previously recognized and are not expected to have a significant impact on the Company&#x2019;s consolidated financial
statements in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS
                                            2 Inventories&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to IAS 2, inventories are stated at the lower amount of cost or their net realizable value. Cost comprises direct materials and, where
applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and
condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less
all estimated costs of completion and costs to be incurred in marketing, selling and distribution.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.55pt; text-indent: -17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            15 Revenue from contracts with customers&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
will be recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer.
An asset is transferred when the customer obtains control of that asset. Revenue will be recognized at the point in time that the control
of the products is transferred to the customer and measured considering return liabilities. As of June 30, 2023, no revenue has been
recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            17 Insurance Contracts&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting
                                            Estimates&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies -&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group&#x2019;s
consolidated financial statements is being assessed:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IFRS 16 Leases: Leases on Sale and Leaseback&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 53.85pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or
                                            Non-current and Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</infrx:DisclosureOfSummaryOfSignificantAccountingPolicy>
    <infrx:DisclosureOfReportingEntityAndGroupsStructure contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reporting
entity and the Group&#x2019;s structure&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;InflaRx
N.V. (the &#x201c;Company&#x201d; or &#x201c;InflaRx&#x201d;) is a Dutch public company with limited liability (&lt;i&gt;naamloze vennootschap&lt;/i&gt;)
with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce
Business Register under CCI number 68904312. The Company&#x2019;s registered office is at Winzerlaer Stra&#xdf;e 2 in 07745 Jena, Germany.
Since November 10, 2017, InflaRx N.V.&#x2019;s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;InflaRx
is a biopharmaceutical company focused on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize
first-in-class, potent and specific inhibitors of the complement activation factor known as C5a. On April 4, 2023, the US Food and Drug
Administration (FDA) issued an Emergency Use Authorization (EUA) for the emergency use of the Company&#x2019;s monoclonal anti-C5a antibody
vilobelimab, under the brand name Gohibic, for the treatment of COVID-19 in hospitalized adults. These consolidated financial statements
of InflaRx comprise the Company and its wholly-owned subsidiaries, InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann
Arbor, Michigan, United States (together referred to as the &#x201c;Group&#x201d;).&lt;/span&gt;&lt;/p&gt;</infrx:DisclosureOfReportingEntityAndGroupsStructure>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basis
of preparation&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
interim condensed consolidated financial statements for the three- and six-month reporting periods ended June 30, 2023, and 2022 have
been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include
all the information and disclosures required in the annual financial statements. Accordingly, this report is to be read in conjunction
with the financial statements in our annual report for the year ended December 31, 2022 on form 20-F.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the &#x201c;Board
of Directors&#x201d;) on August 9, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements are presented in euros (&#x20ac;). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional
currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar. Effective January 1, 2023, the functional currency of InflaRx N.V. changed
from the U.S. dollar to the euro due to a change in the Company&#x2019;s operational function and, in turn, a change in the primary currency
of its underlying transactions. This change in functional currency has been accounted for prospectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
financial information presented in euros have been rounded. Accordingly, numerical figures shown as totals in some tables may not be
an arithmetic aggregation of the figures that precede them or may deviate from other tables.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accounting policies adopted are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial
statements for the year ended December 31, 2022, except for the adoption of new standards effective as of January 1, 2023, as set out
below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following IFRS standards have been applied starting in Q2 2023 for the first time ever, as no transactions in the scope of these IFRS
standards had been previously recognized and are not expected to have a significant impact on the Company&#x2019;s consolidated financial
statements in future periods.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IAS
                                            2 Inventories&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to IAS 2, inventories are stated at the lower amount of cost or their net realizable value. Cost comprises direct materials and, where
applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and
condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less
all estimated costs of completion and costs to be incurred in marketing, selling and distribution.&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.7pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            15 Revenue from contracts with customers&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
will be recognized when a performance obligation has been satisfied through the transfer of a promised good or service to a customer.
An asset is transferred when the customer obtains control of that asset. Revenue will be recognized at the point in time that the control
of the products is transferred to the customer and measured considering return liabilities. As of June 30, 2023, no revenue has been
recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following amendments were adopted effective January 1, 2023, and do not have a material impact on the consolidated financial statements
of the Group:&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;IFRS
                                            17 Insurance Contracts&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors: Definition of Accounting
                                            Estimates&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 12 Deferred Tax related to Assets and Liabilities arising from a Single Transaction&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies -&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group&#x2019;s
consolidated financial statements is being assessed:&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IFRS 16 Leases: Leases on Sale and Leaseback&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 35.85pt"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 18pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-right: 26.05pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amendments
                                            to IAS 1 Presentation of Financial Statements: Classification of Liabilities as Current or
                                            Non-current and Non-current Liabilities with Covenants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <infrx:DisclosureOfOtherIncomeTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months ended June
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;
ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt"&gt;Income from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;4,874,934&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;14,415,368&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;12,609,789&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;14,415,368&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; width: 60%"&gt;Other&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;7,974&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;26,173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;19,307&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,767&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,882,908&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,441,541&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,629,096&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,443,135&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
income for the three months ended June 30, 2023 amounted to &#x20ac;4.9 million (PY: &#x20ac;14.4 million) and for the six months ended June
30, 2023 amounted to &#x20ac;12.6 million (PY: &#x20ac;14.4 million), which is primarily attributable to income recognized from grant payments
received from the German federal government for the development of vilobelimab as treatment for critically ill COVID patients, including
expenses related to clinical development and manufacturing process development. The decrease in income from government grants is primarily
due to a non-recurring catch-up effect of costs incurred in preceding periods for which income recognition was deferred until the three
months ended June 30, 2022 when the recognition criteria were met.&lt;/span&gt;&lt;/p&gt;</infrx:DisclosureOfOtherIncomeTextBlock>
    <infrx:SummaryofotherIncometableTextBlock contextRef="c0">Other
income&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months ended June
    30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;
ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt"&gt;Income from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;4,874,934&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;14,415,368&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;12,609,789&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;14,415,368&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; width: 60%"&gt;Other&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;7,974&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;26,173&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;19,307&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 1.5pt solid; text-align: right"&gt;27,767&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,882,908&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,441,541&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;12,629,096&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,443,135&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:SummaryofotherIncometableTextBlock>
    <infrx:IncomeFromGovernmentGrants contextRef="c1" decimals="0" unitRef="eur">4874934</infrx:IncomeFromGovernmentGrants>
    <infrx:IncomeFromGovernmentGrants contextRef="c2" decimals="0" unitRef="eur">14415368</infrx:IncomeFromGovernmentGrants>
    <infrx:IncomeFromGovernmentGrants contextRef="c0" decimals="0" unitRef="eur">12609789</infrx:IncomeFromGovernmentGrants>
    <infrx:IncomeFromGovernmentGrants contextRef="c3" decimals="0" unitRef="eur">14415368</infrx:IncomeFromGovernmentGrants>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates contextRef="c1" decimals="0" unitRef="eur">7974</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates contextRef="c2" decimals="0" unitRef="eur">26173</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates contextRef="c0" decimals="0" unitRef="eur">19307</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates contextRef="c3" decimals="0" unitRef="eur">27767</ifrs-full:OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates>
    <infrx:OtherIncomeTotal contextRef="c1" decimals="0" unitRef="eur">4882908</infrx:OtherIncomeTotal>
    <infrx:OtherIncomeTotal contextRef="c2" decimals="0" unitRef="eur">14441541</infrx:OtherIncomeTotal>
    <infrx:OtherIncomeTotal contextRef="c0" decimals="0" unitRef="eur">12629096</infrx:OtherIncomeTotal>
    <infrx:OtherIncomeTotal contextRef="c3" decimals="0" unitRef="eur">14443135</infrx:OtherIncomeTotal>
    <ifrs-full:OtherFinanceIncome contextRef="c1" decimals="-5" unitRef="eur">4900000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c2" decimals="-5" unitRef="eur">14400000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c0" decimals="-5" unitRef="eur">12600000</ifrs-full:OtherFinanceIncome>
    <ifrs-full:OtherFinanceIncome contextRef="c3" decimals="-5" unitRef="eur">14400000</ifrs-full:OtherFinanceIncome>
    <infrx:DisclosureOfNetFinancialResult contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
financial result&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,087,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;82,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,543,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;110,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(363&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,243&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,102&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,081,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;74,456&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,532,467&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;77,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Foreign exchange result&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Foreign exchange income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,090,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,947,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,381,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4,057,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Foreign exchange expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,323,348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,383,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,751,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,766,116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;767,646&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,563,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(369,664&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,291,513&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Foreign
exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx
GmbH and InflaRx N.V.&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Other financial result&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(195,567&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;39,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
financial result is attributable to the expected credit loss allowance, which is deducted from the Company&#x2019;s current and non-current
financial assets.&lt;span style="clear: both; display: block;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</infrx:DisclosureOfNetFinancialResult>
    <infrx:ScheduleOfNetFinancialResultTableTextBlock contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
net financial result comprises the following items for the three- and six-months ended June 30, 2023 and 2022, respectively:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Interest income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,087,011&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;82,401&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;1,543,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;110,362&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Financial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Interest expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(363&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,243&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(782&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(22,102&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,689&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,702&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(10,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,081,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;74,456&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,532,467&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;77,831&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:ScheduleOfNetFinancialResultTableTextBlock>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss contextRef="c1" decimals="0" unitRef="eur">1087011</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss contextRef="c2" decimals="0" unitRef="eur">82401</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss contextRef="c0" decimals="0" unitRef="eur">1543047</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss contextRef="c3" decimals="0" unitRef="eur">110362</ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss>
    <ifrs-full:InterestExpense contextRef="c1" decimals="0" unitRef="eur">363</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c2" decimals="0" unitRef="eur">2243</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c0" decimals="0" unitRef="eur">782</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpense contextRef="c3" decimals="0" unitRef="eur">22102</ifrs-full:InterestExpense>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c1" decimals="0" unitRef="eur">4689</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c2" decimals="0" unitRef="eur">5702</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c0" decimals="0" unitRef="eur">9798</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c3" decimals="0" unitRef="eur">10429</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <infrx:NetFinancialResult contextRef="c1" decimals="0" unitRef="eur">1081959</infrx:NetFinancialResult>
    <infrx:NetFinancialResult contextRef="c2" decimals="0" unitRef="eur">74456</infrx:NetFinancialResult>
    <infrx:NetFinancialResult contextRef="c0" decimals="0" unitRef="eur">1532467</infrx:NetFinancialResult>
    <infrx:NetFinancialResult contextRef="c3" decimals="0" unitRef="eur">77831</infrx:NetFinancialResult>
    <infrx:ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income is derived from marketable securities and short-term deposits held by the Company and its subsidiary InflaRx GmbH:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Foreign exchange result&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-left: 0pt"&gt;Foreign exchange income&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,090,994&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,947,221&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;2,381,519&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;4,057,629&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Foreign exchange expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,323,348&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,383,641&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,751,183&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,766,116&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;767,646&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,563,580&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(369,664&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,291,513&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock>
    <infrx:ForeignExchangeIncome contextRef="c1" decimals="0" unitRef="eur">2090994</infrx:ForeignExchangeIncome>
    <infrx:ForeignExchangeIncome contextRef="c2" decimals="0" unitRef="eur">2947221</infrx:ForeignExchangeIncome>
    <infrx:ForeignExchangeIncome contextRef="c0" decimals="0" unitRef="eur">2381519</infrx:ForeignExchangeIncome>
    <infrx:ForeignExchangeIncome contextRef="c3" decimals="0" unitRef="eur">4057629</infrx:ForeignExchangeIncome>
    <infrx:ForeignExchangeExpense contextRef="c1" decimals="0" unitRef="eur">1323348</infrx:ForeignExchangeExpense>
    <infrx:ForeignExchangeExpense contextRef="c2" decimals="0" unitRef="eur">1383641</infrx:ForeignExchangeExpense>
    <infrx:ForeignExchangeExpense contextRef="c0" decimals="0" unitRef="eur">2751183</infrx:ForeignExchangeExpense>
    <infrx:ForeignExchangeExpense contextRef="c3" decimals="0" unitRef="eur">1766116</infrx:ForeignExchangeExpense>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c1" decimals="0" unitRef="eur">767646</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c2" decimals="0" unitRef="eur">1563580</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c0" decimals="0" unitRef="eur">-369664</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c3" decimals="0" unitRef="eur">2291513</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <infrx:ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock contextRef="c0">Foreign
exchange income and expense is mainly derived from the translation of the U.S. Dollar cash, cash equivalents and securities held by InflaRx
GmbH and InflaRx N.V.&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the three months &lt;br/&gt;ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the six months &lt;br/&gt;ended June 30&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022 &lt;br/&gt;(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Other financial result&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(195,567&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;39,000&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock>
    <infrx:OtherFinancialResult contextRef="c1" decimals="0" unitRef="eur">195567</infrx:OtherFinancialResult>
    <infrx:OtherFinancialResult contextRef="c2" decimals="0" unitRef="eur">86000</infrx:OtherFinancialResult>
    <infrx:OtherFinancialResult contextRef="c0" decimals="0" unitRef="eur">-2241</infrx:OtherFinancialResult>
    <infrx:OtherFinancialResult contextRef="c3" decimals="0" unitRef="eur">-39000</infrx:OtherFinancialResult>
    <ifrs-full:DisclosureOfInventoriesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0pt"&gt;Raw materials and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,407&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Unfinished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108,674&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;578,705&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company valued inventories at manufacturing cost in its consolidated statements of financial position as of June 30, 2023. Inventories
do not include costs relating to production of products before the granting of the EUA for Gohibic (vilobelimab), since those were expensed
in previous reporting periods as research and development expenses in the period incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three and the six months ended June 30, 2023, there were no write-downs of inventories.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="c0">Inventories&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0pt"&gt;Raw materials and supplies&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;337,407&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;&#160;&#160;&#160;&#160;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Unfinished goods&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,624&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108,674&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;578,705&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies contextRef="c4" decimals="0" unitRef="eur">337407</ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies>
    <infrx:UnfinishedGoods contextRef="c4" decimals="0" unitRef="eur">132624</infrx:UnfinishedGoods>
    <ifrs-full:FinishedGoods contextRef="c4" decimals="0" unitRef="eur">108674</ifrs-full:FinishedGoods>
    <ifrs-full:CurrentFinancialAssets contextRef="c4" decimals="0" unitRef="eur">578705</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="c1" decimals="0" unitRef="eur">0</ifrs-full:ReversalOfInventoryWritedown>
    <ifrs-full:ReversalOfInventoryWritedown contextRef="c0" decimals="0" unitRef="eur">0</ifrs-full:ReversalOfInventoryWritedown>
    <infrx:DisclosureOfOtherAssets contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other
assets&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Non-current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;283,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;283,784&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Prepayments on research &amp;amp; development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,757,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,776,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Prepaid expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,146,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;501,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,405,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;14,170,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Total other assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,689,651&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,478,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, prepayments on research &amp;amp; development projects amounted to &#x20ac;4.8 million compared to &#x20ac;9.8 million as of
December 31, 2022, and consist of prepayments on clinical and R&amp;amp;D material production contracts. The decrease in prepayments results
from manufacturing development activities, which were partly completed in the six months ended June 30, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
expenses mainly consist of prepaid insurance expense.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reduction of the amounts in the category &#x201c;others&#x201d; primarily relate to credit notes issued to the Company by CROs, which were
still outstanding as of December 31, 2022 and were paid in 2023.&lt;/span&gt;&lt;/p&gt;</infrx:DisclosureOfOtherAssets>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="c0">Other
assets&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Non-current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;283,784&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;283,784&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;308,066&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Current other assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Prepayments on research &amp;amp; development projects&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,757,771&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,776,505&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Prepaid expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,146,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,841,935&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt"&gt;Others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;501,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,552,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;6,405,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;14,170,511&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Total other assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;6,689,651&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;14,478,577&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <infrx:NonPrepaidExpenses contextRef="c4" decimals="0" unitRef="eur">283784</infrx:NonPrepaidExpenses>
    <infrx:NonPrepaidExpenses contextRef="c5" decimals="0" unitRef="eur">308066</infrx:NonPrepaidExpenses>
    <ifrs-full:OtherNoncurrentAssets contextRef="c4" decimals="0" unitRef="eur">283784</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets contextRef="c5" decimals="0" unitRef="eur">308066</ifrs-full:OtherNoncurrentAssets>
    <infrx:PrepaymentsOnResearchDevelopmentProjects contextRef="c4" decimals="0" unitRef="eur">4757771</infrx:PrepaymentsOnResearchDevelopmentProjects>
    <infrx:PrepaymentsOnResearchDevelopmentProjects contextRef="c5" decimals="0" unitRef="eur">9776505</infrx:PrepaymentsOnResearchDevelopmentProjects>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c4" decimals="0" unitRef="eur">1146674</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c5" decimals="0" unitRef="eur">1841935</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:OtherCurrentReceivables contextRef="c4" decimals="0" unitRef="eur">501422</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c5" decimals="0" unitRef="eur">2552071</ifrs-full:OtherCurrentReceivables>
    <infrx:CurrentOtherAssetsTotal contextRef="c4" decimals="0" unitRef="eur">6405867</infrx:CurrentOtherAssetsTotal>
    <infrx:CurrentOtherAssetsTotal contextRef="c5" decimals="0" unitRef="eur">14170511</infrx:CurrentOtherAssetsTotal>
    <ifrs-full:CurrentAssetsLiabilities contextRef="c4" decimals="0" unitRef="eur">6689651</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:CurrentAssetsLiabilities contextRef="c5" decimals="0" unitRef="eur">14478577</ifrs-full:CurrentAssetsLiabilities>
    <ifrs-full:NoncurrentPrepayments contextRef="c4" decimals="-5" unitRef="eur">4800000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:NoncurrentPrepayments contextRef="c5" decimals="-5" unitRef="eur">9800000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
assets and financial liabilities&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30,
2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Non-current financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,951,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,900,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Financial assets from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,193,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;732,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Other current financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,601,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,791,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Financial liabilities at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Liabilities from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,209,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,200,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,987,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to &#x20ac;100.7
million (Level 1). The Group&#x2019;s debt instruments at amortized cost consist solely of quoted securities that are graded highly by
credit rating agencies such as S&amp;amp;P Global and, therefore, are considered low credit risk investments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of June 30, 2023, liabilities from government grants amounted to &#x20ac;0.8 million. Liabilities from government grants partly comprise
funds received for advance payments to third parties. If goods or services from such third parties have not been received, corresponding
amounts are not recognized as other income. The Company&#x2019;s right to retain these funds is contingent on meeting all grant conditions.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Set
out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of June 30,
2023 and December 31, 2022:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
June 30,&lt;br/&gt;
2023&lt;br/&gt;
(unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt;
December&#160;31, &lt;br/&gt;
2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Financial assets at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Non-current financial assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18,951,267&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,900,902&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Financial assets from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,193,245&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;732,971&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Other current financial assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;77,601,286&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,791,088&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Financial liabilities at amortized cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Liabilities from government grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;801,632&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,209,266&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Trade and other payables&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,200,809&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,987,538&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c4" decimals="0" unitRef="usd">18951267</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets contextRef="c5" decimals="0" unitRef="usd">2900902</ifrs-full:NoncurrentFinancialAssets>
    <infrx:FinancialAssetsFromGovernmentGrants contextRef="c4" decimals="0" unitRef="usd">5193245</infrx:FinancialAssetsFromGovernmentGrants>
    <infrx:FinancialAssetsFromGovernmentGrants contextRef="c5" decimals="0" unitRef="usd">732971</infrx:FinancialAssetsFromGovernmentGrants>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c4" decimals="0" unitRef="usd">77601286</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets contextRef="c5" decimals="0" unitRef="usd">64791088</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:GovernmentGrants contextRef="c4" decimals="0" unitRef="usd">801632</ifrs-full:GovernmentGrants>
    <ifrs-full:GovernmentGrants contextRef="c5" decimals="0" unitRef="usd">6209266</ifrs-full:GovernmentGrants>
    <ifrs-full:TradeAndOtherPayables contextRef="c4" decimals="0" unitRef="usd">5200809</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables contextRef="c5" decimals="0" unitRef="usd">4987538</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss contextRef="c4" decimals="-5" unitRef="eur">100700000</ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss>
    <infrx:AssetsFromGovernmentGrants contextRef="c4" decimals="-5" unitRef="eur">800000</infrx:AssetsFromGovernmentGrants>
    <ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; June 30, 2023 (unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-left: 0pt"&gt;Deposits held in U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7,825,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Deposits held in euros&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;13,925,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Cash held in U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,340,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,645,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Cash held in euros&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;2,249,144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;7,616,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,590,033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19,515,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;16,265,354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory>
    <infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of&lt;br/&gt; June 30, 2023 (unaudited)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;As of &lt;br/&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(in &#x20ac;)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;Short-term deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-left: 0pt"&gt;Deposits held in U.S. dollars&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7,825,926&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Deposits held in euros&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,100,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;13,925,926&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;3,422&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0pt"&gt;Cash at banks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Cash held in U.S. dollars&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,340,889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,645,014&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Cash held in euros&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;2,249,144&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: normal; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: normal; text-align: right"&gt;7,616,918&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: normal; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;5,590,033&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;16,261,932&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Total cash and cash equivalents&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;19,515,959&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;16,265,354&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal contextRef="c43" decimals="0" unitRef="eur">7825926</infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal contextRef="c44" decimals="0" unitRef="eur">3422</infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal contextRef="c45" decimals="0" unitRef="eur">6100000</infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal contextRef="c4" decimals="0" unitRef="eur">13925926</infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal contextRef="c5" decimals="0" unitRef="eur">3422</infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal>
    <infrx:CashAtBankstotal contextRef="c43" decimals="0" unitRef="eur">3340889</infrx:CashAtBankstotal>
    <infrx:CashAtBankstotal contextRef="c44" decimals="0" unitRef="eur">8645014</infrx:CashAtBankstotal>
    <infrx:CashAtBankstotal contextRef="c45" decimals="0" unitRef="eur">2249144</infrx:CashAtBankstotal>
    <infrx:CashAtBankstotal contextRef="c46" decimals="0" unitRef="eur">7616918</infrx:CashAtBankstotal>
    <infrx:CashAtBankstotal contextRef="c4" decimals="0" unitRef="eur">5590033</infrx:CashAtBankstotal>
    <infrx:CashAtBankstotal contextRef="c5" decimals="0" unitRef="eur">16261932</infrx:CashAtBankstotal>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c4" decimals="0" unitRef="eur">19515959</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:OtherCashAndCashEquivalents contextRef="c5" decimals="0" unitRef="eur">16265354</ifrs-full:OtherCashAndCashEquivalents>
    <ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company issued 3,235,723 ordinary shares under its ATM program resulting in $15.7 million (or &#x20ac;14.4 million) in
net proceeds. The existing ATM program expired in July 2023 and no more shares are issuable under this program.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Through
an underwritten public offering in April 2023, the Company sold and issued an aggregate of 10,823,529 ordinary shares, of which 1,411,764
were sold pursuant to the exercise of an overallotment option by the underwriters. The ordinary shares were sold at a price of $4.25
per share and have a nominal value of &#x20ac;0.12 per share. Proceeds of this offering after deducting &#x20ac;2.5 million ($2.8 million)
in underwriting discounts amounted to &#x20ac;39.1 million ($43.2 million). Other offering expenses amounted to &#x20ac;0.4 million, resulting
in a total of &#x20ac;38.7 million in net proceeds from this offering.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory>
    <infrx:CommonSharesSaleAgreement contextRef="c47" decimals="0" unitRef="shares">3235723</infrx:CommonSharesSaleAgreement>
    <ifrs-full:Equity contextRef="c48" decimals="-5" unitRef="usd">15700000</ifrs-full:Equity>
    <ifrs-full:ProceedsFromIssuingOtherEquityInstruments contextRef="c49" decimals="-5" unitRef="eur">14400000</ifrs-full:ProceedsFromIssuingOtherEquityInstruments>
    <infrx:SoldCommonSharesThroughAPublicOffering contextRef="c47" decimals="0" unitRef="shares">10823529</infrx:SoldCommonSharesThroughAPublicOffering>
    <infrx:ShareBasedPaymentTransactions contextRef="c49" decimals="0" unitRef="shares">1411764</infrx:ShareBasedPaymentTransactions>
    <infrx:SaleOfPricePerShare contextRef="c47" decimals="2" unitRef="usdPershares">4.25</infrx:SaleOfPricePerShare>
    <infrx:NominalValuePerShare contextRef="c47" decimals="2" unitRef="eurPershares">0.12</infrx:NominalValuePerShare>
    <ifrs-full:ProceedsFromSalesOfInvestmentProperty contextRef="c49" decimals="-5" unitRef="eur">2500000</ifrs-full:ProceedsFromSalesOfInvestmentProperty>
    <ifrs-full:ProceedsFromSalesOfInvestmentProperty contextRef="c49" decimals="-5" unitRef="usd">2800000</ifrs-full:ProceedsFromSalesOfInvestmentProperty>
    <ifrs-full:CurrentInvestments contextRef="c47" decimals="-5" unitRef="eur">39100000</ifrs-full:CurrentInvestments>
    <ifrs-full:CurrentInvestments contextRef="c47" decimals="-5" unitRef="usd">43200000</ifrs-full:CurrentInvestments>
    <ifrs-full:OtherExpenseByNature contextRef="c49" decimals="-5" unitRef="eur">400000</ifrs-full:OtherExpenseByNature>
    <infrx:OtherOfferingExpensesTotal contextRef="c47" decimals="-5" unitRef="eur">38700000</infrx:OtherOfferingExpensesTotal>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based
payments&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 25.1pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: italic bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity
settled share-based payment arrangements&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prior
to 2016, InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary
shares of InflaRx N.V. at the time of its IPO in November 2017:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Outstanding as of January 1,&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Exercised during the six months ended June 30&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;thereof vested&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH&#x2019;s ordinary shares
to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx
N.V. at the time of its IPO in November 2017:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; width: 76%; font-weight: bold"&gt;Outstanding as of January 1,&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 9%; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 9%; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-indent: 0in"&gt;Exercised during the six months ended June 30&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; font-style: italic; text-align: left"&gt;thereof vested&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;InflaRx
also granted share options under the 2017 LTIP subsequently to its IPO in November 2017. The total number of share options granted during
the six months ended June 30, 2023 under the 2017 LTIP was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-indent: 0in"&gt;Total number of options outstanding as of January 1,&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,170,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0in"&gt;Granted during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,561,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0in"&gt;Exercised during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0in"&gt;Forfeited during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0in"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,447,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,614,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in"&gt;thereof vested&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;4,788,759&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;3,306,162&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
number of share options granted during the six months ended June 30, 2023 under the 2017 LTIP was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Share options
granted 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value per&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;FX rate as of grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value per&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Share price at grant date /&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Risk-free rate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(interpolated, U.S. sovereign strips curve)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;January 24&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,454,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;3.571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;January 24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.565&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;May 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;60,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;3,61&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.820&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;b&gt;1,567,250&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Of the 1,567,250 options granted in the six months ended June 30, 2023 (ended June 30, 2022: 1,561,666), 1,246,000 options (June 30, 2022: 1,362,500) were granted to members of the executive management or Board of Directors.&lt;/span&gt; &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;Expected dividends are nil for all share options listed above. &#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;b)&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-based payment expense recognized&lt;/i&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the six months ended June 30, 2023, the Company has recognized &#x20ac;2.2 million (ended June 30, 2022: &#x20ac;4.7 million) of share-based
payment expense/(benefit) in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;None
of the share-based payment awards were dilutive in determining earnings per share due to the Group&#x2019;s loss position.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24.95pt; text-indent: -17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.25in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Share
                                            options exercised&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, 105,327 shares (ended June 30, 2022: 0) were issued upon the exercise of share options, resulting
in proceeds to the Company in the amount of &#x20ac;98 thousand (ended June 30, 2022: 0). All share options exercised during the six months
ended June 30, 2023 were granted under the 2017 LTIP.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <infrx:SchdeuleOfStockOptionActivityTableTextBlock contextRef="c0">Prior
to 2016, InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary
shares of InflaRx N.V. at the time of its IPO in November 2017&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Outstanding as of January 1,&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Exercised during the six months ended June 30&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0pt; padding-left: 0pt"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left; text-indent: 0pt; padding-left: 0.125in"&gt;thereof vested&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;148,433&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding: 0pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding: 0pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; width: 76%; font-weight: bold"&gt;Outstanding as of January 1,&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 9%; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; width: 9%; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt; text-indent: 0in"&gt;Exercised during the six months ended June 30&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt; font-weight: bold"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding: 0pt 0pt 0pt 0.125in; font-style: italic; text-align: left"&gt;thereof vested&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: right"&gt;888,632&lt;/td&gt;&lt;td style="padding: 0pt; font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Number of share options&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; font-weight: bold; text-indent: 0in"&gt;Total number of options outstanding as of January 1,&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,985,523&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,170,046&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0in"&gt;Granted during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,567,250&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,561,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0in"&gt;Exercised during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;105,327&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0in"&gt;Forfeited during the six months ended June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(117,259&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-indent: 0in"&gt;Outstanding as of June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,447,446&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,614,453&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in"&gt;thereof vested&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;4,788,759&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-style: italic; text-align: right"&gt;3,306,162&lt;/td&gt;&lt;td style="font-style: italic; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:SchdeuleOfStockOptionActivityTableTextBlock>
    <infrx:OutstandingBalance contextRef="c54" decimals="INF" unitRef="shares">148433</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c55" decimals="INF" unitRef="shares">148433</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c58" decimals="INF" unitRef="shares">148433</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c59" decimals="INF" unitRef="shares">148433</infrx:OutstandingBalance>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c56" decimals="INF" unitRef="shares">148433</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c57" decimals="INF" unitRef="shares">148433</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:OutstandingBalance contextRef="c60" decimals="INF" unitRef="shares">888632</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c61" decimals="INF" unitRef="shares">888632</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c63" decimals="INF" unitRef="shares">888632</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c64" decimals="INF" unitRef="shares">888632</infrx:OutstandingBalance>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c62" decimals="INF" unitRef="shares">888632</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c65" decimals="INF" unitRef="shares">888632</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:CommonSharesDescription contextRef="c0">The total number of share options granted during
the six months ended June 30, 2023 under the 2017 LTIP was as follows:</infrx:CommonSharesDescription>
    <infrx:OutstandingBalance contextRef="c66" decimals="INF" unitRef="shares">4985523</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c67" decimals="INF" unitRef="shares">3170046</infrx:OutstandingBalance>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares contextRef="c68" decimals="INF" unitRef="shares">1567250</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares contextRef="c69" decimals="INF" unitRef="shares">1561666</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares>
    <infrx:ExercisedNumberOfShares contextRef="c68" decimals="INF" unitRef="shares">105327</infrx:ExercisedNumberOfShares>
    <infrx:ForfeitedShares contextRef="c69" decimals="INF" unitRef="shares">-117259</infrx:ForfeitedShares>
    <infrx:OutstandingBalance contextRef="c70" decimals="INF" unitRef="shares">6447446</infrx:OutstandingBalance>
    <infrx:OutstandingBalance contextRef="c71" decimals="INF" unitRef="shares">4614453</infrx:OutstandingBalance>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c68" decimals="INF" unitRef="shares">4788759</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares contextRef="c69" decimals="INF" unitRef="shares">3306162</infrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares>
    <infrx:ScheduleOfFairValueOfOptionsGrantedTableTextBlock contextRef="c0">The
number of share options granted during the six months ended June 30, 2023 under the 2017 LTIP was as follows&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Share options
granted 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value per&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;FX rate as of grant date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Fair value per&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Share price at grant date /&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Expected volatility&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Expected life&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(midpoint based)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Risk-free rate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;(interpolated, U.S. sovereign strips curve)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%"&gt;January 24&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,454,250&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2.11&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;5.30&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;3.571&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;January 24&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.13&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.92&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2.37&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.565&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;May 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;60,500&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;3,61&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.9203&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#x20ac;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.32&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4.19&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.35&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.50&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.820&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;b&gt;1,567,250&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</infrx:ScheduleOfFairValueOfOptionsGrantedTableTextBlock>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c72" decimals="0" unitRef="pure">1454250</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <infrx:FairValuePerOption contextRef="c72" decimals="2" unitRef="usdPershares">2.11</infrx:FairValuePerOption>
    <infrx:FXRateAsOfGrantDate contextRef="c72" decimals="4" unitRef="usdPershares">0.9008</infrx:FXRateAsOfGrantDate>
    <infrx:FairValuePerOptions contextRef="c72" decimals="2" unitRef="usdPershares">1.9</infrx:FairValuePerOptions>
    <infrx:SharePriceAtGrantDateExercisePrice contextRef="c72" decimals="2" unitRef="usdPershares">2.37</infrx:SharePriceAtGrantDateExercisePrice>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c72" decimals="4" unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <infrx:ExpectedLifemidpointBased contextRef="c72" decimals="2" unitRef="usdPershares">5.3</infrx:ExpectedLifemidpointBased>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c72" decimals="5" unitRef="pure">0.03571</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c73" decimals="0" unitRef="pure">52500</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <infrx:FairValuePerOption contextRef="c73" decimals="2" unitRef="usdPershares">2.13</infrx:FairValuePerOption>
    <infrx:FXRateAsOfGrantDate contextRef="c73" decimals="4" unitRef="usdPershares">0.9008</infrx:FXRateAsOfGrantDate>
    <infrx:FairValuePerOptions contextRef="c73" decimals="2" unitRef="usdPershares">1.92</infrx:FairValuePerOptions>
    <infrx:SharePriceAtGrantDateExercisePrice contextRef="c73" decimals="2" unitRef="usdPershares">2.37</infrx:SharePriceAtGrantDateExercisePrice>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c73" decimals="4" unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <infrx:ExpectedLifemidpointBased contextRef="c73" decimals="2" unitRef="usdPershares">5.5</infrx:ExpectedLifemidpointBased>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c73" decimals="5" unitRef="pure">0.03565</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c74" decimals="0" unitRef="pure">60500</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <infrx:FXRateAsOfGrantDate contextRef="c74" decimals="4" unitRef="usdPershares">0.9203</infrx:FXRateAsOfGrantDate>
    <infrx:FairValuePerOptions contextRef="c74" decimals="2" unitRef="usdPershares">3.32</infrx:FairValuePerOptions>
    <infrx:SharePriceAtGrantDateExercisePrice contextRef="c74" decimals="2" unitRef="usdPershares">4.19</infrx:SharePriceAtGrantDateExercisePrice>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c74" decimals="4" unitRef="pure">0.0135</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <infrx:ExpectedLifemidpointBased contextRef="c74" decimals="2" unitRef="usdPershares">4.5</infrx:ExpectedLifemidpointBased>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c74" decimals="5" unitRef="pure">0.0382</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c0" decimals="0" unitRef="pure">1567250</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c50" decimals="0" unitRef="pure">1567250</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c3" decimals="0" unitRef="pure">1561666</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c0" decimals="0" unitRef="pure">1246000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c51" decimals="0" unitRef="pure">1362500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <infrx:SharebasedPaymentExpense contextRef="c0" decimals="-5" unitRef="eur">2200000</infrx:SharebasedPaymentExpense>
    <infrx:ValuationPastGrantAmount contextRef="c0" decimals="-5" unitRef="eur">4700000</infrx:ValuationPastGrantAmount>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c0" decimals="0" unitRef="pure">105327</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c52" decimals="0" unitRef="pure">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c53" decimals="-3" unitRef="pure">98000</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c3" decimals="-3" unitRef="pure">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <infrx:DisclosureOfProtectiveFoundationExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Protective
foundation&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According
to the Articles of Association of the Company, up to 110,000,000 ordinary shares and up to 110,000,000 preferred shares with a nominal
value of &#x20ac;0.12 per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to deter acquisition bids, the Company`s shareholders approved the right of an independent foundation under Dutch law, or protective
foundation, to exercise a call option on preferred shares. Pursuant to the call option agreement, the Company shall issue an amount of
preferred shares to the protective foundation, amounting to up to 100% of the Company&#x2019;s issued capital held by others than the
protective foundation, minus one share. In order to exercise its right to such share issue, the protective foundation is expected to
enter into a finance arrangement with a bank, or subject to applicable restrictions under Dutch law, the protective foundation may request
the Company to provide, or cause the Company&#x2019;s subsidiaries to provide, sufficient funding to the protective foundation to enable
it to satisfy its payment obligation under the call option agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
preferred shares will have both a liquidation and dividend preference over the Company`s ordinary shares and will accrue cash dividends
at a pre-determined rate. The protective foundation would be expected to require us to cancel its preferred shares once the perceived
threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. We believe that the call option
does not represent a significant fair value based on a Level 3 valuation, since the preference shares are restricted in use and can be
canceled by us.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the six months ended June 30, 2023, the Company expensed &#x20ac;45 thousand (2022: &#x20ac;30 thousand) of ongoing costs to reimburse expenses
incurred by the protective foundation.&lt;/span&gt;&lt;/p&gt;</infrx:DisclosureOfProtectiveFoundationExplanatory>
    <infrx:AuthorisedCapitalCommonSharesone contextRef="c4" decimals="0" unitRef="shares">110000000</infrx:AuthorisedCapitalCommonSharesone>
    <infrx:AuthorisdCapitalPreferenceSharesone contextRef="c4" decimals="0" unitRef="shares">110000000</infrx:AuthorisdCapitalPreferenceSharesone>
    <infrx:PricePerShares contextRef="c4" decimals="2" unitRef="eurPershares">0.12</infrx:PricePerShares>
    <infrx:PercentageOfIssuedCapital contextRef="c0" decimals="2" unitRef="pure">1</infrx:PercentageOfIssuedCapital>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c0" decimals="-3" unitRef="eur">45000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c3" decimals="-3" unitRef="eur">30000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
events&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 17.85pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Effective
July 1, 2023, Dr. Camilla Chong was appointed the Company&#x2019;s Chief Medical Officer.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c2"
      id="hidden-fact-0"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="c3"
      id="hidden-fact-1"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c0"
      id="hidden-fact-4"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c2"
      decimals="2"
      id="hidden-fact-6"
      unitRef="eurPershares">0.01</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c1"
      decimals="2"
      id="hidden-fact-7"
      unitRef="eurPershares">-0.14</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c3"
      decimals="2"
      id="hidden-fact-8"
      unitRef="eurPershares">-0.31</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c0"
      decimals="2"
      id="hidden-fact-9"
      unitRef="eurPershares">-0.38</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:Inventories
      contextRef="c5"
      id="hidden-fact-10"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c12"
      id="hidden-fact-11"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c14"
      id="hidden-fact-13"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c16"
      id="hidden-fact-14"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c13"
      id="hidden-fact-16"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c14"
      id="hidden-fact-17"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c15"
      id="hidden-fact-18"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c12"
      id="hidden-fact-19"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c13"
      id="hidden-fact-20"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c14"
      id="hidden-fact-21"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c14"
      id="hidden-fact-22"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c15"
      id="hidden-fact-23"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IssueOfEquity
      contextRef="c16"
      id="hidden-fact-24"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c12"
      id="hidden-fact-25"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c14"
      id="hidden-fact-26"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c15"
      id="hidden-fact-27"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ShareIssueRelatedCost
      contextRef="c16"
      id="hidden-fact-28"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c12"
      id="hidden-fact-29"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c13"
      id="hidden-fact-30"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c15"
      id="hidden-fact-31"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c16"
      id="hidden-fact-32"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c14"
      id="hidden-fact-33"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c15"
      id="hidden-fact-34"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="c16"
      id="hidden-fact-35"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c31"
      id="hidden-fact-36"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c32"
      id="hidden-fact-37"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c33"
      id="hidden-fact-38"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProfitLoss
      contextRef="c35"
      id="hidden-fact-39"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c31"
      id="hidden-fact-40"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c32"
      id="hidden-fact-41"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c33"
      id="hidden-fact-42"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax
      contextRef="c34"
      id="hidden-fact-43"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c31"
      id="hidden-fact-44"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c32"
      id="hidden-fact-45"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ComprehensiveIncome
      contextRef="c33"
      id="hidden-fact-46"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c31"
      id="hidden-fact-47"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c32"
      id="hidden-fact-48"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c34"
      id="hidden-fact-49"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="c35"
      id="hidden-fact-50"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="c3"
      id="hidden-fact-51"
      unitRef="eur"
      xsi:nil="true"/>
    <infrx:ProceedsFromIssuanceOfCommonShares
      contextRef="c3"
      id="hidden-fact-52"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="c3"
      id="hidden-fact-53"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:ProceedsFromExerciseOfOptions
      contextRef="c3"
      id="hidden-fact-54"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies
      contextRef="c5"
      id="hidden-fact-55"
      unitRef="eur"
      xsi:nil="true"/>
    <infrx:UnfinishedGoods
      contextRef="c5"
      id="hidden-fact-56"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:FinishedGoods
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="eur"
      xsi:nil="true"/>
    <ifrs-full:CurrentFinancialAssets
      contextRef="c5"
      id="hidden-fact-58"
      unitRef="eur"
      xsi:nil="true"/>
    <infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal
      contextRef="c46"
      id="hidden-fact-59"
      unitRef="eur"
      xsi:nil="true"/>
    <infrx:ExercisedNumberOfShares
      contextRef="c56"
      id="hidden-fact-60"
      unitRef="shares"
      xsi:nil="true"/>
    <infrx:ExercisedNumberOfShares
      contextRef="c57"
      id="hidden-fact-61"
      unitRef="shares"
      xsi:nil="true"/>
    <infrx:ExercisedNumberOfShares
      contextRef="c62"
      id="hidden-fact-62"
      unitRef="shares"
      xsi:nil="true"/>
    <infrx:FairValuePerOption
      contextRef="c74"
      decimals="0"
      id="hidden-fact-63"
      unitRef="usdPershares">361</infrx:FairValuePerOption>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentPeriodEndDate contextRef="c0">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:EntityCentralIndexKey contextRef="c0">0001708688</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_11_fact"
          xlink:label="ix_11_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_7_fact"
          xlink:label="ix_7_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_6_fact"
          xlink:label="ix_6_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_9_fact"
          xlink:label="ix_9_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_10_fact"
          xlink:label="ix_10_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_8_fact"
          xlink:label="ix_8_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_13_fact"
          xlink:label="ix_13_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_12_fact"
          xlink:label="ix_12_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unaudited</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_11_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_7_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_6_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_9_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_10_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_8_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_13_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_12_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>54
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M?5N9.32Q+G9<6[TZQ9I SR/4I]363QWHR/1$_]?;T(\9TDP$KFXB,'=@ZDP
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M9,6K)D#^?E>6XNE+T\#^/9VK_P!02P,$%     @ $T *5S"F,!D7!P  O!T
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RM66%OVS@2_2N$%RBZ0%V+
MI$1):6*@];;8'G9O@_9Z]YF1:)NWDN@EZ:2]7W]#2;%LB6+313ZTL>7AZ+TA
M.>]1NGY0^D^S%\*BKW75F)O%WMK#U6IEBKVHN7FM#J*!7[9*U]S"5[U;F8,6
MO&P'U=6*1!%;U5PVB_5U>^U6KZ_5T5:R$;<:F6-=<_WMG:C4P\T"+QXO?)*[
MO7475NOK ]^)S\)^.=QJ^+8Z92EE+1HC58.TV-XLWN*K#4W<@#;BWU(\F+//
MR%&Y4^I/]^5C>;.('")1B<*Z%!S^W(N-J"J7"7#\U2==G.[I!IY_?LS^H24/
M9.ZX$1M5_4>6=G^SR!:H%%M^K.PG]?"KZ FU  M5F?9_]-#'1@M4'(U5=3\8
M$-2RZ?[RKWTAS@9 'O\ T@\@XP'QS #:#Z MT0Y92^L7;OGZ6JL'I%TT9',?
MVMJTHX&-;-PT?K8:?I4PSJZ_-/Q82BM*M%%-"=/3?3*JDB5WES];^ /S9@U2
M6[3A9H\^P-P;M$3OOWQ"+U_\E%$6O_GY>F4!CDNZ*OI;O^MN369NS=#OJK%[
M@][#C<O+\2N@<>)"'KF\(\&$_S@VKQ&-7B$2$>K!LWGZ<!* 0T^EI6T^.I/O
MCX/0W,IFUZU5::4POBIU66)_%K>-K\R!%^)F ?O4"'TO%NL7/V$6O?%1?*9D
M%X3C$^$XE'W]FS(&06=!=B\0D)>J]/'MDB1M$M=E[M=+G),LR1E,VOTY&5\D
M32AC27R*O$":G) FP:EY6_X7ME:WJ@'PE0]F\IS3\DS)+LBR$UD6G)9?!"0M
M)&_;Y@M>']X@7BMMY?^Z2["M#QIT0=MOB#<E$G\=Y<'5YA72K@DNU79Y- )Q
M8P34RX7(QO)F)^^JQZN^ G:HV-GLD9Q2DHTF>1I&HRA+(_\,IR?2:9#T/T$!
MM[+A32$ ;:%JX8.83NZ]Q)@E41R/0'H"21QE-$[\,+,3S"P(\_.>:[%T.E2B
M __FJH[$UX/KPSZ\V;2DA.8T3T=PIW$Q8UF<83_:_(0V_WY1E09I; !EL8<U
M(% IMUNA!13:NPIR3^5HGHRW^C0,TXC&J1\PC@9YBX([?=."-+ &O)N\'_U,
MN_RYLEUR/9-R')R>#^UZE[QZW*I;K6JT4_="-^W*VFG>^/=JG_EBFN*8120=
M[P1?9$98E$1T9J[(@)\$\?\!NJ$##:4??GYK1O(D3Y,Q1D\@QED\AW!0=!S4
MS_7[^E"I;T*@.]&(K9R!23VUQ#B=EM(3R.((8S*#<Q!B'%;BKI*5Y'>RFO4=
M?8Z+*D'G&^],3]@RS5@^@W&08!P4O?5O [J9A0K'A$* R?>ZB#[[!:PDCE)&
M)V7V1#*<Q!F;:=YX4%8<EM9_:5Z*5A%56W%HX1Q$T5]NCQYB2LZ$KH<[C5LR
MAM-XIGGC01)Q6!,_-O=07*7GUH-'Y)(4E'BRO8*W\;<Y%.IP@UKBL%Q^;"Q(
MC;'AE3%5OR1A$1L;#T\<HQC$?Z;.@TKBL$R>4!ZX]"/TB"*.TG0LX[XX2B(Z
ML_?(H(HDJ$2MD!?N*'=TQD."!WSB6:7/>RGGF&4)B\D(O#<TH4D>S=D0,B@=
MP4%5=RO9/ 5N4#!_5-Z?*]LEZ4$>25@>;X\:+!<8<3#L$P/^:L;#>ZLRE4=P
MLRP==WY?7)Z>&?A+(H.*DK"*GA,ICEJ[CK\=>1<O;H]>9C1*P;)/H/LT.(TH
MAL4Z W\05Q(6UUNM"B'*7K7<6;?F]J@EE!X(/8G(5%*3A$0DSO&8AR<2',_%
M">62QJ"_)*R_IQ[@:*Q>]IW@9_CWQ+WED5629G#$B]F8Q304DR2)<337"08%
M)BS8"7K/^WVT02'_X4[P3-DN20]"3L)"?KD"I3'']ISKMI.J:SC2&W>L]-=A
M*O+0NS.:DWP\:<^L\F10>1)6>7!5C>'=8]Y"&?NW>$[%?4DIN  R69Q!,'^#
MY^ 32-@G7$ZC^"IT(;NNV/("478E\-.;.@-"63XQ[V$$/TZ.#A:#ABW&)_'X
M/ /X5,*U^^^<1ZC',,"A+9TT17\@B?!,3Z2#KZ#A$_1<3]P^L<O0Z>$XH3A-
MXF3LH3V180Z#3:!AF^ XR*;0KN2KEZ7H/KF^WE%S]J#]X#S"/:_$S",!.E5_
M,&\,?,*8BL<F8)+#$3&?.6#1LT?HWSEP;[>B:)?0Z7D3^%2!BOZQCOI14AY?
M0.,D8V/WZ@DD&.8RF3F;T\$^T+!]V,SA1=RB.[&33>,6FGLJ._L(G4YM 8;.
M!NYZLLZFD82!T9B?F\% T+"!"!(1[DP<I)!,'N[C/,'.W8PI>"+!.[#I7*S.
MWH/50N_:UX,&Q.+8V.XUTNGJZ17DV_;%V^CZ.WRUZ5XD#FFZ]YJ_<PTS9*"C
M;2%E]#H%6+I[5=A]L>K0OFV[4]:JNOVX%[P4V@7 [UNE[.,7=X/3"]OU_P%0
M2P,$%     @ $T *5S-#BKDU"@  11D  !@   !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6R]65%3V[H2?O>OT*0SG9Z9$"!0VE)@)D#I:>>TY4+I?59L)=:M
M+?E(,I#^^OOM2G8,-Z6=\W!G.DT<KU:[W^Y^NQ)'=]9]]Z520=S7E?''HS*$
MYG![V^>EJJ6?V$89O%E85\N 1[?<]HU3LN!%=;4]W=DYV*ZE-J.3(_[MTIT<
MV394VJA+)WQ;U]*M3E5E[XY'NZ/NARN]+ /]L'URU,BENE;AIKET>-KNM12Z
M5L9K:X13B^/1;/?P=)_D6>";5G=^\%V0)W-KO]/#A^)XM$,&J4KE@31(?-RJ
M,U55I AF_)UTCOHM:>'P>Z?]@GV'+W/IU9FM_JV+4!Z/7H]$H1:RK<*5O?M3
M)7]>DK[<5I[_%W=1]N#E2.2M#[9.BV%!K4W\E/<)A\&"USL_63!-"Z9L=]R(
MK3R709X<.7LG'$E#&WUA5WDUC-.&@G(='-YJK LGUS$8PB[$M5X:O="Y-$',
M\MRV)FBS%)>VTKE67DA3B"^A5$Z<:Y]7UK=.^:/M "M(UW:>=CR-.TY_LN.!
M^&1-*+UX9PI5/%R_#>M[%Z:="Z?3)Q5^;,U$[.V,Q71GNO>$OKT>DCW6M_=_
MA"3NN+]Y1RJ\0]_(7!V/4%E>N5LU.GG^;/=@Y^T3_NSW_NP_I7WHCQ_X(]?^
M-$-_+/M3/.W/TSON3D3:-/NGFV;R#W&E&NM(-E-8$E8L"4'QWMFV>?[L]73W
MU5LO?'!M'K!(?#"+2E[=9Y\GWR;B!4F2T'3G[9FM&VE6_+3[5EC7O4@KTHL_
MA(8YXKP->2F:=@X#11Z7HBQ#*2I=ZZ *?,JYKLBD%\)(65?VAQ*WRAAK WA3
M-KTIK'"N;5-*<$BNV@ @JE[KPJ+&H9#XJ6FJ%0&C@Q>-LXW3*E#<@)O>.GLI
MV7U\7HF@\M+8RBX)OF 9-WNKW!A\= N>;5@4>]3*Y5I6^H?*%MKYL*7-5EY)
M[\> /R@*" 1]HW(*D-"FU',=K/.4+(0?V5FIFB6)/R53Z0+?@>%W8^]@MR>C
M)N*+$3/87(G]6(EC5G!S+2ZL+7B?<]<NLUD!%M.(653UXN)\1K#[5I&0> >3
ME\KD*W'CE9BUH;1._TBR[VX@BT;$FE4O"00[>P>!YMRHK;%(*0/(!S &/;?%
M*KO5E9TKQ%3.QZ(%&T7%<T?&&EDCT2P!DH_[30,:7V XL.'9EV\?SK=VWP W
M45K?Z,!0PX\"/<%/Q-<2Q0P,C4>N%Y(R9Z&--!03I"U^(%6>BB3E"P/N-%8-
MO&'P*"ON2EM5JRV@#DV^G7M=:(DT03B[]>_K^9]C\5$9.1;O%5+.K,:\OA.X
M?)"('K_GD[&8&9/-W-PBA3[IO-1+:<;BQG"R7Y.A'O5DEXK+%'U3.8<W2#U$
M?U!G?6%2,4VR^1_B5'K-#H+8&IF"SKADV@3E=$WX%.CRJO@U4NLXE$ZIK9B]
M^GZKIHX"NQ)?B :*;>&%HA8CT"!4WR B&O@V%:6\5=E<*9.,@Z@V3%&NP-8J
MUOR'V;78VP=.T=J+WJR>G@:!_FU'"BN,#=@OK]I"9;*JV"]MXIS% POL'# B
MW/N[U<E(DI7&M%"Z2?V$NY4K8%RUHD+4/J%##(>PS96@$8Y4P=;_M(9GI(P=
M)MT;;8:P;5VW;]+7162EI$MXGZM<U7,DRM[N.")-G &_\+!UP6C]H^#?*7"\
M3)1 0MB:F4/,5[%RK70%568!G/(ACW65-&P*IR1-J7G>2?=M /;.VB6F+_$F
M9DTT>J-5R!O!7=N$&!O5.HMR@;*]@WV4 2WE'QE[ C?!37V@12$1APTH@+O7
ML&2IIJ.6]<ILT\I-M=UM>C.YGB#KJDJZB7BW6"@>A\5'B6"BR>P.2?MW#$27
M,TM59 MGZ\<;4(:%SND"\2&B2"NZ['W,U#AF1':@E$[[$PIC7M Z\-%C%2!*
M'FPZ&RF61)-,Y;&7HLT8+UD9\S' 6.O8Y&8)0F-*2)-*2C/T8^J2!%FU0G55
MU2 9AD6[(1.(9J).L",5R*/J-"TZ&4\%"[WD2O=E:JS!!HHC5'F+=A3DO,+K
M6JZ8/.;@#8@Y%&VM$'(AETNGEM&0E/B=RE#*0,;EJN#>4M,01(HP,6CDLN X
MQC$L;A-3?N/ 5MB&/*3,IZI%-Z>.F,C#@@D72 -[MZ:J(?DGPQ[.<(E3-G-
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M%FCG@.LKI>QAX#887G"+_P!02P,$%     @ $T *5U<'QJ,W P  [ 8  !D
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M!3,=+ <;Y-:'X"N$G14F1K,_V!\>;X"=\(DJM5$EO-DK31O4JA:;MV-PG"L
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M_I.P(W]XL:KQ=X"ELG2C\,.*KG"HG0%]7RFJZ?V+6^!X*5S\"U!+ P04
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MJ)T![6^5LJ>).V#LY.O_ %!+ P04    "  30 I7GUDJQTT&  !4$0  &0
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M=8&,]#0$M#\30K<?1D#W0\K)GU!+ P04    "  30 I7!XS6Q!@%   A#
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6RE5]]OVS80?M=?0;A8L0&>
M+<M)6J2)@:1=T0[K$+3;^CI:.EM<*%+ECSC>7[_O*%EQ&CLO>W LD7?????=
M\<Q<;*R[]351$/>--OYR5(?0GD^GOJRID7YB6S+865G7R(!7MY[ZUI&LDE.C
MIT6>GTT;J<QH<9'6;MSBPL:@E:$;)WQL&NFVUZ3MYG(T&^T6/JMU'7AANKAH
MY9J^4/BSO7%XFPXHE6K(>&6-<+2Z'%W-SJ]/V#X9_*5HX_>>!6>RM/:67SY6
MEZ.<"9&F,C""Q-<=O26M&0@TOO68HR$D.^X_[]#?I]R1RU)Z>FOU5U6%^G+T
M>B0J6LFHPV>[^4!]/J>,5UKMTU^QZ6R+8B3*Z(-M>F<P:)3ION5]K\.>P^O\
MB$/1.Q2)=Q<HL7PG@UQ<.+L1CJV!Q@\IU>0-<LIP4;X$AUT%O["X<3904D:\
MM]%4DK6ZF 9 L\&T[&&N.YCB",R9^&1-J+WXQ514/?:?@M+ J]CQNBZ>!?PU
MFHF8YV-1Y,7\&;SYD.<\X<W_;YX=S,EA&#XBY[Z5)5V.< 8\N3L:+5Z^F)WE
M;YXA>3*0/'D.?9_DZEF2S\/,\HEX@,H>H,1565I7*;/.@A6A)G'E@BHU>6%7
MXLI[6ZK.$*^\_=8VK33;L8BM@,=LEH_S/'U$PL$Q%KZ64$)(4QVP@D@K<HZJ
MG=E&A5I(82QZ6>KL3NI('.WEB]?SLY,W^616B)9<9R[2)X;:.O4O, "^)*&\
MCU1-Q)760W#8.5HK'^@AUD3\;GN<DI#G2I4RP!A+\-P#^F@R9(.@P*\($)@5
MWZ+R*DFQ5)4?[ZOQM^]0:ZOAA.!MZ^P=TX.-XRG "4DC%,X"AF=%)NS54^ !
M(=[%4-9"R\T84D*G ^4:,R&Z)U<J#QU$R;QMVQ7(/-$618_.1XEH?77W'>3:
M$6&:AD>Y]&(D)9BR;!"=^6=/*M=CMH=Z=-P[HK/8KN^#//_ANT9"E8O9JS>^
MEQX$6Q6D%C7I2BRWPL(6BH8:5/"8'0F&WHEH64,=-ZZ@&"HX"*:"[\N!51^A
M=M<,*?;X>#(P $B+]=1R&30#LC) D6*%MC4E=Z:39IT$W?7T4IK;5$P?E__
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M'Y;V;D+E$NQZ(:4Y!FZ#_K9+_P)02P,$%     @ $T *5V"A=W9#"@  0!D
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M']9T-:%V!K2_5LK>3YR#X;);_@%02P,$%     @ $T *5T+.M.:S @  $@8
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MMGR* @\CXI'@"%\P-AUT?,'_FLZM 1]-[^NUIPKW4]F9N5 -S6'NF*%0(-_
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MCM5R>54)5!W)EN:I>V%2/9RFN5#%$W -4/,SQN2VHP,TY5CR!U!+ P04
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ML8MU0(<@;K=G1KJVB$BD1])Q]N]W*2FJ+3-&MN5%(JES#N^YI,@[W2O]8$H
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M[;VJ'0MM8&3E.VLKC>U3ORSL) 7E$NQY+J4Y!.Z"?C8G/P%02P,$%     @
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MY>:I7"FAKS(=IQ97&R+HX:FN*P$7Y$[W6TEP\($JPE+Y!AR"*ST/DC*E@*_
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M4')O<',O8V]R92YX;6Q02P$"% ,4    "  30 I7F5R<(Q &  "<)P  $P
M            @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M !- "E=6?#&"+0,  " +   8              " @0P(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  30 I7Z&&GJV0&  "/&P  &
M            @(%O"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ $T *5_ %N5&V @  2 @  !@              ("!"1(  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !- "E?U$\NJ=@8  /L<
M   8              " @?44  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  30 I7(>69V9('  "S,P  &               @(&A&P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ $T *5S"F,!D7
M!P  O!T  !@              ("!:2,  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( !- "E<S0XJY-0H  $49   8              "
M@;8J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  30 I7
M-E*DM,$#  !^"   &               @($A-0  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ $T *5U3KBLY)!   S0D  !@
M     ("!&#D  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M !- "E=7!\:C-P,  .P&   9              " @9<]  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ $T *5_U1&J/' P  50@  !D
M             ("!!4$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  30 I7AP/\CF4$   @"@  &0              @($#10  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !- "E<P&.)KJ (
M !H&   9              " @9])  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ $T *5["J)Z.# P  U0<  !D              ("!
M?DP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  30 I7
MGUDJQTT&  !4$0  &0              @($X4   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( !- "E<'C-;$& 4  "$,   9
M      " @;Q6  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ $T *5R#+.'0W @  ^00  !D              ("!"UP  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  30 I78*%W=D,*  ! &0
M&0              @(%Y7@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( !- "E?ISJ(@H@(  +0%   9              " @?-H  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ $T *5R6(][11
M!   V0H  !D              ("!S&L  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  30 I7K:V (5,"   \!0  &0
M@(%4<   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !-
M"E?M'$+WL0(  .L%   9              " @=YR  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ $T *5Y)FK_L' P  ^ 8  !D
M         ("!QG4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  30 I70LZTYK,"   2!@  &0              @($$>0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !- "E<9R\ -?@0  +(+
M   9              " @>Y[  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ $T *5PR"5I-S @  J <  !D              ("!HX
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  30 I7YV-W
M=NT"  ":"0  &0              @(%-@P  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( !- "E>EP@R@-0,  "$,   9
M  " @7&&  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M$T *5VN7,+ W P   0H  !D              ("!W8D  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  30 I7Y+5V(ZL"  #R!P  &0
M            @(%+C0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( !- "E<1@T;R+ (  *<%   9              " @2V0  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ $T *5[=KZG*# @
M;0<  !D              ("!D)(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  30 I7'V @2RD"   0!0  &0              @(%*
ME0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !- "E>]
MQ.JO"0,  ,X)   9              " @:J7  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ $T *5TY-(L,T @  \ 0  !D
M     ("!ZIH  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !- "E?_=-IE1P0  'T5   9              "
M@:^M  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ $T *
M5]&&B]R!!   V18  !D              ("!+;(  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  30 I7V>9LE_H"   <"0  &0
M        @('EM@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( !- "E>G^@U2? ,  )48   -              "  1:Z  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ $T *5Y>*NQS     $P(   L
M ( !O;T  %]R96QS+RYR96QS4$L! A0#%     @ $T *5]X;I'F) P  %1P
M  \              ( !IKX  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M !- "E>^RS-!F0$  '49   :              "  5S"  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( !- "E<CU6X-J $  +@9   3
M              "  2W$  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     R
- #( E0T   ;&      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>75</ContextCount>
  <ElementCount>185</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>17</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Unaudited Condensed Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Changes in Shareholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Unaudited Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Summary of Significant Accounting Policies and Other Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures</Role>
      <ShortName>Summary of Significant Accounting Policies and Other Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Net Financial Result</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/NetFinancialResult</Role>
      <ShortName>Net Financial Result</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherAssets</Role>
      <ShortName>Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Financial Assets and Financial Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities</Role>
      <ShortName>Financial Assets and Financial Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CashandCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Protective Foundation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ProtectiveFoundation</Role>
      <ShortName>Protective Foundation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Other Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherIncomeTables</Role>
      <ShortName>Other Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherIncome</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Net Financial Result (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/NetFinancialResultTables</Role>
      <ShortName>Net Financial Result (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NetFinancialResult</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/Inventories</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherAssetsTables</Role>
      <ShortName>Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Financial Assets and Financial Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables</Role>
      <ShortName>Financial Assets and Financial Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/CashandCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CashandCashEquivalents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ShareBasedPayments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherIncomeDetails</Role>
      <ShortName>Other Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherIncomeTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Other Income (Details) - Schedule of Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable</Role>
      <ShortName>Other Income (Details) - Schedule of Other Income</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherIncomeTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Net Financial Result (Details) - Schedule of Net Financial Result</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable</Role>
      <ShortName>Net Financial Result (Details) - Schedule of Net Financial Result</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NetFinancialResultTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable</Role>
      <ShortName>Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NetFinancialResultTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable</Role>
      <ShortName>Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/NetFinancialResultTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Inventories (Details) - Schedule Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleInventoriesTable</Role>
      <ShortName>Inventories (Details) - Schedule Inventories</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/InventoriesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/OtherAssetsDetails</Role>
      <ShortName>Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherAssetsTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Other Assets (Details) - Schedule of Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable</Role>
      <ShortName>Other Assets (Details) - Schedule of Other Assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/OtherAssetsTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails</Role>
      <ShortName>Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable</Role>
      <ShortName>Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable</Role>
      <ShortName>Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/CashandCashEquivalentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/Equity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Share-Based Payments (Details) - Schedule of Stock Option Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Share-Based Payments (Details) - Schedule of Stock Option Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Share-Based Payments (Details) - Schedule of Fair Value of Options Granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable</Role>
      <ShortName>Share-Based Payments (Details) - Schedule of Fair Value of Options Granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea183075-6k_inflarxnv.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Protective Foundation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inflarx.de.com/role/ProtectiveFoundationDetails</Role>
      <ShortName>Protective Foundation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inflarx.de.com/role/ProtectiveFoundation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: ifrs-full:DilutedEarningsLossPerShare, infrx:FairValuePerOption -  ea183075ex99-1_inflarxnv.htm 2153, 2154, 2155, 2156, 2210</Log>
  </Logs>
  <InputFiles>
    <File doctype="6-K" original="ea183075-6k_inflarxnv.htm">ea183075-6k_inflarxnv.htm</File>
    <File doctype="6-K" original="ea183075ex99-1_inflarxnv.htm">ea183075ex99-1_inflarxnv.htm</File>
    <File>ea183075ex99-2_inflarxnv.htm</File>
    <File>ea183075ex99-3_inflarxnv.htm</File>
    <File>infrx-20230630.xsd</File>
    <File>infrx-20230630_cal.xml</File>
    <File>infrx-20230630_def.xml</File>
    <File>infrx-20230630_lab.xml</File>
    <File>infrx-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="352">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>60
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea183075-6k_inflarxnv.htm ea183075ex99-1_inflarxnv.htm": {
   "axisCustom": 0,
   "axisStandard": 6,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 12,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 352
   },
   "contextCount": 75,
   "dts": {
    "calculationLink": {
     "local": [
      "infrx-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "infrx-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea183075-6k_inflarxnv.htm",
      "ea183075ex99-1_inflarxnv.htm"
     ]
    },
    "labelLink": {
     "local": [
      "infrx-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "infrx-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "infrx-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 287,
   "entityCount": 1,
   "hidden": {
    "http://www.inflarx.de.com/20230630": 7,
    "http://xbrl.sec.gov/dei/2022": 5,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 57,
    "total": 69
   },
   "keyCustom": 60,
   "keyStandard": 125,
   "memberCustom": 10,
   "memberStandard": 6,
   "nsprefix": "infrx",
   "nsuri": "http://www.inflarx.de.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075-6k_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inflarx.de.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075-6k_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.inflarx.de.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Other Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.inflarx.de.com/role/OtherAssets",
     "shortName": "Other Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Financial Assets and Financial Liabilities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities",
     "shortName": "Financial Assets and Financial Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Cash and Cash Equivalents",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.inflarx.de.com/role/CashandCashEquivalents",
     "shortName": "Cash and Cash Equivalents",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.inflarx.de.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Share-Based Payments",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.inflarx.de.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfProtectiveFoundationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Protective Foundation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.inflarx.de.com/role/ProtectiveFoundation",
     "shortName": "Protective Foundation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfProtectiveFoundationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.inflarx.de.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "infrx:DisclosureOfSummaryOfSignificantAccountingPolicy",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfReportingEntityAndGroupsStructure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Accounting Policies, by Policy (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "infrx:DisclosureOfSummaryOfSignificantAccountingPolicy",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfReportingEntityAndGroupsStructure",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:SummaryofotherIncometableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Other Income (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://www.inflarx.de.com/role/OtherIncomeTables",
     "shortName": "Other Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:SummaryofotherIncometableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:ScheduleOfNetFinancialResultTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Net Financial Result (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.inflarx.de.com/role/NetFinancialResultTables",
     "shortName": "Net Financial Result (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:ScheduleOfNetFinancialResultTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.inflarx.de.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Other Assets (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.inflarx.de.com/role/OtherAssetsTables",
     "shortName": "Other Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Financial Assets and Financial Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables",
     "shortName": "Financial Assets and Financial Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Cash and Cash Equivalents (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.inflarx.de.com/role/CashandCashEquivalentsTables",
     "shortName": "Cash and Cash Equivalents (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:SchdeuleOfStockOptionActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Share-Based Payments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.inflarx.de.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:SchdeuleOfStockOptionActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherFinanceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Other Income (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.inflarx.de.com/role/OtherIncomeDetails",
     "shortName": "Other Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:OtherFinanceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:IncomeFromGovernmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Other Income (Details) - Schedule of Other Income",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable",
     "shortName": "Other Income (Details) - Schedule of Other Income",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfOtherIncomeTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:IncomeFromGovernmentGrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Net Financial Result (Details) - Schedule of Net Financial Result",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable",
     "shortName": "Net Financial Result (Details) - Schedule of Net Financial Result",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:ForeignExchangeIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable",
     "shortName": "Net Financial Result (Details) - Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:ForeignExchangeIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals",
     "shortName": "Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:OtherFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable",
     "shortName": "Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfNetFinancialResult",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:OtherFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReversalOfInventoryWritedown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.inflarx.de.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ReversalOfInventoryWritedown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Inventories (Details) - Schedule Inventories",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.inflarx.de.com/role/ScheduleInventoriesTable",
     "shortName": "Inventories (Details) - Schedule Inventories",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentRawMaterialsAndCurrentProductionSupplies",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentPrepayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Other Assets (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.inflarx.de.com/role/OtherAssetsDetails",
     "shortName": "Other Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentPrepayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:NonPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Other Assets (Details) - Schedule of Other Assets",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable",
     "shortName": "Other Assets (Details) - Schedule of Other Assets",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "infrx:DisclosureOfOtherAssets",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:NonPrepaidExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Financial Assets and Financial Liabilities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails",
     "shortName": "Financial Assets and Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable",
     "shortName": "Financial Assets and Financial Liabilities (Details) - Schedule of Financial Assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NoncurrentFinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable",
     "shortName": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "infrx:DisclosureOfCashAndCashEquivalentsTableTextBlock",
       "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:ShorttermDepositsClassifiedAsCashEquivalentsTotal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c47",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:CommonSharesSaleAgreement",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.inflarx.de.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c49",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:ProceedsFromIssuingOtherEquityInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:CommonSharesDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Share-Based Payments (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:CommonSharesDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Financial Position",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
     "shortName": "Unaudited Condensed Consolidated Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c54",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "infrx:OutstandingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Share-Based Payments (Details) - Schedule of Stock Option Activity",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable",
     "shortName": "Share-Based Payments (Details) - Schedule of Stock Option Activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c54",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "infrx:OutstandingBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Share-Based Payments (Details) - Schedule of Fair Value of Options Granted",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable",
     "shortName": "Share-Based Payments (Details) - Schedule of Fair Value of Options Granted",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfProtectiveFoundationExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:AuthorisedCapitalCommonSharesone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Protective Foundation (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.inflarx.de.com/role/ProtectiveFoundationDetails",
     "shortName": "Protective Foundation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "infrx:DisclosureOfProtectiveFoundationExplanatory",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "infrx:AuthorisedCapitalCommonSharesone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c25",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EquityAttributableToOwnersOfParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.inflarx.de.com/role/ShareholdersEquityType2or3",
     "shortName": "Unaudited Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c25",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:EquityAttributableToOwnersOfParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.inflarx.de.com/role/ConsolidatedCashFlow",
     "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfSummaryOfSignificantAccountingPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Summary of Significant Accounting Policies and Other Disclosures",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures",
     "shortName": "Summary of Significant Accounting Policies and Other Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfSummaryOfSignificantAccountingPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Other Income",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.inflarx.de.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfNetFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Net Financial Result",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.inflarx.de.com/role/NetFinancialResult",
     "shortName": "Net Financial Result",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea183075ex99-1_inflarxnv.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "infrx:DisclosureOfNetFinancialResult",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 17,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other current assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in employee benefit liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in employee benefit liabilities",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInEmployeeBenefitLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in other liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments for:"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r13",
      "r65",
      "r66",
      "r67",
      "r92",
      "r94"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Income (Loss) per share (basic) (in Euro per share)"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r9",
      "r51",
      "r62"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [Standard Label]",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r46",
      "r52"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash from/(used in) financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r46",
      "r52"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash from/(used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r52"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r82",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories"
       }
      }
     },
     "localname": "ClassesOfInventoriesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      }
     },
     "localname": "ClassesOfOrdinarySharesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r1",
      "r21",
      "r54",
      "r56",
      "r61",
      "r109"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive loss",
        "totalLabel": "Total Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrencyInWhichInformationIsDisplayedAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Currency in which information is displayed [axis]"
       }
      }
     },
     "localname": "CurrencyInWhichInformationIsDisplayedAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r14",
      "r57",
      "r109"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentAssetsLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets less the amount of current liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets (liabilities)",
        "terseLabel": "Total other assets"
       }
      }
     },
     "localname": "CurrentAssetsLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentFinancialAssets": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current financial assets",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "CurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentInvestments": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      },
      "en-us": {
       "role": {
        "label": "Current investments",
        "terseLabel": "Discounts amount"
       }
      }
     },
     "localname": "CurrentInvestments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r15",
      "r59",
      "r109"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepaid expenses",
        "terseLabel": "Prepaid expense"
       }
      }
     },
     "localname": "CurrentPrepaidExpenses",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentRawMaterialsAndCurrentProductionSupplies": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of current raw materials and current production supplies. [Refer: Current production supplies; Current raw materials]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current raw materials and current production supplies",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "CurrentRawMaterialsAndCurrentProductionSupplies",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxAssets": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The excess of amount paid for current tax in respect of current and prior periods over the amount due for those periods. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax assets",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "CurrentTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation &amp; amortization of property and equipment, right-of-use assets and intangible assets"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      },
      "en-us": {
       "role": {
        "label": "Expected volatility, share options granted",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk free interest rate, share options granted",
        "terseLabel": "Risk-free rate (interpolated, U.S. sovereign strips curve)"
       }
      }
     },
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Income (Loss) per share (diluted)"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of cash and cash equivalents [text block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/CashandCashEquivalents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets and liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]",
        "terseLabel": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Schedule Inventories"
       }
      }
     },
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other assets [text block]",
        "terseLabel": "Schedule Other Assets"
       }
      }
     },
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r48",
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r0",
      "r26",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense",
        "terseLabel": "Reimburse expenses"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r13",
      "r16",
      "r53",
      "r55",
      "r65",
      "r66",
      "r67"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [Standard Label]",
        "terseLabel": "Equity amount (in Dollars)",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet",
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "TOTAL EQUITY AND LIABILITIES"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParent": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParent",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAttributableToOwnersOfParentMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity attributable to the owners of the parent."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity attributable to owners of parent [member]",
        "terseLabel": "Other components of equity"
       }
      }
     },
     "localname": "EquityAttributableToOwnersOfParentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from equity-settled share-based payment transactions",
        "terseLabel": "Share-based payment expense"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r85",
      "r110"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets",
        "terseLabel": "Financial assets from government grants"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinishedGoods": {
     "auth_ref": [
      "r103",
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "FinishedGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FunctionalOrPresentationCurrencyMember": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member indicates information displayed in the functional or presentation currency. It also represents the standard value for the \u2018Currency in which information is displayed\u2019 axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Functional or presentation currency [member]"
       }
      }
     },
     "localname": "FunctionalOrPresentationCurrencyMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationNetOfTax": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, net of tax, before reclassification adjustments. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on exchange differences on translation of foreign operations, net of tax",
        "terseLabel": "Exchange differences on translation of foreign currency"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "auth_ref": [
      "r5",
      "r37"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign exchange gain (loss)",
        "terseLabel": "Foreign exchange result",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome",
      "http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The gains (losses) recognised in other comprehensive income on financial assets measured at fair value through other comprehensive income applying paragraph 4.1.2A of IFRS 9, net of tax, before reclassification adjustments. [Refer: Financial assets measured at fair value through other comprehensive income; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Gains (losses) on financial assets measured at fair value through other comprehensive income, net of tax",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "GainsLossesOnFinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeNetOfTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GovernmentGrants": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Government grants",
        "terseLabel": "Liabilities from government grants"
       }
      }
     },
     "localname": "GovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r30",
      "r40",
      "r64",
      "r91"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of options, equity",
        "terseLabel": "Share options exercised"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Equity-settled share-based payments"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpense": {
     "auth_ref": [
      "r63",
      "r90",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense",
        "negatedLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "negatedLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest income on financial assets designated at fair value through profit or loss. [Refer: Interest income; Financial assets at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest income on financial assets designated at fair value through profit or loss",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOnFinancialAssetsDesignatedAtFairValueThroughProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r8",
      "r34",
      "r101"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issuance of common shares"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r13",
      "r65",
      "r66",
      "r67",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r14",
      "r58",
      "r109"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial assets",
        "terseLabel": "Non-current financial assets"
       }
      }
     },
     "localname": "NoncurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets measured at fair value through profit or loss. [Refer: Financial assets at fair value through profit or loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current financial assets at fair value through profit or loss",
        "terseLabel": "Fair value of current and non-current financial assets"
       }
      }
     },
     "localname": "NoncurrentFinancialAssetsAtFairValueThroughProfitOrLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r15",
      "r60",
      "r109"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentPrepayments": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current prepayments. [Refer: Prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current prepayments",
        "terseLabel": "Prepayments on research and development"
       }
      }
     },
     "localname": "NoncurrentPrepayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "terseLabel": "Exercise of share options"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options expired in share-based payment arrangement",
        "terseLabel": "Number of Share options granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted in share-based payment arrangement",
        "terseLabel": "Number of grants"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r41",
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]",
        "terseLabel": "Shares outstanding",
        "verboseLabel": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails",
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherAssets": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCashAndCashEquivalents": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents that the entity does not separately disclose in the same statement or note. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other cash and cash equivalents",
        "terseLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "OtherCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentAssets": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current assets",
        "terseLabel": "Current other assets"
       }
      }
     },
     "localname": "OtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other current financial assets"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentNonfinancialLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current non-financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current non-financial liabilities",
        "terseLabel": "Liabilities from government grants"
       }
      }
     },
     "localname": "OtherCurrentNonfinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentReceivables": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current receivables",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherCurrentReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherEquityInterest": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of equity interest of an entity without share capital that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other equity interest",
        "terseLabel": "Other components of equity"
       }
      }
     },
     "localname": "OtherEquityInterest",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherExpenseByNature": {
     "auth_ref": [
      "r26",
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses that the entity does not separately disclose in the same statement or note when the entity uses the 'nature of expense' form for its analysis of expenses. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other expenses, by nature",
        "terseLabel": "Other offering expenses"
       }
      }
     },
     "localname": "OtherExpenseByNature",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncome": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinanceIncomeCost": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of finance income or cost that the entity does not separately disclose in the same statement or note. [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other finance income (cost)",
        "terseLabel": "Other financial result"
       }
      }
     },
     "localname": "OtherFinanceIncomeCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherFinancialAssets": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other financial assets",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncome": {
     "auth_ref": [
      "r39",
      "r98",
      "r99"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or expense from subsidiaries, jointly controlled entities and associates that the entity does not separately disclose in the same statement or note. [Refer: Associates [member]; Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other income (expense) from subsidiaries, jointly controlled entities and associates",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIncomeExpenseFromSubsidiariesJointlyControlledEntitiesAndAssociates",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherLiabilities": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current assets",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentFinancialAssets": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current financial assets",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "OtherNoncurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Other capital reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReservesMember": {
     "auth_ref": [
      "r4",
      "r19"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing reserves within equity, not including retained earnings. It also represents the standard value for the 'Reserves within equity' axis if no other member is used. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves [member]",
        "terseLabel": "Other capital reserves"
       }
      }
     },
     "localname": "OtherReservesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedLabel": "Transaction costs from issuance of common shares"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing other equity instruments",
        "terseLabel": "Net proceeds from equity investments"
       }
      }
     },
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentProperty": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investment property. [Refer: Investment property]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investment property",
        "terseLabel": "Proceeds from sales of investment property"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentProperty",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r20",
      "r47",
      "r54",
      "r56",
      "r92",
      "r93",
      "r109",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Loss for the period",
        "totalLabel": "Income (Loss) for the Period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome",
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r80",
      "r98",
      "r99",
      "r111",
      "r112"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss for the period"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r6",
      "r32"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfAvailableforsaleFinancialAssets": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of available-for-sale financial assets",
        "negatedLabel": "Purchase of current financial assets"
       }
      }
     },
     "localname": "PurchaseOfAvailableforsaleFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Purchase of intangible assets, property and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RateregulatedActivitiesMember": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an entity\u2019s activities that are subject to rate regulation. It also represents the standard value for the 'Types of rate-regulated activities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Rate-regulated activities [member]"
       }
      }
     },
     "localname": "RateregulatedActivitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r4",
      "r100"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RevenueAndOperatingIncome": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue and other operating income",
        "totalLabel": "Operating Result"
       }
      }
     },
     "localname": "RevenueAndOperatingIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReversalOfInventoryWritedown": {
     "auth_ref": [
      "r25",
      "r35"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount recognised as a reduction in the amount of inventories recognised as an expense due to the reversal of any write-down of inventories resulting from an increase in net realisable value. [Refer: Inventories; Inventory write-down]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reversal of inventory write-down",
        "terseLabel": "Write-downs of inventories"
       }
      }
     },
     "localname": "ReversalOfInventoryWritedown",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_RevenueAndOperatingIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Sales and marketing expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SegmentsAxis": {
     "auth_ref": [
      "r44",
      "r70",
      "r92",
      "r106",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "localname": "SegmentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable",
      "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable",
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_SegmentsMember": {
     "auth_ref": [
      "r44",
      "r70",
      "r97",
      "r106",
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all segments of an entity. It also represents the standard value for the 'Segments' axis if no other member is used."
       }
      }
     },
     "localname": "SegmentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable",
      "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable",
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "negatedLabel": "Transaction costs"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [member]",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsAccruals": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accruals for employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services. [Refer: Accruals classified as current]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits accruals",
        "terseLabel": "Employee benefits"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsAccruals",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of profit or loss and other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:"
       }
      }
     },
     "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherPayables": {
     "auth_ref": [
      "r10"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRateregulatedActivitiesAxis": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of rate-regulated activities [axis]"
       }
      }
     },
     "localname": "TypesOfRateregulatedActivitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share",
        "terseLabel": "Weighted average number of shares outstanding (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_AdjustmentsForDecreaseIncreaseInFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of financial assets adjusted.",
        "label": "Adjustments For Decrease Increase In Financial Assets",
        "terseLabel": "Financial assets from government grants"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInFinancialAssets",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_AssetsFromGovernmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets From Government Grants.",
        "label": "Assets From Government Grants",
        "terseLabel": "Assets from government grants"
       }
      }
     },
     "localname": "AssetsFromGovernmentGrants",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/FinancialAssetsandFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_AuthorisdCapitalPreferenceSharesone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorisd Capital Preference Sharesone",
        "terseLabel": "Preferred shares authorized"
       }
      }
     },
     "localname": "AuthorisdCapitalPreferenceSharesone",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_AuthorisedCapitalCommonSharesone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Authorised Capital Common Sharesone",
        "terseLabel": "Common shares authorized"
       }
      }
     },
     "localname": "AuthorisedCapitalCommonSharesone",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_BoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board Of Directors Member",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_CashAtBanksAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash At Banks Abstract",
        "terseLabel": "Cash at banks"
       }
      }
     },
     "localname": "CashAtBanksAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_CashAtBankstotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash at banks total.",
        "label": "Cash At Bankstotal",
        "terseLabel": "Cash at banks\ttotal"
       }
      }
     },
     "localname": "CashAtBankstotal",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents (Details) - Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "CashandCashEquivalentsDetailsScheduleofCashandCashEquivalentsTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ChangesInCashFlowAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes In Cash Flow Abstract",
        "terseLabel": "Changes in:"
       }
      }
     },
     "localname": "ChangesInCashFlowAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_CommonSharesDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares, description.",
        "label": "Common Shares Description",
        "terseLabel": "Common shares, description"
       }
      }
     },
     "localname": "CommonSharesDescription",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_CommonSharesSaleAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of common shares.",
        "label": "Common Shares Sale Agreement",
        "terseLabel": "Sale of common shares (in Shares)"
       }
      }
     },
     "localname": "CommonSharesSaleAgreement",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_CurrentOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Other Assets Abstract",
        "terseLabel": "Current other assets"
       }
      }
     },
     "localname": "CurrentOtherAssetsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_CurrentOtherAssetsTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other current assets.",
        "label": "Current Other Assets Total",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "CurrentOtherAssetsTotal",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_DepositsHeldInEurosMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Held In Euros Member",
        "terseLabel": "Deposits Held in Euros [Member]"
       }
      }
     },
     "localname": "DepositsHeldInEurosMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_DepositsHeldInUSDollarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposits Held In USDollars Member",
        "terseLabel": "Deposits Held in U.S. Dollars [Member]"
       }
      }
     },
     "localname": "DepositsHeldInUSDollarsMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_DisclosureOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Cash And Cash Equivalents Table Text Block",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/CashandCashEquivalentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfCashAndCashEquivalentsTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisclosureOfCashAndCashEquivalentsTextBlockAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_DisclosureOfNetFinancialResult": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Net Financial Result",
        "terseLabel": "Net financial result"
       }
      }
     },
     "localname": "DisclosureOfNetFinancialResult",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/NetFinancialResult"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfOtherAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "DisclosureOfOtherAssets",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfOtherIncomeTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Other Income Text Block",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "DisclosureOfOtherIncomeTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfProtectiveFoundationExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Protective Foundation Explanatory",
        "terseLabel": "Protective foundation"
       }
      }
     },
     "localname": "DisclosureOfProtectiveFoundationExplanatory",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfReportingEntityAndGroupsStructure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Reporting Entity And Groups Structure",
        "terseLabel": "Reporting entity and the Group\u2019s structure"
       }
      }
     },
     "localname": "DisclosureOfReportingEntityAndGroupsStructure",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DisclosureOfSummaryOfSignificantAccountingPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Summary Of Significant Accounting Policy",
        "terseLabel": "Summary of significant accounting policies and other disclosures"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPolicy",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/SummaryofSignificantAccountingPoliciesandOtherDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ExchangeDifferencesOnTranslationOfForeignCurrency1": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange differences on translation of foreign currency.",
        "label": "Exchange Differences On Translation Of Foreign Currency1",
        "terseLabel": "Exchange differences on translation of foreign currency"
       }
      }
     },
     "localname": "ExchangeDifferencesOnTranslationOfForeignCurrency1",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ExercisedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of exercised shares",
        "label": "Exercised Number Of Shares",
        "terseLabel": "Exercised during the six months ended June 30"
       }
      }
     },
     "localname": "ExercisedNumberOfShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_ExpectedLifemidpointBased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of option life share options granted.",
        "label": "Expected Lifemidpoint Based",
        "terseLabel": "Expected life (midpoint based)"
       }
      }
     },
     "localname": "ExpectedLifemidpointBased",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_FXRateAsOfGrantDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at grant date fx rate as of grant date.",
        "label": "FXRate As Of Grant Date",
        "terseLabel": "FX rate as of grant date"
       }
      }
     },
     "localname": "FXRateAsOfGrantDate",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_FairValuePerOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value per option.",
        "label": "Fair Value Per Option",
        "terseLabel": "Fair value per option"
       }
      }
     },
     "localname": "FairValuePerOption",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_FairValuePerOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value per option.",
        "label": "Fair Value Per Options",
        "terseLabel": "Fair value per option"
       }
      }
     },
     "localname": "FairValuePerOptions",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_FinancialAssetsAndFinancialLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets and Financial Liabilities"
       }
      }
     },
     "localname": "FinancialAssetsAndFinancialLiabilitiesAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_FinancialAssetsAtAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets At Amortized Cost Abstract",
        "terseLabel": "Financial assets at amortized cost"
       }
      }
     },
     "localname": "FinancialAssetsAtAmortizedCostAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_FinancialAssetsFromGovernmentGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]",
        "label": "Financial Assets From Government Grants",
        "terseLabel": "Financial assets from government grants"
       }
      }
     },
     "localname": "FinancialAssetsFromGovernmentGrants",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_FinancialExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Expenses Abstract",
        "terseLabel": "Financial expenses"
       }
      }
     },
     "localname": "FinancialExpensesAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_FinancialIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Income Abstract",
        "terseLabel": "Financial income"
       }
      }
     },
     "localname": "FinancialIncomeAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_FinancialLiabilitiesAtAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Liabilities At Amortized Cost Abstract",
        "terseLabel": "Financial liabilities at amortized cost"
       }
      }
     },
     "localname": "FinancialLiabilitiesAtAmortizedCostAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFinancialAssetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ForeignExchangeExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange expense.",
        "label": "Foreign Exchange Expense",
        "negatedLabel": "Foreign exchange expense"
       }
      }
     },
     "localname": "ForeignExchangeExpense",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ForeignExchangeIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange income.",
        "label": "Foreign Exchange Income",
        "terseLabel": "Foreign exchange income"
       }
      }
     },
     "localname": "ForeignExchangeIncome",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ForeignExchangeResultAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Exchange Result Abstract",
        "terseLabel": "Foreign exchange result"
       }
      }
     },
     "localname": "ForeignExchangeResultAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofInterestIncomeisDerivedfromMarketableSecuritiesandShortTermDepositsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ForfeitedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of forfeited shares",
        "label": "Forfeited Shares",
        "terseLabel": "Forfeited during the six months ended June 30"
       }
      }
     },
     "localname": "ForfeitedShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_IncomeFromGovernmentGrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income from government grants.",
        "label": "Income From Government Grants",
        "terseLabel": "Income from government grants"
       }
      }
     },
     "localname": "IncomeFromGovernmentGrants",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_InventoriesDetailsScheduleInventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories (Details) - Schedule Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesDetailsScheduleInventoriesTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_IssuanceOfCommonSharesAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common shares and warrants.",
        "label": "Issuance Of Common Shares And Warrants",
        "terseLabel": "Issuance of common shares (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonSharesAndWarrants",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_JanuaryTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Twenty Four Member",
        "terseLabel": "January Twenty four [Member]"
       }
      }
     },
     "localname": "JanuaryTwentyFourMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_JanuaryTwentyFourOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January Twenty Four One Member",
        "terseLabel": "January twenty four one [Member]"
       }
      }
     },
     "localname": "JanuaryTwentyFourOneMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_LiabilitiesFromGovernmentGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liabilities from government grants.",
        "label": "Liabilities From Government Grants",
        "terseLabel": "Liabilities from government grants received"
       }
      }
     },
     "localname": "LiabilitiesFromGovernmentGrants",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_MayThirtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May Thirty Member",
        "terseLabel": "May thirty [Member]"
       }
      }
     },
     "localname": "MayThirtyMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_NetFinanceIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net finance income.",
        "label": "Net Finance Income",
        "terseLabel": "Net finance income"
       }
      }
     },
     "localname": "NetFinanceIncome",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_NetFinancialResult": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net financial total value.",
        "label": "Net Financial Result [Standard Label]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "NetFinancialResult",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofNetFinancialResultTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_NetFinancialResultAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Financial Result"
       }
      }
     },
     "localname": "NetFinancialResultAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Financial Result (Details) - Schedule of Foreign Exchange Income and Expense [Table]"
       }
      }
     },
     "localname": "NetFinancialResultDetailsScheduleofForeignExchangeIncomeandExpenseTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_NetFinancialResultLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Financial Result [Abstract]"
       }
      }
     },
     "localname": "NetFinancialResultLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_NetForeignExchangeDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net foriegn exchange difference.",
        "label": "Net Foreign Exchange Differences",
        "terseLabel": "Net foreign exchange differences"
       }
      }
     },
     "localname": "NetForeignExchangeDifferences",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_NominalValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of nominal  value of price per share.",
        "label": "Nominal Value Per Share",
        "terseLabel": "Nominal value of price per share (in Euro per share)"
       }
      }
     },
     "localname": "NominalValuePerShare",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_NonCurrentOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Current Other Assets Abstract",
        "terseLabel": "Non-current other assets"
       }
      }
     },
     "localname": "NonCurrentOtherAssetsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_NonPrepaidExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses.",
        "label": "Non Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "NonPrepaidExpenses",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_NumberOfShareOptionsUnderThe2012PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Options Under The2012 Plan Member",
        "terseLabel": "Number of share options under the 2012 Plan [Member]"
       }
      }
     },
     "localname": "NumberOfShareOptionsUnderThe2012PlanMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_NumberOfShareOptionsUnderThe2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Options Under The2016 Plan Member",
        "terseLabel": "Number of share options under the 2016 Plan [Member]"
       }
      }
     },
     "localname": "NumberOfShareOptionsUnderThe2016PlanMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_NumberOfShareOptionsUnderTheLTIPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Share Options Under The LTIPMember",
        "terseLabel": "Number of share options under the LTIP [Member]"
       }
      }
     },
     "localname": "NumberOfShareOptionsUnderTheLTIPMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_OptionLTIPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option LTIPMember",
        "terseLabel": "Option LTIP [Member]"
       }
      }
     },
     "localname": "OptionLTIPMember",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "infrx_OtherAssetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_OtherFinancialResult": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other financial result.",
        "label": "Other Financial Result",
        "negatedLabel": "Other financial result"
       }
      }
     },
     "localname": "OtherFinancialResult",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofForeignExchangeIncomeandExpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_OtherIncomeDetailsScheduleofOtherIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Details) - Schedule of Other Income [Table]"
       }
      }
     },
     "localname": "OtherIncomeDetailsScheduleofOtherIncomeTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_OtherIncomeTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeTablesLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherIncomeTables"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_OtherIncomeTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income (Tables) [Table]"
       }
      }
     },
     "localname": "OtherIncomeTablesTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherIncomeTables"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_OtherIncomeTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other income total.",
        "label": "Other Income Total",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OtherIncomeTotal",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_OtherIncomesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "OtherIncomesAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_OtherIncomesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Incomes [Abstract]"
       }
      }
     },
     "localname": "OtherIncomesLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_OtherOfferingExpensesTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other offering expenses total.",
        "label": "Other Offering Expenses Total",
        "terseLabel": "Other offering expenses total"
       }
      }
     },
     "localname": "OtherOfferingExpensesTotal",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_OutstandingBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares outstanding.",
        "label": "Outstanding Balance",
        "periodEndLabel": "Outstanding Ending Balance",
        "periodStartLabel": "Outstanding Beginning Balance"
       }
      }
     },
     "localname": "OutstandingBalance",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_PercentageOfIssuedCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issued capital.",
        "label": "Percentage Of Issued Capital",
        "terseLabel": "Percentage of issued capital"
       }
      }
     },
     "localname": "PercentageOfIssuedCapital",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "infrx_PrepaymentsOnResearchDevelopmentProjects": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments on research &amp; development projects.",
        "label": "Prepayments On Research Development Projects",
        "terseLabel": "Prepayments on research &amp; development projects"
       }
      }
     },
     "localname": "PrepaymentsOnResearchDevelopmentProjects",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherAssetsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_PricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of price per shares.",
        "label": "Price Per Shares",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "PricePerShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_ProceedsFromIssuanceOfCommonShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of prceeds from issuance of common shares.",
        "label": "Proceeds From Issuance Of Common Shares",
        "terseLabel": "Proceeds from issuance of common shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ProceedsFromTheMaturityOfFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preceeds from the maturity of financial assets.",
        "label": "Proceeds From The Maturity Of Financial Assets",
        "terseLabel": "Proceeds from the maturity of financial assets"
       }
      }
     },
     "localname": "ProceedsFromTheMaturityOfFinancialAssets",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ProtectiveFoundationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Protective Foundation"
       }
      }
     },
     "localname": "ProtectiveFoundationAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ProtectiveFoundationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Protective Foundation Explanatory [Abstract]"
       }
      }
     },
     "localname": "ProtectiveFoundationDetailsLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ProtectiveFoundationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Protective Foundation (Details) [Table]"
       }
      }
     },
     "localname": "ProtectiveFoundationDetailsTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ProtectiveFoundationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_RepaymentOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of repayment of lease liabilities.",
        "label": "Repayment Of Lease Liabilities",
        "negatedLabel": "Repayment of lease liabilities"
       }
      }
     },
     "localname": "RepaymentOfLeaseLiabilities",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_SaleOfPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares sold price per share.",
        "label": "Sale Of Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfPricePerShare",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_SchdeuleOfStockOptionActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schdeule Of Stock Option Activity Table Text Block",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "SchdeuleOfStockOptionActivityTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_ScheduleInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Inventories Abstract"
       }
      }
     },
     "localname": "ScheduleInventoriesAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfCashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Cash And Cash Equivalents Abstract"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfFairValueOfOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Options Granted Abstract"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfOptionsGrantedAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfFairValueOfOptionsGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of Options Granted Table Text Block",
        "terseLabel": "Schedule of Fair Value of Options Granted"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfOptionsGrantedTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_ScheduleOfFinancialAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Assets And Liabilities Abstract"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfForeignExchangeIncomeAndExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Foreign Exchange Income And Expense Abstract"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeIncomeAndExpenseAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Foreign Exchange Income And Expense Table Text Block",
        "terseLabel": "Schedule of Foreign Exchange Income and Expense"
       }
      }
     },
     "localname": "ScheduleOfForeignExchangeIncomeAndExpenseTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/NetFinancialResultTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest Income Is Derived From Marketable Securities And Short Term Deposits Abstract"
       }
      }
     },
     "localname": "ScheduleOfInterestIncomeIsDerivedFromMarketableSecuritiesAndShortTermDepositsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Interest Income Marketable Securities And Short Term Deposits Table Text Block",
        "terseLabel": "Schedule of Interest Income is Derived from Marketable Securities and Short-Term Deposits"
       }
      }
     },
     "localname": "ScheduleOfInterestIncomeMarketableSecuritiesAndShortTermDepositsTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/NetFinancialResultTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_ScheduleOfInventoriesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventories [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoriesLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfNetFinancialResultAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Financial Result Abstract"
       }
      }
     },
     "localname": "ScheduleOfNetFinancialResultAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfNetFinancialResultTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Financial Result Table Text Block",
        "terseLabel": "Schedule of Net financial result"
       }
      }
     },
     "localname": "ScheduleOfNetFinancialResultTableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/NetFinancialResultTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_ScheduleOfOtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Assets Abstract"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Other Income Abstract"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ScheduleOfStockOptionActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Stock Option Activity Abstract"
       }
      }
     },
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based payment transactions.",
        "label": "Share Based Payment Transactions",
        "terseLabel": "Share based payment transactions (in Shares)"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactions",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_ShareBasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedPaymentsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) - Schedule of Fair Value of Options Granted [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsScheduleofFairValueofOptionsGrantedTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) - Schedule of Stock Option Activity [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsScheduleofStockOptionActivityLineItems",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) - Schedule of Stock Option Activity [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsScheduleofStockOptionActivityTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareBasedPaymentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payments (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentsDetailsTable",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Information Abstract",
        "terseLabel": "Share Information"
       }
      }
     },
     "localname": "ShareInformationAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShareOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share options exercised.",
        "label": "Share Options Exercised",
        "terseLabel": "Share options exercised (in Shares)"
       }
      }
     },
     "localname": "ShareOptionsExercised",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_SharePriceAtGrantDateExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price at grant date / Exercise price.",
        "label": "Share Price At Grant Date Exercise Price",
        "terseLabel": "Share price at grant date / Exercise price"
       }
      }
     },
     "localname": "SharePriceAtGrantDateExercisePrice",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofFairValueofOptionsGrantedTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of option granted shares",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Granted Number Of Shares",
        "terseLabel": "Granted during the six months ended June 30"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantedNumberOfShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vested shares.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Option Vested Number Of Shares",
        "terseLabel": "thereof vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionVestedNumberOfShares",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofStockOptionActivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_SharebasedPaymentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share-based payment expense.",
        "label": "Sharebased Payment Expense",
        "terseLabel": "Share-based payment expense (in Euro)"
       }
      }
     },
     "localname": "SharebasedPaymentExpense",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ShortTermDepositsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Deposits Abstract",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "ShortTermDepositsAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "stringItemType"
    },
    "infrx_ShorttermDepositsClassifiedAsCashEquivalentsTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A total of cash equivalents representing short-term deposits.",
        "label": "Shortterm Deposits Classified As Cash Equivalents Total",
        "terseLabel": "Short-term deposits\ttotal"
       }
      }
     },
     "localname": "ShorttermDepositsClassifiedAsCashEquivalentsTotal",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofCashandCashEquivalentsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_SoldCommonSharesThroughAPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of public offering.",
        "label": "Sold Common Shares Through APublic Offering",
        "terseLabel": "Sold common shares through a public offering (in Shares)"
       }
      }
     },
     "localname": "SoldCommonSharesThroughAPublicOffering",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "infrx_SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies and Other Disclosures"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAndOtherDisclosuresAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_SummaryofotherIncometableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summaryofother Incometable Text Block",
        "terseLabel": "Schedule of Other Income"
       }
      }
     },
     "localname": "SummaryofotherIncometableTextBlock",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/OtherIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "infrx_UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statements Of Changes In Shareholders Equity Abstract"
       }
      }
     },
     "localname": "UnauditedCondensedConsolidatedStatementsOfChangesInShareholdersEquityAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unaudited Condensed Consolidated Statements Of Operations And Comprehensive Loss Abstract"
       }
      }
     },
     "localname": "UnauditedCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossAbstract",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "xbrltype": "stringItemType"
    },
    "infrx_UnfinishedGoods": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfinished goods.",
        "label": "Unfinished Goods",
        "terseLabel": "Unfinished goods"
       }
      }
     },
     "localname": "UnfinishedGoods",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleInventoriesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "infrx_ValuationPastGrantAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of valuation past grant.",
        "label": "Valuation Past Grant Amount",
        "terseLabel": "Valuation past grants amount (in Euro)"
       }
      }
     },
     "localname": "ValuationPastGrantAmount",
     "nsuri": "http://www.inflarx.de.com/20230630",
     "presentation": [
      "http://www.inflarx.de.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Component of Operating Income [Abstract]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inflarx.de.com/role/ScheduleofOtherIncomeTable"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r101": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r102": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r103": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r104": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r112": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r115": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r116": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r118": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "r",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r122": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2017-en-b&anchor=para_16&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "57",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_57_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "30",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_30&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "115",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_115&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F__IFRS07_g13A-13F_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r99": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001213900-23-065270-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-065270-xbrl.zip
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M47*BM@GEG1)OA[I2M!QWQ[*C#Y_72C#]6^C?T_6K&/;I1=K*"H^S!]Z*@26
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MAO5BO.\WR+?,%4 U4&UJA#^I")OB#79NIGY6Z[Z1H]H Y5'6Q-464W%,R4?
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MG+$!P&EMET;<D")Y.!SS-S[B/X5XWY][(PG8NJY5%DZ,]&+).\E\,:2 FVE
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MLFFXO4R'ZF%+_O@"L3IYF I<FR:Y !*Q**LZ@C6W]NXK?D 7],/63*^)F5Z
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MFKO?2Q@$M2^U#0<T8)P2CGD=G'T^8M%<CV!KW2A5PPW<OSC4!G:%)BQW!/T
MY19L E0.QOAE&CYGZB-8WV]E[*>AHAF "3PSID_<4-4-U0O#XNX>;A^,'#@:
M]Q3QV,_J7+X+RW!"DQR.-8ZB0AWT>AOX4[!U]"OIYGAI<D!@8IZ_HA]01MC
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MXN. XF_DW?UT:XF#QI>.WT78'C/7C3_E3Q<!5#B8.(X5,L:^R-(:)#O1F"\
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MA+TG^%J">7UHG&E)EO:A :=E.V2*C95,7X4U5*E:;'AI >]*2PE5QEVS4<)
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MG<VD88J9N1G]>D2?@RJ*:<J>'28#I.=<734C.:]<Y3$74T3+VI;[K;<]58X
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MV_87=<+DR5>_86XB$5_[R8T\A!7-M>2P,"S7<Y9^CN.6/ABEO+FVR0"( /L
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MFQ+BYWYL97JU>2!-R .YFX%ETX4MS4&;Y.-$VFZZNQ,_!D+:<9X? V#ZN9*
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M=OD4W#C.-V'FM\O*#3I)Z0U7#NS5Q.6R(;@^N<3"RVEN.#O]#Q,()6%Z_-H
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M$$@6@(QK<:;T0+( 8'RK*>4'D@4@XUH4H2&0+( 9UYH(M8%D_B"ESU=**',
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MD RZP(Y2L$8JS6:Z6U']3][4/E\1V.QWF(_F293SE9CK+ _+X]:>;='IGOK
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M[%A%;$1,M!X&A%@NBA(IH"-JK:R/X@):7>,%8*M"+@&W&F?&4ERG@44&)DQ
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MG^+/UO&Q])K]^N[T#[5.GOTX">?P2'.>J/4<#\,D"6>_6%W\;AA&H*[K[][
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M+!A>CV^01%3FU"UZ-/_]X^#KB3YHS+S&:'81CFT8?BF932E(I,P3QE$DFRI
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MTJH<C+X[BYRMQ@'^-D//MHH"%X'G4$2IOU+VA3,/A2S8EUU&8.1N.'<"M!#
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MK>JRYY/NY*04/GK"SAG08!%_J;;PW.;%\S/#OO9C2N5P*7RK.-&0YO9C024
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M7:J4JL1[U+S-RKVY/E=<GV6Y(&%A/4)M,)-N)FZIB!(%:QJ*<<8$DTSI9#I
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M3BD]0/74D0D#K"-*VK>:IE.XF<)$[]SJC!+\<99MY>*CVJA!A!:/.5;2*&+
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M<2W:2+CA)/#^$>2+T/DBF!LB1S822[IJ)]MI57]H0_K6I86,RJ6%K#1^/&2
M/*T5OI01K4S9Q.=MA=\8&'?#"K_)[>Z %7YCVSU8X7?+"K\D$AS7:PUD?^K
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MKVVW.V6KYAU 6A)1ZSV[4[^STO^@-.H:.>*14F5O?O Q$W=W?S6/I'%\""/
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MZNT2N:>/)&HV0!7KKIB_GVPY=KN%FLPM!=_'5U 4VCR:!1[.J2"?ZRG,[W!
MG5:)9.X'7TD3JYO<,JO\J7+_\Q+-PYU-=V!WNR52_Q_^<.SF *C=:I6A)U-A
M@:YT&W:CMSUY_[?49F_*;=@]G09KT]W=B+XOWH36X!:I3_L+!B!>=J]TM:K=
M\:G(!GU'&/C]0@?+<[. YZP\- 9VLP\ZV6J9S(,^=E>0MD TZV+NUP&D&P)I
MQ^YAY$O](8P&6R-?O%=BZL@;CT6$K75B3+))(B>(?6Z3'HYU8@PU/PG<Q1[P
MG$;/;C3N;57=91  @C?Z=K]1UG&XQP((@**%%3[V**ZCG45U@!0RC\14!#&&
M#LI,NJ-/*)7<@<#O0Q8JBB"M.H9WW$C=;]VP[OD!LP=$!/Z_ZB(^P/+VB-FP
MVR ;-]LWJH6'3HJE.BD.#IT492?%P:&3XD:3H9]#AS.G7(>S&X/)#VG/A[3G
MIT[SW)[$V$/:\SYO]Y#VO-U]SDK)S!=3+QH=8_68Q=:ECS::;7O0NGOCK<)7
MRJ)'B3?OM,][I29M=#4[=YY/973ZZ?57$<5A$ C_T<)A&G#/^_U;MSBX+1&\
M#1!*,ZCR^'R'>;<*X%L0;/S3ZT]B(I.GL4Y7ZI-6,A8/CZ/MIMT?W+KIQ0%%
M'Q/>VV.HW].\%6SI43:$_1X(NZ_NYT,.]B-@UA:PJ6L==_$]:C3<WQNR,=='
M4?Q?N33Z]H:IPSZXB$I2AOO6(WZN^+0]7C+I7]B8L^S#E\\7N;L2)PM?_&(%
M831S? Q7Q/C$:N6&<J97PIHZ(PPCP&"@D2ZFV]+%=,/QM90+BP&+.,N@L)Q(
MJ'+ &*H08F7C<%RMK)0VQMA)J6^Z(=;=Q0FRIV#7(@J0;HKHTL-()HRY'&'5
M)"PQ# /4?GV)4'B]+2!7")!?U,$75>B+&I;S196K G=P2#VM0ZJ41;F,V_TY
M.Z0V!L3=<$AM<KL[X)#:V'8/#JGM=DBMZH0Y:>(89!ODB.K \!'DDPWDHMOL
MIVK6[4Z]7M3NXSZNJL=VSG3M7K]I#SHK8=([M(F6W6OTBK+/G];'=!_$?WS7
M4\MN-Q";;UGQ\P'MWG:SV;$[@Q+E4!\IT[;?@/6LUG;;HCR8\@CV9.ZCAEWO
M]^Q&=VNJDK5[#;O5W9HN[EU LG[],0M%W+,HV6VP;M_<0-B-KM7<M"-H]^#0
MZ($,4;HMX_["H=U'6K*9G/=M==_<2GXG1T]TV\X%S\37L;Y/PJ']XMT NK9O
MPP&@=P+HVCX2AXZ6Q;/\*:P4>SNF(.7,YGZX$(*HGA>,(R=.HM1-THC*)L$C
M+O9+=-PHC&-KAB+XW!?KB>4\"B>1,XNMD1=QY\4DO'(B_1 *\)>>'PZ%[\V<
M(;V/ZYA'XMCUO0 9AQZD9OV)7JD 4Y%<X"J.%^!2$N^2&T[&*:X@1N4@B>#[
M_++@Q73LX%9PTG!<.._(B]T0.-8B6WDR!28UF=+/B6':N13!*(P>O47D \UR
MHXLF\RZ.PZA:*=%D,>N)ZE)_1CI\JK?BAC!0/ \#O(ZR^@H\3BT9LV:@[5I=
M>1F7FY52&]$(3B[RL(WH**5&I5.XQ(:DCB,"*OR5!BX53;CR$C[%][^?6,Y\
M[@-RJ6H*)B[ :V^__''Z[K@Q(+\H.4*M4>0!7EA7(A+2TQD)WV&,SN,6K,>
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M&GV<#F<>/P+8Z%AO/IV0%6&<^K[ES $)X9I2[-D-I? M50G?9HJ#RYC-D-2
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MG1%U1<1I.45\&;[F-HB\5D%AJ8Q@='"XJ"!,B*<XE[!ER9_2?<EJQ@( Y((
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MK\CDL0"S]E'\T"&],L)7&8MC;^8A20+PH90G)<J$O>&83Z$.U"0SY*7/<M.
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M%1?+,K*'"^7=0P^.[US1*F5Y1;1ID$F%^\3!6:=S#M:.J(9GS-5"K[G:,LT
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ML5(/^D#(4.E'R0A$"B/"<.3TZQ\79Q6C2\:PPU*89OF=#@^0*&#>'H]_'XM
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M'\].7@-K!I%T.LIMPNU>P<.5[#QL;^QB<O[F(#*8+3VA(%L\^!'(A>&^XPD
MCS8Z\'2DS@ ?-##@>YER<LND8!QQ:\B4@+B%B4#X*G@O/O_Q&FQ_%*$^R&44
M81R>&?%1SV<>)^+G9,"].%GL]//7UW"T9:\&)7&/ VQ3!S$0\XQK*'&9@63R
M11 LTB]FR%@HM4-._F466U3M!17K%%@X+7J1XZKCPDN=DXJ69=K@! C2BM )
ME4H&C!U-031&!Y;<,?2._NH'Z T)X@,61[&1$9Q>%,=_D^VNDA/YYN%!P$9
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M'!EM:AAY';'/DAC 7C$ZM&,LY+\]BAAVG2W0V%(HZ$;><S';('9&VWX(6]F
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MVJ*\-%=\"<Z&*6?7O716#DC(5+M*P,/0Y;92#RH]AE4Z8S89[>)"Q8)M<L'
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MS7A1U $F,QCC_$@/056?'U@DZ!-@D6$.E%ZN3!64EK/%T!21-*S.,ZT, MO
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M;SY\/?N/C'3_?O/Y\OW_!U!+ P04    "  30 I7\!_;G,<1   ARP  $@
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M1!^R(3J,AO4S'!A\T X9E*,M;(\G#AML_FR$X.!HB\^K[8BW/QW0?TUA1F4
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M5R-8K];J76IY:B+4$E#E'ZFHVWCS<L1]LZZX%U?M[@L0-093]0DYKZ212!E
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M?B"^[3L# QYVL#WA7E&KE;@7U/;*_JCBB;>?2CHF/]X>F9*00@/!=K99M=@
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MD\1!GIK3FV39<-W1&5B!CN7D6J#=.N:"FT8CZ8+%(O#357C@.Y\MB"9XM4L
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M,K9&1+([X?V;8&F_A":^.\TXGJ-_'<))<U-D3BT4:.["(D#%@^%26C?L<2T
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M4E0'0.NED2DH$'&1\4G68+N&T]@:4\F:9L@+03M.8B)V6R)YXB''<7TI,S!
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M&B-F=8H:V=C485.?DS>I%]""#TPW7GH[M\^4\MU!Q$@*BNJU@8ZM-3S;B.'
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MZ>)R>QN%_G*UPK2FH:5ZLUS,><5>*[!4FH],;JF]G,]''MJP%8ABY$M(%2)
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MQDL]W@NG3/BYSKV<W<LRZ%8A \ $:,\T"F#%)\ 6XD%IY5+@(?;32)"ZH\A
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M_,\S^#"T&"HX9$$5H$^$Z2!B.U('$1NZH$_U=RP9\FA7#1&?]N+12P,N;Z+
M:-^L*9&P([)S.H$_,#R=F H**7@66G]V<O,CS@:(S0.;-8L[VS/@/[G J(D,
MXH?L@&J(A&U>(!C3]YK6DB0T%E 0FECIN"G#'^(33M(\Q^GZ!&^2+,RSXS(
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M%C*ZKY/1?<=1O]7.7UL0\.M9$/!K'0&_!B/@5Q8$_&H6!/Q*1\"OX)R>O&2
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M!K4+M2C+M6-OFD&\A?'/7]1V8)>0[6T6!J%'P?H^">,\VATGY+*?1!$.F!.
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M.#KB%KU.^42V+\(57H?!AEZCCNA7H-)%Q014GX'8%+A(<R467388$ 8MO5/
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M 34B)WFZM22(BW.;YAP?%Z5I,M^+?L%>>AH')UZN=#P5P5-\ J(S$)F"Z!S
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MK>\-AY$8,'DD3,IZ[CBYE\49#7M*XNP\_ND^].]9%/TRO<;I0^CCC%C\.'S
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M*Q7>^-7E]S;I1F3-=ETK.YG:KI61-'TAU91'VX!'F[B,#YN(([HA_\^@YRZ
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M_1W[51VEZY4FZ*K6O(=EV /?49^@*PM5(=@J XX&"_HLWU_(N0A"Z9L48L"
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MIMKA>4MB&'8J(&K(X+7@@\:&<;6!X!E26=9+)E/!^KPS^8G&0B]S\Q"M$;0
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M;<DEVFF%=?CD)8#]LWM;4FQXL]\)OC\=451HPQ+]K_\'4$L! A0#%     @
M$T *5R3J>O8I#0  3DD  !D              ( !     &5A,3@S,#<U+39K
M7VEN9FQA<GAN=BYH=&U02P$"% ,4    "  30 I724G0L*YP  !?AP8 '
M            @ %@#0  96$Q.#,P-S5E>#DY+3%?:6YF;&%R>&YV+FAT;5!+
M 0(4 Q0    ( !- "E<7N&YKYF0  (,: P <              "  4A^  !E
M83$X,S W-65X.3DM,E]I;F9L87)X;G8N:'1M4$L! A0#%     @ $T *5P+!
M76M</   >&(" !P              ( !:.,  &5A,3@S,#<U97@Y.2TS7VEN
M9FQA<GAN=BYH=&U02P$"% ,4    "  30 I7\!_;G,<1   ARP  $@
M        @ '^'P$ :6YF<G@M,C R,S V,S N>'-D4$L! A0#%     @ $T *
M5T3!KTV?"@  O'L  !8              ( !]3$! &EN9G)X+3(P,C,P-C,P
M7V-A;"YX;6Q02P$"% ,4    "  30 I7.ECT-JXE  !-+P( %@
M    @ '(/ $ :6YF<G@M,C R,S V,S!?9&5F+GAM;%!+ 0(4 Q0    ( !-
M"E?OO\SP[UP  ...!  6              "  :IB 0!I;F9R>"TR,#(S,#8S
M,%]L86(N>&UL4$L! A0#%     @ $T *5T9-M"K\)0  B5," !8
M     ( !S;\! &EN9G)X+3(P,C,P-C,P7W!R92YX;6Q02P4&      D "0!U
) @  _>4!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
